


































This unpublished thesis/dissertation is copyright of the author and/or third 
parties. The intellectual property rights of the author or third parties in respect 
of this work are as defined by The Copyright Designs and Patents Act 1988 or 
as modified by any successor legislation.   
 
Any use made of information contained in this thesis/dissertation must be in 
accordance with that legislation and must be properly acknowledged.  Further 
distribution or reproduction in any format is prohibited without the permission 








A	 retrospective	 cohort	 study	 assessed	 the	 distribution	 of	 disease	 on	 digital	 subtraction	




Secondly,	 in	a	prospective	 study,	24	patients	with	active	 foot	ulceration	were	 recruited	
and	 grouped	 as	 having	 no	 significant	 arterial	 disease	 (n=14)	 and	 those	 requiring	
percutaneous	 angioplasty	 (PCA,	 n=10).	 Laser	 Doppler	 fluxmetry	 (LDF)	 assessed	 the	
microcirculation	 at	 regular	 intervals	 until	 healing.	 Using	 LDF,	 the	 time	 to	 maximum	 flux	
















data	management	 and	 the	 statistical	 design.	 Jayne	Robbie	has	been	a	 font	 of	 information	
and	guidance	on	the	process	of	gaining	ethical	approval.	
Recruitment	and	the	follow-up	of	participants	would	not	have	been	possible	without	the	





































































CHAPTER	 2:	 THE	DISTRIBUTION	OF	ATHEROSCLEROSIS	 IN	 THE	 LOWER	 LIMB	ARTERIES:	 A	
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6.2.2.1.	 Evidence	 of	 difference	 in	 the	 level	 of	 change	 in	 the	 time	 to	maximum	 flux	 between	when	 ulceration	



























































































































































































































































primarily	 defined	 by	 the	 level	 of	 hyperglycaemia	 giving	 rise	 to	 risk	 of	 microvascular	
damage.1”	 As	 well	 as	 being	 characterised	 by	 chronic	 hyperglycaemia	 DM	 also	 involves	
disturbances	of	carbohydrate,	fat	and	protein	metabolism.	These	are	the	results	of	defects	
in	 insulin	 secretion,	 insulin	 action	 or	 both2.	 Long	 term	 the	 effects	 of	 DM	 include	 both	
macrovascular	 and	 microvascular	 complication,	 namely	 retinopathy,	 nephropathy,	
























DM	 is	 an	 increasing	problem	worldwide.	Between	1980	and	2014	 the	prevalence	of	DM	
increased	from	4.3%	to	9.0%	in	men	and	from	5.0%	to	7.9%	in	women3.	This	is	based	on	a	
sophisticated	 statistical	 analysis,	 performed	 by	 the	 NCD	 Risk	 Factor	 Collaborative,	 that	
pooled	 the	population-based	data	 for	 751	 studies,	 4.4	million	 adults,	 from	146	 countries.	
The	definition	the	NCD	Risk	Factor	Collaborative	used	for	DM	was	fasting	plasma	glucose	of	
7.0	 mmol/l	 or	 higher	 or	 history	 of	 diagnosis	 with	 diabetes,	 or	 use	 of	 insulin	 or	 oral	





As	 of	 2014,	 422	million	 adults	were	 living	with	DM	worldwide3.	 In	 the	United	 Kingdom,	
there	 are	 almost	 3.7	 million	 people	 currently	 living	 with	 DM,	 with	 an	 estimated	 million	
people	who	are	as	yet	undiagnosed4.	The	increase	in	prevalence	includes	patients	with	both	
type	1	and	type	2	DM	although	90%	of	affected	patients	suffer	from	type	24.	The	accepted	
causes	 for	 type	 1	 DM	 include	 genetic	 factors5,	 viral	 infections	 and	 other	 environmental	
factors6,7.	With	type	2	DM	there	are	also	factors	related	to	genetics	and	ethnicity8,9	however	
the	main	 driving	 factors	 for	 the	 continued	 increase	 in	 prevalence	 are	 thought	 to	 be	 the	
obesity	 epidemic,	 lack	of	 physical	 activity	 and	 increasing	 age	of	 the	population9,10.	As	 the	
prevalence	 of	 DM	 has	 increased	 so	 have	 the	 complications	 related	 to	 persistent	
hyperglycaemia.	 These	 complications	 include	 diabetic	 retinopathy,	 nephropathy	 and	
diabetic	 peripheral	 neuropathy	 (DPN)	 as	 well	 as	 increased	 cardiovascular	 risk	 and	 risk	 of	
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(95%	CI	1.53	–	1.84,	p	=	0.009)17.	 In	 the	population	of	 the	United	States	of	America,	aged	
over	 40	 years,	 the	 prevalence	 of	 PAD	 has	 been	 found	 to	 be	 double	 in	 those	 with	 DM	
compared	to	those	without	(4%	[95%	CI	2.9	–	5.2]	vs	9.5%	[5.5	–	13.4])18.	There	is	overlap	
between	 the	 risk	 factors	 for	 coronary	 artery	 disease	 (CAD)	 and	 PAD,	 however	 some	 risk	
factors	seem	to	play	a	larger	role	in	the	development	of	atherosclerosis	in	one	vascular	bed	
over	 the	 other.	 A	 large	 prospective	 cohort	 study	 based	 in	 Scotland	 found	 the	 strongest	
predictors	 for	development	of	PAD	were	DM	(hazard	ratio	3.38)	and	smoking	(2.15)19.	For	
CAD	the	largest	hazard	ratio	was	still	for	DM	(2.21)	followed	by	gender	(1.99)	however	the	
spread	 of	 risk	 across	 the	 other	 risk	 factors	 considered	 was	 much	 more	 evenly	 spread	
compared	to	PAD19.	While	there	is	overlap	between	the	risk	factors	for	PAD	and	CAD	it	has	




density-lipoproteins	 (LDLs)	 in	 the	 vascular	 sub-endothelial	 space,	 increased	 expression	 of	
cell	 adhesion	 molecules	 leading	 to	 macrophage	 migration,	 increased	 tissue	 factor	 and	
matrix	 metalloproteinase	 expression	 and	 smooth	 muscle	 cell	 proliferation	 with	
vasovasorium	 neovascularisation	 (Figure	 1.3-1)22.	 DM	 predisposes	 to	 accelerated	
atherosclerosis	 through	 a	 combination	 of	 insulin	 resistance,	 hyperglycaemia	 and	
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dyslipidaemia.	 Through	 different	 and	 interconnected	 processes	 these	 lead	 to	
vasoconstriction,	 inflammation	 and	 thrombosis	 which	 in	 turn	 contribute	 to	
atherogenesis23,24.		
Dysfunction	of	the	endothelium	may	well	precede	the	development	of	insulin	resistance	
or	 promote	 the	 conversion	 from	 a	 pre-diabetes	 state	 to	 overt	 DM25.	 The	 endothelium	
consists	of	a	single	layer	of	cells	that	coat	the	inner	surface	of	all	blood	vessels.	These	cells	























The	 inter-related	 combination	 of	 hyperglycaemia,	 dyslipidaemia,	 hypertension	 and	








molecule	 and	 vascular	 cellular	 adhesion	 molecule.	 Monocytes	 couple	 with	 the	 adhesion	
molecules	 and	migrate	 into	 the	 sub-endothelial	 space.	 In	 the	 sub-endothelial	 space,	 they	
differentiate	 into	macrophages	 and	 scavenge	 the	 ox-LDL,	 forming	 foam	 cells.	 The	 lesions	
progress	sequentially	from	isolated	foam	cells	to	fatty	streaks	with	mainly	intracellular	lipid	
accumulation.	 Extracellular	 lipids	 then	 also	 start	 to	 accumulate	 and	 form	 an	 extracellular	
lipid	core.	Fibroatheromatous	lesions	subsequently	form,	containing	a	combination	of	lipid,	
foam	 cells,	 VSMC.	 Cellular	 apoptosis	 leads	 to	 the	 formation	 of	 a	 lipid-rich	 necrotic	 core.	




In	 the	physiological	 state	 insulin	binds	with	 insulin	 receptors	on	endothelial	cells	which	
induce	the	production	of	nitric	oxide	(NO).	NO	causes	vasodilatation,	increasing	blood	flow,	
which	 augments	 the	 disposal	 of	 glucose	 in	 skeletal	muscle28.	 In	more	 detail	when	 insulin	
binds	to	the	insulin	receptor	the	transmural	ß	subunit	undergoes	auto-phosphorylation	with	
adenosine	 triphosphate	 at	 specific	 tyrosine	 sites29.	 The	 activated	 receptor	 itself	 becomes	
tyrosine	 kinase	which	 in	 turn	 phosphorylates	 intracellular	 substrates	 like	 insulin	 receptor	
substrate-1	 (IRS-1)	 and	 Shc	 proteins28,29.	 There	 are	 two	 main	 insulin	 signal	 transduction	
pathways	(Figure	1.3-2)	The	phosphatidylinositol	3-kinase	(PI-3	kinase)	pathway,	in	vascular	
endothelium,	 leads	 to	 increased	 activity	 in	 endothelial	 nitric	 oxide	 synthase	 (eNOS),	
increased	 production	 of	 NO	 and	 vasodilatation22,28.	 The	 growth	 factor	 like	 pathway	 is	
mediated	 by	 mitogen-activated	 protein	 kinase	 (MAP-kinase).	 It	 initiates	 a	 cascade	 of	
signalling	 events	 that	 lead	 to	 the	 induction	 of	 genes	 involved	 in	 cell	 proliferation	 and	
differentiation22,28.	In	DM	the	anti-atherogenic	PI-3	kinase	pathway	is	down	regulated	so	the	
protective	 factors	of	 decreased	expression	 and	 secretion	of	 vascular	 adhesion	molecule-1	
and	 E-selectin,	 pro-inflammatory	 cytokines,	 tumour	 necrosis	 factor-⍺,	 monocyte	
chemoattractant	 protein-1	 and	 subsequent	 reduced	 platelet	 adhesion	 and	 prostacyclin	




Hyperglycaemia	 in	 DM	 contributes	 to	 oxidative	 stress	 and	 formation	 of	 advanced	
glycation	end-products	(AGEs)25.	Oxidative	stress	is	a	condition	in	which	the	overproduction	
of	 reactive	 oxygen	 species	 (ROS)	 overwhelms	 endogenous	 antioxidant	 defence	
mechanisms30.	AGEs	occur	as	a	result	of	non-enzymatic	glycation	of	proteins	and	lipids.	They	
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are	 found	 deposited	 in	 macrophages	 and	 vascular	 smooth	 muscle	 cells	 and	 cause	
mechanical	 dysfunction	 in	 vessel	 walls	 among	 other	 actions22.	 By	 interacting	 with	 the	
receptor	 for	AGEs	 (RAGE)	AGEs	 cause	a	 variety	of	 adverse	effects	 including	uncoupling	of	
eNOS	and	its	inactivation,	increased	nicotinamide	adenine	dinucleotide	phosphate	(NADPH)	
oxidase	expression,	increased	protein	kinase	C	(PKC)	activity,	increased	MAP-kinase	activity	
and	 increased	 nuclear	 factor-	"B	 (NF-	 "B)	 expression25.	 NADPH	 oxidase	 is	 an	 enzyme,	 or	
family	of	enzymes,	that	are	the	predominant	source	of	the	superoxide	anion	(O2•–),	a	ROS,	
in	the	vasculature.	As	well	as	being	activated	by	RAGE,	NADPH	oxidase	is	also	activated	by	
angiotensin	 II,	 endothelin-1,	 growth	 factors,	 cytokines	 and	 mechanical	 shear	 stress	 and	









the	 production	 of	 NO24,25.	 They	 are	 also	 associated	 with	 mitochondrial	 uncoupling	 and	
increased	expression	of	NADPH	oxidase	leading	to	increased	ROS24,25,30.	The	combination	of	
oxidative	 stress	 and	 hyperglycaemia	 leads	 to	 an	 oxidative	 modification	 of	 LDLs	 (oxLDL).	






obesity	 and	 DM22,25.	 As	 well	 as	 producing	 inflammatory	 molecules	 like	 tumour	 necrosis	
factor-a,	interleukins-6,8	and	10,	and	plasminogen	activator	inhibitor-1,	adipocytes	produce	
adipokines	 like	 adiponectin,	 leptin	 and	 angiotensinogen22.	 Adiponectin,	 unlike	 the	 other	
adipokines,	 increases	sensitivity	 to	 insulin	and	 is	downregulated	 in	obesity	and	type	 II	DM	
and	 so	 its	 anti-inflammatory	 and	 anti-thrombotic	 properties	 are	 reduced.	 It	 has	 these	
effects	by	decreasing	the	expression	of	adhesion	molecule,	reducing	oxLDL	uptake,	reducing	
foam	 cell	 formation	 and	 reducing	 proliferation	 of	 VSMCs22,25,28,31.	 Leptin	 conversely	 is	
upregulated	in	DM	and	reduces	sensitivity	to	insulin,	stimulates	cholesterol	accumulation	by	
macropahges	and	encourages	VSMC	proliferation22,25.	There	is	also	increased	production	of	
angiotensinogen	 which	 is	 a	 precursor	 to	 angiotensin	 II.	 Angiotensin	 II	 is	 a	 major	
vasoconstrictor	 which	 also	 enhances	 foam	 cell	 formation,	 stimulates	 adhesion	molecules	












protein	 2;	 IL-1,	 interleukin-1;	 IRS,	 insulin	 receptor	 substrates;	MCP-1,	monocyte	 chemoattractant	 protein-1;	 NADPH,	 reduced	 nicotinamide	









supply	 for	 the	 skin	 is	 derived	 from	 a	 combination	 of,	 tributaries	 of	 the	 major	 vessels,	
musculocutaneous	 perforators	 and	 fasciocutaneous	 perforators.	 These	 tributaries	 are	
organised	into	anastomotic	plexi	that	give	off	capillary	loops	into	the	dermal	papillae.	Within	
the	 deep	 layers	 of	 the	 dermis,	 there	 are	 arterio-venous	 anastomoses	 which	 can	 rapidly	
increase	and	decrease	 the	blood	 flow	 to	 the	 skin34.	 In	normothermic	 conditions	 the	blood	
flow	to	the	skin	 is	approximately	250ml/min,	however,	 this	can	range	 from	almost	zero	to	
8l/min	 in	 extreme	 conditions35.	 There	 are	many	more	 anastomoses	 in	 glabrous	 skin	 (non-
hairy	skin,	i.e.	palms,	soles	and	lips)	than	non-glabrous	(hairy)	skin36.	Two	sets	of	sympathetic	
nerves	 control	 the	 cutaneous	 circulation;	 sympathetic	 adrenergic	 vasoconstrictors	 and	
sympathetic	 cholinergic	 vasodilators.	 Within	 non-glabrous	 skin,	 both	 these	 systems	 are	
active	 whereas	 in	 glabrous	 skin	 only	 sympathetic	 vasoconstrictors	 are	 found.	 The	
vasoconstrictors	 have	 tonic	 activity	 during	 normothermic	 conditions	 and	 increase	 their	
activity	during	cooling	to	reduce	blood	flow	to	the	skin.	However,	the	vasodilators	are	only	
active	when	the	body	temperature	rises,	i.e.	during	exercise35.		
The	 historical	 concept	 was	 that	 patients	 with	 DM	 suffered	 from	 occlusion	 of	 the	
microcirculation	 meaning	 that	 macrovascular	 revascularisation	 was	 often	 considered	
hopeless.	 However	 further	 investigation	 using	 various	 techniques	 has	 not	 found	 occlusive	
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microvascular	 disease37	 in	 these	 patients.	 Histological	 examination	 of	 the	 capillaries	







activator-1	 and	 vascular	 endothelial	 growth	 factor	 (VEGF)44-46.	 These	 induce	 the	 increased	
synthesis	of	collagen	IV,	the	degradation	of	proteoglycans	and	the	unbalanced	synthesis	of	
other	 basement	 membrane	 constituents38,42,44,46.	 Changes	 to	 the	 basement	 membrane	
appear	 early	 in	 the	 diabetic	 disease	 process,	 before	 the	 development	 of	 overt	
complications47.	 It	 is	 thought	 that	 thickening	 of	 the	 basement	 membrane	 reduces	 the	
distensibility	of	the	vessels	and	provides	a	barrier	to	the	diffusion	of	NO48,49.	These	changes	






1.5. THE	 IMPACT	 OF	 DIABETES	MELLITUS	 ON	 FOOT	 ULCER	 DEVELOPMENT	
AND	WOUND	HEALING		
Foot	ulcers	in	DM	can	be	classified	as	neuropathic,	neuro-ischaemic	or	ischaemia15.	It	has	









chronic	 sensorimotor	 distal	 symmetric	 polyneuropathy	 (DSPN)	 and	 autonomic	
neuropathies53.	 Other	 types	 of	 neuropathies	 include	 acute	 sensory	 neuropathy,	 focal	 and	
multifocal	 neuropathies	 including	 cranial	 nerve	 neuropathies	 and	 diabetic	 amyotrophy53.	 I	
am	 not	 going	 to	 concentrate	 on	 these	 rarer	 forms	 any	 further	 here	 as	 they	 have	 less	
relevance	to	the	development	of	foot	ulceration.		




on	 peripheral	 nerves	 include	 oxidative	 stress,	 polyol	 shunting,	 accumulation	 of	 AGEs,	 and	
activation	of	PKC54,55,61.	Persistent	hyperglycaemia,	as	mentioned	above	(Section	1.3),	causes	
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oxidative	 stress	 in	many	 tissues	 including	 peripheral	 nerves54.	Multiple	 free	 radicals	 have	
been	 shown	 to	 be	 associated	 with	 DPN	 and	 they	 have	 been	 shown	 to	 both	 activate	
pathological	pathways	 (i.e.	polyol	pathway)	and	occur	as	 the	result	of	 these	pathways54-56.	
The	free	radicals	cause	damage	to	the	lipids	in	myelinated	structures	and	there	is	associated	
apoptosis	 of	 neurons	 and	 Schwann	 cells57.	 The	 damage	 also	 results	 in	 hyperexcitability	 in	
afferent	nociceptors	and	central	neurons	resulting	in	neuropathic	pain57.	In	addition,	there	is	
damage	 to	 the	 microvasculature	 of	 the	 neurons	 leading	 to	 endogenous	 hypoxia	 and	
decreased	neurological	function57.		
Polyol	shunting	occurs	in	the	presence	of	hyperglycaemia	and	associated	ROS	leading	to	
inhibition	 of	 glyceraldehyde	 3-phosphate	 dehydrogenase	 and	 subsequent	 upregulation	 of	
the	polyol	pathway55.	In	normoglycaemic	conditions	the	glycolytic	pathway	is	dominant	but	
becomes	saturated	in	hypergylcaemia57.	In	the	polyol	pathway	aldose	reductase	uses	NADPH	
to	 reduce	 glucose	 to	 sorbitol.	 Sorbitol	 dehydrogenase	 then	 uses	 oxidised	 nicotinamide	
adenine	dinucleotide	to	reduce	sorbitol	to	fructose55,57.	Sorbitol	and	fructose	are	too	large	to	
cross	 cell	membranes	 and	 so	 accumulate	 in	 nerve	 cells55.	 This	 leads	 to	 change	 in	 osmotic	
pressure	within	the	cells,	efflux	of	other	electrolytes	and	swelling	of	the	axons57.	In	addition,	
there	 is	 reduction	 in	 the	 osmolytes	 myoinositol	 and	 turin,	 and	 inhibition	 of	 the	 Na+/K+	
ATPase	 pump	 with	 accumulation	 of	 intracellular	 sodium55,57.	 As	 well	 as	 damage	 to	 the	
Schwann	 cells	 and	 a	 reduction	 in	 nerve	 conduction	 velocity,	 these	 changes	 cause	
consumption	 of	 NADPH	 leading	 to	 endothelial	 damage	 and	 reduced	 NO-dependant	
vasodilatation	 and	 increases	 in	 MAP-kinase	 and	 NF-!B	 activity55,57.	 AGEs	 accumulate	 in	
peripheral	 nerves	 and	 there	 is	 an	 associated	 upregulation	 in	 RAGE.	 The	 AGEs	 themselves	
induce	 tissue	 damage,	 including	 endothelial	 damage,	 by	 causing	 protein	 cross	 linking,	
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apoptosis	of	Schwann	cells	and	driving	oxidative	stress55,57.	Associated	upregulation	of	RAGE	
leads	 to	 increased	NF-!B,	 ROS	 and	 nuclear	 DNA	 degradation	 leading	 to	 apoptosis,	 axonal	
degradation	 and	 nerve	 atrophy55,57.	 As	 well	 as	 stimulation	 of	 the	 hexosamine	 and	 PKC	
pathways	 (Sections	 1.3	 and	 1.4),	 which	 are	 also	 active	 in	 peripheral	 nerves,	 leading	 to	
upregulation	 of	 TGF-ß	 and	 VEGF	 and	 subsequent	 endothelial	 fibrosis,	 there	 is	 down	
regulation	of	nerve	growth	factor	(NGF)54-57.	Physiologically	NGF	stimulates	neuronal	growth	
and	differentiation	and	protects	nerve	 cells	 from	apoptosis,	 particularly	 small	 sensory	and	









careful	 examination	may	 elicit	 signs	 of	 neuropathy53.	 Symptoms	 of	 DSPN	 include	 burning,	
tingling	or	shooting	pains	and/or	hyperaesthia	that	affect	the	feet	or	hands	in	a	symmetrical	












Once	 ulceration	 has	 occurred,	 healing	may	 be	 interrupted	by	 a	 combination	 of	 chronic	
inflammation,	 hyperglycaemia,	 disruption	 of	 collagen	 synthesis	 and	 abnormal	 action	 of	




vulnerable	 to	 chronic	 infection.	 Hypoxia	 and	 hyperglycaemia	 and	 biomechanical	
disturbances	combine	to	encourage	overgrowth	of	bacteria	and	adversely	affect	the	function	
of	neutrophils	and	macrophages66.	In	any	open	wound	there	is	the	risk	of	invasion	of	micro-
organisms,	 if	 the	 organisms	 multiply,	 within	 the	 tissues,	 at	 a	 rate	 sufficient	 to	 cause	
inflammation	 then	 this	 is	 defined	 as	 infection70.	 These	 infections	 can	 be	 graded	 as	 mild,	
moderate	or	 severe.	The	 International	Working	Group	on	 the	Diabetic	Foot	and	 Infectious	
Diseases	Society	of	America	definitions	are	shown	in	Table	1.5-1.	Samples	taken	from	mildly	
infected	wounds	are	more	likely	to	have	a	single	organism	isolated	whilst	severe	infections	in	
chronic	 wounds	 are	 more	 likely	 to	 be	 polymicrobial70,71.	 Potential	 organisms	 that	 cause	








infections	will	 settle	with	one	 to	 two	weeks	of	oral	 antibiotics.	Whereas	 severe	and	 some	
moderate	 infections	 with	 require	 intravenous	 antibiotics	 with	 an	 appropriate	 oral	 switch	
once	there	has	been	a	satisfactory	response.	 In	cases	of	osteomyelitis	where	the	bone	has	
not	been	resected	at	least	6	weeks	of	treatment	will	be	required15.	
To	 optimise	 the	 chances	 of	 a	 diabetic	 foot	 ulcer	 healing,	 all	 elements	 contributing	 to	 the	
initiation	of	the	ulcer	must	be	tackled.	Glycaemic	control	should	be	tightened,	blood	supply	
enhanced,	infection	treated,	wounds	dressed	and	pressure	areas	offloaded73,74.	For	each	of	
these	 areas	 there	 are	 clinicians	 with	 specialist	 knowledge	 and	 skills,	 e.g.	 diabetologists,	
vascular	 surgeons,	 microbiologists	 and	 podiatrists.	 By	 working	 together	 as	 a	 multi-
disciplinary	 team,	 in	 conjunction	 with	 the	 patient,	 it	 has	 been	 shown	 to	 be	 possible	 to	
improve	 outcomes	 and	 reduce	 rates	 of	 major	 amputation15,73,75.	 Unfortunately	 despite	









Table	 1.5-1:	 International	 Working	 Group	 on	 the	 Diabetic	 Foot	 (IWGDF)	 and	 Infectious	













-	 Other	 causes	 of	 an	 inflammatory	 response	 of	 the	 skin	 should	 be	 excluded	 (e.g.	
trauma,	 gout,	 acute	 Charcot	 neuro-osteoarthropathy,	 fracture,	 thrombosis	 and	
venous	stasis)	
2	(Mild	infection)	 -	 Infection	 involving	 only	 the	 skin	 or	 subcutaneous	 tissue	
(without	 involvement	 of	 deeper	 tissues	 and	 without	
systemic	manifestations	as	described	next)	
-	Any	erythema	present	extends	<2	cm*	around	the	wound	
-	 No	 systemic	 signs	 or	 symptoms	 of	 infection	 (see	 the	
following	discussions)	
3	(Moderate	infection)	 -	 Infection	 involving	 structures	 deeper	 than	 skin	 and	
subcutaneous	tissues	(e.g.	bone,	joint,	tendon	or	muscle)	
or	erythema	extending	≥2	cm*	from	the	wound	margin	
-	 No	 systemic	 signs	 or	 symptoms	 of	 infection	 (see	 the	
following	details)	













Patients	 with	 DM	 have	 been	 found	 to	 have	 higher	 rates	 of	 failed	 revascularisation	
compared	to	patients	without	DM.	This	is	true	of	both	peripheral	bypass	surgery	(PBS)	and	
percutaneous	angioplasty	(PCA).	 In	2008	Söderström	et	al.	performed	infra-inguinal	bypass	
surgery	 on	 150	 limbs	 with	 tissue	 loss.	 Fifty	 percent	 of	 the	 participants	 had	 DM.	 Wound	
healing	had	occurred	in	63%	of	the	patients	with	DM	and	87%	of	patients	without	DM	at	12	
months	 follow-up76.	 Lee	et	 al.	 compared	 the	 restenosis,	 occlusion	 and	 amputation	 rate	 in	
239	(176	with	DM,	63	without)	patients	undergoing	PCA	for	symptomatic	PAD.	They	found	
that	those	with	DM	had	a	higher	rate	of	restenosis	after	2	years	follow-up	(54.4%	vs	31.5%,	
p=0.02)	 and	 a	 trend	 towards	 occlusion	 (38.2%	 vs	 26.3%,	 p=0.21)	 and	 major	 amputation	
(5.1%	vs	1.5%,	p=0.46)77.	The	reasons	for	these	high	failure	rates	are	poorly	understood	and	
the	following	work	aims	to	investigate	this	further.	





death	 or	 not	 attending	 the	 appointment.	 Neuropathy	was	 assessed	 using	 peroneal	 nerve	
conduction	velocity	(NCV)	and	Neuropathy	Symptom	Score	(NSS)	and	microcirculation	using	









NSS,	Neuropathy	Disability	 Score,	 vibration	perception	 threshold	 (VPT)	 and	monofilament.	
Laser	 Doppler	 fluxmetry	 (LDF)	 was	 used	 to	 measure	 hyperaemic	 response	 to	 heat,	
acetylcholine	and	sodium	nitroprusside	and	the	neurovascular	response.	Follow-up	occurred	
at	 4	 to	 6	 weeks.	 Following	 bypass,	 there	 was	 a	 statistically	 significant	 improvement	 in	
cutaneous	vasodilatory	response	that	brought	 the	DI	group	up	to	a	similar	 level	 to	the	DN	
group.	 The	 eight	 patients	 with	 tissue	 loss	 showed	 full	 healing	 in	 four	 patients,	 signs	 of	
healing	in	two	and	healing	digital	amputation	sites	in	the	two	patients	who	required	minor	
amputation.	There	was	no	significant	change	in	the	neurovascular	response.		











Patients	with	DM	have	a	different	distribution	of	 arterial	 disease	 compared	 to	patients	
without	DM	and	this	impacts	the	healing	of	foot	ulcers.	
1.8. AIMS		
This	 research	project	aims	 to	examine	both	 the	macrovascular	and	microvascular	blood	
supply	to	the	leg	and	foot	in	patients	with	DM.	
1.9. STUDY	DESIGN	
Two	 reviews	 of	 the	 literature	 and	 two	 studies	 were	 planned	 to	 address	 this.	 The	 first	
review	gathered	 the	 current	evidence	 regarding	how	 the	distribution	disease	 in	 the	 lower	
limbs	differs	 in	those	with	DM.	This	was	followed	by	a	retrospective	cohort	study	with	the	




between	 diabetic	 foot	 ulcers	 that	 heal	 and	 those	 that	 do	 not.	 The	 research	 project	








Angiography	 is	 the	gold	 standard	 for	 assessing	 the	patency	of	 the	 lower	 limb	arteries81	
and	 various	 methods	 of	 quantifying	 the	 degree	 of	 disease	 in	 each	 arterial	 segment	 have	
been	described.	The	most	commonly	used	scoring	system	is	the	one	described	by	Bollinger	
in	198182-90.	The	system	semi-quantitatively	assesses	ten	arterial	segments	(per	leg)	from	the	
infra-renal	 aorta	 down	 to	 the	 proximal	 3cm	 of	 the	 anterior	 tibial	 artery	 (ATA)	 and	 the	
proximal	5cm	of	the	posterior	tibial	artery	(PTA)	and	peroneal	artery	(PEA)	(Figure	1.10-1).	
Each	segment	 is	scored	individually	using	the	scoring	matrix	shown	in	Table	1.10-1.	One	of	
the	 limitations	of	 the	 scoring	 system	 is	 that	 it	does	not	extend	beyond	 the	proximal	 tibial	
arteries	 which	 means	 the	 arterial	 runoff	 is	 not	 adequately	 assessed.	 Three	 studies	 have	
extended	 the	 Bollinger	 score	 to	 include	 the	 distal	 vessels.	 Willenberg	 et	 al.	 in	 their	
assessment	 of	 progression	of	 disease	 in	 patients	with	 intermittent	 claudication	 imply	 that	
they	are	assessing	the	whole	of	the	tibial	arteries	although	this,	and	the	boundaries	used,	is	
not	 explicitly	 stated.	 They	 found	 a	 higher	 proportion	 of	 disease	 in	 the	 ATA	 and	 PTA	
compared	to	the	PEA	and	that	DM	was	an	independent	predictor	of	progression	of	disease	
at	2-5	years	 follow-up89.	For	 the	Bypass	versus	Angioplasty	 in	Severe	 Ischaemia	of	 the	Leg	
(BASIL)	trial	Bradbury	et	al.	defined	different	arterial	segments	to	those	originally	described	
by	 Bollinger.	 This	 included	 dividing	 the	 popliteal	 artery	 (PA)	 into	 proximal	 and	 distal	






≥9).	 The	 plantar	 arch	 was	 excluded	 from	 this	 assessment	 due	 to	 the	 high	 proportion	 of	
missing	 data.	 They	 found	 that	 in	 approximately	 75%	 of	 patients	 the	 observers	 agreed	 on	
their	Bollinger	score	group	and	in	less	than	1%	of	patients	the	discrepancy	was	greater	than	
one	Bollinger	score	group	91.	When	the	arterial	segments	were	assessed	individually	 in	this	
cohort	 of	 418	 patients	with	 critical	 limb	 ischaemia,	 in	whom	 approximately	 40%	 suffered	
from	DM91,	 they	 found	 the	highest	burden	of	disease	was	 in	 the	distal	 superficial	 femoral	
artery	(SFA)	and	proximal	popliteal	artery.	Below	the	knee	the	PTA	was	most	diseased	with	








A;	 infrarenal	 aorta,	 CIA;	 common	 iliac	 artery,	 IIA;	 internal	 iliac	 artery,	 EIA;	 external	 iliac	
artery,	 PFA;	 profunda	 femoris	 artery,	 SFA;	 superficial	 femoral	 artery,	 PA;	 popliteal	 artery,	




Location	 Occlusion	 Stenosis	>50%	 Stenosis	≤	50%	 Plaques	≤	25%	
Single	 -	 4	 2	 1	
Multiple	≤	half	 13	 5	 3	 2	
Multiple	>	half	 15	 6	 4	 3	
Adapted	from	Bollinger	et	al.	1981.	Each	arterial	segment	will	have	an	additive	score	based	






The	 screening	 tests	 above	 and	 further	 investigative	 tests	 such	 as	 duplex	 ultrasound,	





that	 in	 critical	 ischaemia	maximum	vasodilatation	has	already	been	 reached	 in	 the	 resting	
period92.	 One	 study	 has	 found	 no	 difference	 in	microvascular	 impairment	 between	 those	





it	 that	 provide	 the	 nutritional	 supply	 to	 the	 skin.	 The	 deep	 plexus	 is	 predominantly	
concerned	with	thermo-regulation93.	Light	microscopy	can	be	used	to	assess	the	number	and	
morphology	of	capillaries	 in	 the	superficial	plexus.	Most	commonly	the	nailfold	 is	used.	By	
use	 of	 videophotometric	 capillaroscopy	 it	 is	 possible	 to	 non-invasively	 visualise	 the	 size,	
shape,	 and	 the	 number	 of	 nutritional	 skin	 capillaries,	 in	 addition	 to	 this	 it	 is	 possible	 to	
measure	the	velocity	of	the	blood	in	the	capillaries93-95.	
Capillary	 microscopy	 (CM)	 has	 the	 advantage	 over	 the	 other	 non-invasive	 methods	 of	
being	 the	only	method	 that	assesses	only	 the	nutritional	 vessels.	 It	has	been	shown	 to	be	
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highly	 reproducible	when	performed	by	one	observer	and	when	 the	 findings	are	classified	
using	a	 staging	 system	 it	has	 the	ability	 to	discriminate	between	 the	 severity	of	 ischaemic	
disease93.	However,	the	method	can	be	time-consuming,	and	as	capillary	morphology	varies	
between	the	toes	on	one	foot	in	a	single	patient,	it	is	important	that	there	is	consistency	in	





shifted.	 This	 results	 in	 an	 arbitrary	 unit,	 flux,	 that	 reflects	 the	 concentration	 and	 average	
speed	of	the	cells97,99.	The	laser	penetrates	the	skin	to	approximately	1.5mm	93	and	as	such	
provides	 information	 on	 both	 the	 superficial	 and	 deep	 dermal	 capillary	 beds	 with	 the	
possibility	 of	 also	 detecting	 flow	 in	 small	 arterioles	 and	 arterio-venous	 anastomoses.	 This	
means	unlike	CM	it	does	not	assess	nutritional	blood	flow	only	and	should	be	regarded	as	a	
total	measure	of	blood	 flow	 in	 the	skin	 94,95.	Resting	 flux	of	 the	skin	can	be	measured	and	
provocation	 tests	 like	 post	 occlusive	 reactive	 hyperaemia	 (PORH),	 skin	 perfusion	 pressure	










blood	 pressure,	 epidermal	 thickness,	 capillary	 density,	 inflammation	 and	 oedema	 95	 and	
when	compared	to	LDF	it	has	less	accuracy	110,112.	






















applied	 is	 sufficient	 to	 cause	 the	monofilament	 to	 buckle.	 The	most	 sensitive	 and	 specific	
areas	 to	 test	 are	 the	 plantar	 aspect	 of	 the	 hallux	 and	 the	 bases	 of	 the	 third	 and	 fifth	
metatarsal	 heads120.	 A	 positive	 result	 (patient	 unable	 to	 detect	 the	 monofilament)	 is	 a	
significant	and	independent	predictor	of	foot	ulceration121,122.	
1.11.4. Ipswich	touch	test	
The	 Ipswich	 touch	 test	 (ITT)	 is	 an	 alternative	 to	 monofilament	 testing	 that	 has	 the	













Nerve	 conduction	 studies	 (NCS)	 are	 the	 gold	 standard	 for	 the	 diagnosis	 of	 peripheral	
neuropathy114,126.	 In	the	diagnosis	of	peripheral	neuropathy	of	the	lower	limb	the	peroneal	
and	 sural	 nerves	 are	 commonly	 used.	 This	 provides	 a	 measure	 of	 both	 the	 motor	 and	
sensory	deficit.	Recording	and	stimulating	electrodes	are	placed	at	either	end	of	the	nerve	
and	electrical	 stimulation	 is	 passed	between	 them.	 The	 velocity,	 amplitude	and	 latency	of	






for	 example	 the	 Neuropathy	 Symptom	 and	 Change	 score	 (also	 known	 as	 the	 Number	
Severity	and	Change	score)	(NSC),	McGill	Pain	Questionnaire,	Neuropathy	Impairment	Score	
and	 Lower	 Limb	 Function	 Test	 include	 assessment	 of	 sensory,	 motor	 and	 autonomic	
symptoms	 and	 include	 an	 element	 of	 examination130.	 Due	 to	 this	 they	 are	 lengthy	
questionnaires	 and	 time	 consuming	 to	 administer,	 such	 as	 the	 NSC	 which	 has	 38	
questions131.	 The	 NSS	 has	 been	 extensively	 used	 in	 clinical	 trials	 and	 has	 been	 found	 to	
correlate	well	with	NCS	and	have	reasonable	sensitivity132,133	but	like	those	above	is	lengthy	
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and	was	not	 explicitly	 developed	 for	 evaluating	 changes	 in	neuropathy	after	 treatment130.	
The	Neuropathy	Total	Symptom	Score	–	6	(NTSS-6)	overcomes	some	of	these	shortcomings.	
It	 consists	 of	 six	 questions	 focusing	 solely	 on	 sensory	 symptoms	 in	 the	 lower	 limbs.	 The	
patient	 is	 asked	 to	 consider	 the	 frequency	 and	 intensity	 of	 the	 symptoms	 they	 have	
experienced	 over	 the	 last	 twenty-four	 hours.	 The	maximum	 score	 is	 21.96	 and	 a	 score	 of	





Full-thickness	 punch	 biopsy	 of	 the	 skin	 allows	 for	 staining	 with	 protein	 gene	 product	
(PGP)	 9.5	 and	 subsequent	 immunofluorescence.	 PGP	 9.5	 is	 a	 pan-axonal	 and	 pan-
neuroendocrine	marker	and	means	the	density	of	nerve	fibres	per	millimetre	squared	can	be	
measured137.	 A	 reduction	 in	 intra-epidermal	 nerve	 fibre	density	 (IENFD)	 is	 associated	with	
severity	 of	 diabetic	 neuropathy138,139.	 It	 has	 also	 been	 shown	 to	 be	 possible	 to	 observe	
axonal	regeneration	over	a	period	of	months	using	this	method140.	As	such	IENFD	represents	

















factor	 for	 PAD3,16.	 Patients	 with	 DM	 have	 a	 predisposition	 towards	 a	 higher	 burden	 of	
atherosclerotic	 disease	 below	 the	 knee	 compared	 to	 patients	 without	 DM	 (NDM).	 This	 is	
considered	 to	 have	 an	 impact	 on	 both	 the	 treatment	 options	 available	 and	 prognosis	
following	revascularisation	in	patients	with	DM147,148.	
This	hypothesis	of	a	higher	burden	of	disease	in	the	tibial	arteries	is	widely	accepted	on	







vascular	 disease”,	 ‘distribution	 of	 disease”,	 “angiography”,	 “computed	 tomography	
angiography”	and	“magnetic	resonance	angiography”.	Synonyms	and	various	combinations	
were	used	in	the	search	strategy	which	involved	both	Medical	Subject	Headings	(MESH)	and	
keyword	 searches.	 Embase	 and	 MEDLINE	 databases	 were	 searched	 including	 papers	
published	 from	1946	 to	present	day	and	 in-process	 citations	 (Search	 terms	 in	Appendix	 I).	
References	from	relevant	studies	were	also	scrutinised	for	potential	studies.	
Papers	were	 included	 if	 arterial	 imaging	of	 the	 lower	 limb	was	undertaken	using	digital	
subtraction	 angiography	 (DSA),	 Computed	 Tomography	 Angiography	 (CTA),	 or	 Magnetic	
Resonance	 Angiography	 (MRA).	 They	were	 excluded	 if	 the	 indication	 for	 imaging	was	 not	
PAD,	if	there	was	no	separation	of	patients	with	and	without	DM	or	only	patients	with	DM	
were	included.	The	final	requirement	was	an	anatomical	description	of	the	arteries	affected	
by	 atherosclerotic	 disease.	 This	 description	 could	 be	 given	 using	 a	 scoring	 system	 or	
proportions	of	arterial	segments	affected.	
2.2.1. Statistical	analysis	
For	 papers	 that	 included	 proportions	 of	 patients	 with	 PAD	 by	 arterial	 segment	 the	
number	of	patients	who	had	disease	in	each	arterial	segment	was	extracted	by	one	author	
(DL).	 These	 papers	 were	 included	 in	 a	 forest	 plot	 that	 was	 produced	 using	 Revman	 5.3	






titles,	 abstracts,	 full	 text	 and	 references	 14	 studies	 were	 included	 in	 the	 review	 (Figure	
2.3-1).	The	papers	dated	from	1964	to	2009	and	were	all	cross-sectional	studies	apart	from	
one	 cohort	 study90	 and	 two	 case-control	 studies149,150	 (Table	 2.3-1	 and	 Table	 2.3.2).	 The	
majority	 of	 papers	 did	 not	 state	 if	 their	 analysis	 was	 by	 patient	 or	 by	 limb,	 in	 most,	 it	
appeared	that	a	single	treated	 limb	was	 included	per	patient90,150-155.	Four	papers	 included	
all	treated	limbs156-159,	one	paper	 included	both	 legs	for	all	patients149,	one	paper	analysed	
by	lesion160	and	one	paper	only	used	the	data	from	the	left	leg	if	there	was	bilateral	imaging	
as	 they	 found	 the	 legs	 to	 be	 comparable83.	 How	 risk	 factors	 for	 PAD	were	 treated	 varied	
between	papers.	 Four	papers	performed	 some	 form	of	multivariate	analysis	 to	 stratify	 for	
risk	factors149,155,159,160,	the	majority	of	remaining	papers	reported	proportions	of	risk	factors	
and	 comparability	 between	 groups	 however	 two	 papers	 made	 no	 mention	 of	 risk	







All	 the	 studies	 used	 angiography	 to	 visualise	 the	 arterial	 tree	 and	 in	 total	 15	 different	
arterial	 segments	were	described	 (Table	2.3-1	 and	Table	2.3.2).	 The	most	 commonly	used	
segments	 that	 differentiated	 between	 proximal	 and	 distal	 disease	 were	 aorto-iliac	 (A-I),	
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femoro-popliteal	 (F-P),	 and	 tibial.	 Seven	 studies	 also	 included	a	 category	 that	 represented	
disease	 at	 multiple	 levels.	 These	 segments	 were	 included	 in	 the	 forest	 plot	 along	 with	
smaller	 segments	 that	 fitted	 in	 the	 same	 group.	 I.e.	 patients	with	 disease	 in	 the	 popliteal	
artery	could	be	included	in	the	F-P	group	but	those	in	a	popliteal/tibial	group	could	not	be	
included.	The	description	of	what	constituted	significant	disease	varied	between	papers.	Of	











Author	 Year	 Country	 Study	design	 Patients	 Groups	 Method	of	describing	pattern	



























Kroger	K153	 2000	 Germany	 Cross-sectional	study	 Patients	with	PAD	
DM=46	
NDM=86	 A-I,	F-P,	tib,	ML	































Author	 Year	 Country	 Study	design	 Patients	 Groups	 Method	of	describing	pattern	
Menzoian	JO159	 1989	 USA	 Cross-sectional	study	 Patients	with	PAD	
DM=115		
NDM=119	 ATA,	PTA,	PEA,	Plant	



































DM	 NDM	 DM	 NDM	 DM	 NDM	
De	Bakey	ME151,a	 16-37b	 4/2	 25/16	 2/4	 29/12	
Haimovici	H156	 -	 -	 -	 -	 -	 -	
Ciavarella	A157	 65	±	9	 64	±	10	 62/27	 44/17	 45/44	 52/9	
Hansen	ME152,a	 43.4	±	5.8	 29/30	 45/14	
Kroger	K153	 61	±	13	 85/47	 -	 -	
Haltmayer	M149	 66.4	(57.9-74.4)c	 63.9	(59.5-68.7)c	 80/26	 32/21	 48/58	 7/45	
Lazaris	AM158	 78.5	(42-92b)	 53/46	 21/19	 47/25	
Rueda	CA154	 66	±	12	 302/148	 -	 -	
Diehm	N160	 70	±	11	 1583/1076	 1144/1515	
Ozkan	U155	 62	±	11	 538/88	 494/132	
Menzoian	JO159	 67	±	1.2/69.8	±	1.6d	 64	±	1/75.4	±	1.3d	 -	 -	 73/42	 98/21	
Jude	EB83	 63.83	±	10.4	 65.3	±	11.11	 34/24	 47/31	 47/11	 60/18	
van	der	Feen	C150	 65.5	±	13.6	 65.7	±	12.7	 20/17	 20/17	 12/25	 12/25	









The	 resulting	 forest	 plot	 (Figure	 2.3-2)	 demonstrates	 that	 those	 with	 DM	 were	
significantly	less	likely	to	have	disease	in	the	aorto-iliac	segment	(OR	0.25	(0.15-0.42),	n=DM	
466/NDM	458)	and	significantly	more	 likely	 to	have	disease	 in	 the	tibial	 segment	 (OR	1.94	
(1.27-2.96),	n=DM	306/NDM	417).	In	the	DM	group,	there	is	a	trend	towards	relative	sparing	
in	the	femoro-popliteal	segment	but	this	does	not	reach	significance	(0.66	(0.33-1.31),	n=DM	
568/NDM	 585).	 There	 is	 also	 a	 suggestion	 that	 those	 with	 DM	were	more	 likely	 to	 have	
multilevel	disease,	again	this	does	not	reach	significance	(1.26	(0.93-1.70),	n=DM	549/NDM	
557).		
The	 two	 papers	 not	 included	 in	 the	meta-analysis	 showed	 a	 similar	 pattern.	 Diehm	 et	
al.160,	 in	 a	 retrospective	 cohort	 that	 examined	 the	 risk	 factors	 for	 distribution	 pattern	 of	
lower	limb	atherosclerosis	in	2659	patients	(891	with	DM),	on	multivariate	logistic	regression	
found	 that	 DM	 had	 a	 relative	 risk	 ratio	 of	 0.59	 (0.49-0.72,	 p<0.001)	 for	 iliac	 disease	
compared	to	1.68	(1.47-1.92,	p<0.001)	for	tibial	disease.	Ozkan	et	al.155	performed	a	similar	
analysis	 in	 626	 patients	 with	 symptomatic	 PAD	 261	 of	 whom	 had	 DM.	 They	 found,	 on	
univariate	 analysis,	 the	 presence	 of	 DM	was	 related	 to	 odds	 ratios	 of	 0.56	 (p=0.001)	 for	









Four	 papers	 reported	 scores	 by	 arterial	 segment83,90,150,159.	 Three	 of	 these	 used	 the	
Bollinger	score82	and	one159	a	score	described	by	LaMorte	et	al.	in	1985161.	Briefly,	Bollinger’s	
score	 is	 a	 semi-quantitative	 score	 that	 considers	 each	 arterial	 segment	 separately.	 Each	
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applying	 this	 score	 to	 227	 patients	 with	 PAD,	Menzoian	 et	 al.	 demonstrated	 significantly	
lower	scores	(i.e.	more	disease)	in	the	posterior	tibial	artery	(PTA)	(0.51	vs	1.02,	p<0.05)	and	




segments	 originally	 described	 by	 Bollinger	 (ten	 arterial	 segments	 (per	 leg)	 from	 the	 infra-
renal	aorta	down	 to	 the	proximal	3cm	of	 the	anterior	 tibial	artery	 (ATA)	and	 the	proximal	
5cm	of	the	PTA	and	PEA82)	and	reported	the	median	score	for	each	segment.	In	136	patients	
they	 found	 those	 in	 the	DM	group	 (n=58)	had	a	 significantly	higher	 score	 in	 the	profunda	
femoris	(mean	score	3	(Inter-quartile	range	(IQR)	0-5)	vs	0	(0-2)),	popliteal	(7	(3-10)	vs	3	(0-
4)),	ATA	(13	(4-15)	vs	3	(0-4)),	PTA	(15	(0-15)	vs	4	(0-14))	and	PEA	(5	(0-5)	vs	0	(0-6))83.	Van	
der	 Feen	 et	 al.	 also	 used	 the	 original	 description	 of	 the	 segments	 but	 did	 not	 report	 the	
individual	scores	for	each	segment.	 Instead,	the	scores	were	combined	to	form	the	"upper	
leg"	(aorta,	iliacs,	profunda	femoris	and	superficial	femoral	artery)	and	"lower	leg"	(popliteal,	




were	not	 reported,	 the	 included	bar	graphs	 show	that	 the	only	 segment	with	a	 significant	
difference	 was	 the	 PEA	 in	 the	 right	 legs	 (p<0.05),	 those	 in	 the	 DM	 group	 had	 a	 higher	
score150.	Diehm	et	al.	only	scored	the	below	the	knee	segments	including	the	plantar	vessels	
and	so	extended	Bollinger's	original	description.	Their	patient	groups	were	patients	with	DM	
(n=25),	 patients	 with	 renal	 insufficiency	 (n=15),	 patients	 with	 both	 DM	 and	 renal	
insufficiency	 (n=25)	and	25	controls	with	neither	DM	or	 renal	 insufficiency.	They	 found	no	










There	was	 a	 trend	 towards	multi-level	 disease	 being	more	 common	 in	 patients	with	 DM.	
Four	 papers	 assessed	 the	 severity	 of	 disease	 in	 individual	 vessels	 rather	 than	
segments83,90,159	although	only	Jude	et	al.	did	for	both	above	and	below	knee	vessels	83.	 In	
	43	




the	 PEA	 has	 also	 been	 demonstrated	 to	 be	 less	 critical	 in	 preventing	 amputation163.	 The	
angiosome	model	holds	that	the	areas	supplied	by	the	PEA	are	the	anterior	and	lateral	ankle	
and	 plantar	 heel164.	 However	 increasingly	 the	 PEA	 has	 been	 shown	 to	 have	 multiple	
collaterals	and	to	commonly	supply	the	pedal	arteries	and	as	such	has	comparable	outcomes	
for	 both	 surgical	 and	 endovascular	 revascularisation	 compared	 to	 other	 distal	 target	
vessels165-168.	 Only	 three	 papers	 included	 in	 the	 review	 considered	 pedal	 vessels90,157,159.	
Ciavarella	et	al	found	that	a	higher	proportion	of	patients	with	DM	had	complete	obstruction	
of	the	plantar	vessels	(53%	vs	29%	p<0.001).	There	was	however	no	significant	difference	in	
the	 rate	 of	 occlusions	 in	 the	 dorsalis	 pedis	 artery	 (43%	 vs	 40%)157.	 Diehm	et	 al,	 using	 the	
Bollinger	score	found	that	both	DM	and	renal	failure	were	associated	with	more	disease	in	
the	pedal	vessels	when	compared	to	the	calf	vessels.	However,	when	patency	of	at	least	one	









related	 to	 outcomes	 following	 revascularisation	 procedures	 in	 patients	 both	 with	 and	
without	 DM84.	 The	 pathophysiology	 behind	 why	 patients	 with	 DM	 have	 increased	 PAD	 is	
complex	but	thought	to	be	related	to	a	combination	of	down-regulation	of	nitric	oxide	and	
prostacyclin,	 upregulation	 of	 vasoconstrictors,	 apoptosis	 of	 endothelial	 cells,	 activated	
coagulation,	 abnormal	 platelet	 activation	 and	 propensity	 towards	 plaque	 rupture	 (Section	
1.3	 for	 more	 detail)175.	 There	 is	 not	 any	 clear	 evidence	 why	 the	 distal	 vessels	 are	
predominantly	 affected	 and	while	 these	 results	 support	 the	 hypothesis	 that	 patients	with	
DM	 have	 a	more	 significant	 disease	 burden	 below	 the	 knee	 they	 provide	 us	with	 limited	
information	on	the	degree	to	which	individual	vessels	or	areas	of	vessels	are	affected.	
A	 strength	 of	 the	 review	 is	 that	 all	 the	 papers	 used	DSA	 as	 the	 imaging	modality.	 DSA	
remains	 the	 gold	 standard	 for	 imaging	 of	 the	 lower	 limbs	 and	 describing	 the	 anatomic	
distribution	of	stenotic	disease176.	The	literature	search	did	include	CTA	and	MRA	as	imaging	
modalities	 but	 no	 papers	 that	 used	 these	 modalities	 and	 met	 the	 inclusion	 criteria	 were	
found.	These	modalities	could	be	used	to	assess	distribution	of	disease	keeping	in	mind	their	
limitations	 compared	 to	 DSA81,176,	 however	 the	 studies	 have	 not	 been	 done.	 In	 terms	 of	
scoring	 systems	 very	 few	 papers	 have	 described	 systems	 that	 employ	 imaging	modalities	
other	than	DSA	and	those	that	have,	have	not	been	validated177-179.	In	the	forest	plot,	there	
was	 low	 heterogeneity	 between	 the	 papers	 apart	 from	 those	 considering	 the	 femoro-
popliteal	 segment	 (I2=68%).	 A	 significant	weakness	 of	 the	 review	 is	 the	 low	quality	 of	 the	
papers	included.	They	are	all	observational	studies,	predominantly	retrospective	and	so	the	
body	 of	 evidence	 is	 low	 to	 very	 low	 quality180.	 An	 attempt	 to	 assess	 the	 methodological	
quality	of	the	papers	using	the	Newcastle-Ottawa	scale181	was	made.	However,	all	but	three	
papers	 were	 cross-sectional	 studies	 making	 it	 not	 possible	 to	 apply	 the	 scale.	 There	 was	
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consistency	 in	 the	 type	of	patients	 selected	with	 the	majority	of	papers	 including	patients	
with	Fontaine	II	to	IV	disease.	However,	one	paper	only	included	patients	with	intermittent	
claudication155,	 two	 papers	 excluded	 those	 with	 intermittent	 claudication154,158	 and	 three	
papers	did	not	define	the	patient	group	beyond	symptomatic	PAD152,156,157.	As	described	in	
the	 results	 section	 there	was	 also	 variance	 in	 how	 significant	 disease	was	defined.	Within	
each	 paper	 the	 demographics	 for	 each	 group,	 when	 reported,	 were	 comparable	 (Table	
2.3-3).		
Additional	weaknesses	 include	that	the	papers	are	all	 relatively	historical	 (earliest	1964,	
latest	2009)	and	the	variety	in	how	the	arterial	segments	were	described	and	grouped.	This	
grouping	meant	 some	data	was	 not	 able	 to	 be	 included	 in	 the	meta-analysis	 because	 the	




was	 published	 in	 the	 late	 nineties59,182.	 When	 studies	 from	 before	 the	 year	 2000	 were	
excluded	from	the	meta-analysis,	the	trends	remained	the	same	although	the	odds	ratio	for	
tibial	disease	was	no	longer	significant	(OR	1.99	(0.94-4.24)).	Between	1964	and	2019	there	
have	 been	 considerable	 improvements	 in	 imaging	 technologies183.	 DSA	 remains	 the	 gold	
standard	for	research	but	in	clinical	practice	duplex	ultrasound,	CTA	and	MRA	are	advised	as	







Patients	 with	 DM	 are	 more	 likely	 to	 have	 atherosclerotic	 disease	 in	 the	 tibial	 vessels	
compared	 to	 patients	 without.	 The	 current	 published	 evidence	 supports	 this	 hypothesis.	
















Queen	 Elizabeth	 Hospital	 Birmingham	 were	 identified	 from	 the	 prospective	 radiology	
database.	From	this	cohort,	all	the	patients	with	DM	were	identified.	Each	of	these	patients	
was	age	and	sex-matched	with	a	patient	without	DM	(NDM)	who	underwent	an	angiogram	
in	 the	 same	 period.	 The	 cohort	 for	 the	 pilot	 study	 consisted	 of	 216	 patients	 randomly	
selected	 from	all	matched	patients	 combined,	 due	 to	 this	 there	were	 uneven	numbers	 of	
patients	between	the	two	study	cohorts.		
The	 first	 angiogram	 performed	 within	 the	 study	 period	 with	 images	 saved	 on	 the	
hospitals	 imaging	 system	 (IMPAX)	 was	 assessed.	 Each	 arterial	 segment,	 as	 described	 by	
Bollinger,	was	scored	for	all	arteries	imaged	from	the	infra-renal	aorta	down	to	the	proximal	
	48	
anterior	 tibial	 (ATA),	 posterior	 tibial	 (PTA)	 and	peroneal	 arteries	 (PEA).	 A	 limitation	of	 the	
Bollinger	score,	as	 it	was	originally	described82,	 is	that	the	described	segments	only	extend	




PTA	and	PEA	divided	 into	 thirds	and	 the	dorsalis	pedis,	medial	 and	 lateral	plantar	arteries	
(LPA)	(Figure	3.3-1).	The	decision	to	divide	the	vessels	into	thirds	was	based	on	advice	from	




Parametric	 data	 (age)	 is	 reported	 as	mean	 (±	 standard	 deviation	 (SD))	 and	 the	 groups	
compared	 using	 unpaired	 T-test.	 Non-parametric	 data	 (Bollinger	 score)	 is	 reported	 as	
median	 (inter-quartile	 range)	 and	 the	 groups	 compared	 using	 Mann-Whitney	 U	 test.	
Categorical	 data	 (ethnic	 group,	 smoking	 status,	 hypertension,	 hypercholesterolaemia	 and	







Figure	 3.3-1:	 Schematic	 representation	 of	 arterial	 segments	 described	 by	 Bollinger	
compared	to	the	arterial	segments	examined	in	the	pilot	study.		
A;	 infrarenal	 aorta,	 CIA;	 common	 iliac	 artery,	 IIA;	 internal	 iliac	 artery,	 EIA;	 external	 iliac	
artery,	 PFA;	 profunda	 femoris	 artery,	 SFA;	 superficial	 femoral	 artery,	 PA;	 popliteal	 artery,	
ATA;	proximal	3cm	of	anterior	tibial	artery,	ATA1;	proximal	3rd	of	anterior	tibial	artery,	ATA2	









DM	group	was	 70	 years	 (SD	 ±11)	 and	NDM	group	 69	 years	 (SD±13,	 p=0.51).	 Seventy-four	
percent	of	NDM	patients	and	71%	of	DM	were	males	 (p=0.65).	Significantly	more	patients	
without	DM	had	bilateral	angiograms	than	patients	with	DM	(26.8%	vs	9.2%,	p	<0.01).	Due	
to	 this	 difference	 and	 the	 potential	 to	 skew	 the	 data	 the	 decision,	 in	 consultation	 with	
statisticians,	was	made	to	only	report	and	include	in	the	analysis	the	results	for	the	left	leg	in	
those	 who	 had	 bilateral	 imaging.	 In	 the	 diabetes	 group,	 there	 were	 significantly	 higher	
proportions	 of	 patients	 in	 the	Asian	 and	 Black	 ethnic	 groups	 and	 also	more	 patients	with	
























Mean	age	(SD)*	 69	(12.8)	 70	(11.20)	 0.51	
	 	 	 	
Sex**	 Male	 74.2	(72)	 70.6	(84)	
0.65	
Female	 25.8	(25)	 29.4	(35)	
	 	 	 	 	





	 	 	 	 	





	 	 	 	 	
Hypertension**	 Yes	 48.5	(47)	 73.9	(88)	
<0.05	No	 40.2	(39)	 17.6	(21)	
Unknown	 11.3	(11)	 8.4	(10)	
	 	 	 	 	
Hypercholesterolaemia**	 Yes	 40.2	(39)	 38.7	(46)	
0.51	No	 29.9	(29)	 24.4	(29)	
Unknown	 29.9	(29)	 37.0	(44)	
	 	 	 	 	











The	 external	 iliac	 artery	was	 the	 only	 artery	 to	 have	 a	 significantly	 higher	 score	 in	 the	
NDM	group	(3	(Inter-quartile	range	(IQR)	0-7))	than	the	DM	group	(2	(IQR	0-3)	p<0.05).	The	
DM	group	had	significantly	higher	scores	 in	all	 segments	of	 the	PTA.	The	proximal,	middle	










Aorta	 3	(1-3)	 3	(3-3)	 0.497	
Common	iliac	 3	(2-7)	 3	(1-3)	 0.192	
Internal	iliac	 3	(0-7)	 3	(0-7)	 0.994	
External	iliac	 3	(0-7)	 2	(0-3)	 <0.05	
Superficial	femoral	 8	(3-13)	 7	(3-13)	 0.411	
Profunda	femoris	 0	(0-3)	 0	(0-3)	 0.889	
Popliteal	 5	(2-13)	 6	(3-10)	 0.369	
Anterior	tibial	(proximal	3cm)	 2	(0-8)	 3	(0-7)	 0.182	
Anterior	tibial	(proximal	3rd)†	 3	(0-13)	 5	(2-13)	 0.109	
Anterior	tibial	(middle	3rd)†	 3	(0-13)	 4	(0-15)	 0.112	
Anterior	tibial	(distal	3rd)†	 3	(0-15)	 7	(0-15)	 0.417	
Dorsalis	pedis†	 13	(0-15)	 13	(0-15)	 0.573	
Peroneal	(proximal	5cm)	 3	(0-7)	 3	(0-10)	 0.386	
Peroneal	(proximal	3rd)†	 3	(0-7)	 3	(0-13)	 0.246	
Peroneal	(middle	3rd)†	 3	(0-7)	 3	(0-13)	 0.675	
Peroneal	(distal	3rd)†	 3	(0-13)	 3	(0-15)	 0.992	
Posterior	tibial	(proximal	5cm)	 3	(0-13)	 6	(0-15)	 <0.05	
Posterior	tibial	(proximal	3rd)†	 3	(0-13)	 8	(2-15)	 <0.05	
Posterior	tibial	(middle	3rd)†	 3	(0-15)	 10	(0-15)	 <0.05	
Posterior	tibial	(distal	3rd)†	 3	(0-15)	 13	(0-15)	 <0.05	
Medial	plantar†	 15	(0-15)	 15	(0-15)	 0.463	




There	 was	 a	 high	 proportion	 of	missing	 data	 throughout	 the	 dataset	 used	 in	 the	 pilot	
study	(Table	3.4-3).	This	was	due	to	absent	or	incomplete	imaging	of	arterial	segments	with	
eighteen	patients	having	only	data	for	the	supra-inguinal	vessels.	The	proportion	of	missing	
data	points	 ranges	 from	15.5%	 (popliteal	 and	ATA)	 to	 75.3%	 (aorta)	 in	 the	DM	group	and	












Missing	 %	 Missing	 %	
Aorta	 107	 89.9	 73	 75.3	 14.66	
Common	iliac	 97	 81.5	 60	 61.9	 19.66	
Internal	iliac	 96	 80.7	 60	 61.9	 18.82	
External	iliac	 95	 79.8	 60	 61.9	 17.98	
Superficial	femoral	 5	 4.2	 16	 16.5	 17.98	
Profunda	femoris	 15	 12.6	 20	 20.6	 12.29	
Popliteal	 4	 3.4	 15	 15.5	 8.01	
Anterior	tibial	 4	 3.4	 15	 15.5	 12.10	
Anterior	tibial	1	 4	 3.4	 17	 17.5	 12.10	
Anterior	tibial	2	 5	 4.2	 19	 19.6	 14.16	
Anterior	tibial	3	 6	 5.0	 22	 22.7	 15.39	
Dorsalis	pedis	 16	 13.4	 29	 29.9	 17.64	
Peroneal	 4	 3.4	 16	 16.5	 16.45	
Peroneal	1	 4	 3.4	 17	 17.5	 13.13	
Peroneal	2	 5	 4.2	 19	 19.6	 14.16	
Peroneal	3	 6	 5.0	 22	 22.7	 15.39	
Posterior	tibial	 4	 3.4	 16	 16.5	 17.64	
Posterior	tibial	1	 4	 3.4	 17	 17.5	 13.13	
Posterior	tibial	2	 5	 4.2	 19	 19.6	 14.16	
Posterior	tibial	3	 6	 5.0	 22	 22.7	 15.39	
Medial	plantar	 21	 17.6	 34	 35.1	 17.64	




Five	clinicians,	with	experience	of	reading	 lower	 limb	angiograms,	 independently	scored	
twenty-five	randomly	selected	angiograms	from	the	dataset.	The	scorers	included	the	author	
of	 this	 project,	 a	 vascular	 surgery	 consultant,	 a	 radiology	 senior	 trainee	 and	 two	 surgical	
research	 registrars	 with	 vascular	 backgrounds.	 Intra-class	 correlation	 (ICC)	 and	 Cohen’s	
kappa	coefficient	were	calculated	to	assess	the	level	of	agreement.	ICC	was	also	calculated	




arterial	 segment	 separately	 and	 all	 segments	 combined.	 There	 was	 no	 pattern	 that	
demonstrated	any	significant	disagreement	by	arterial	segment	between	scorers	and	so	only	
the	combined	data	is	presented	here.	Examination	of	the	Bland-Altman	plots	(Figure	3.4-1)	





















1	vs	2	(427)	 -1.76	(4.44)	 <0.001	 6.95	 -10.47	
1	vs	3	(421)	 -0.40	(5.04)	 0.105	 9.49	 -10.29	
1	vs	4	(446)	 -0.45	(4.55)	 0.037	 8.46	 -9.37	
1	vs	5	(442)	 -0.74	(4.25)	 <0.001	 7.58	 -9.07	
2	vs	3	(405)	 1.45	(4.10	 <0.001	 9.49	 -6.58	
2	vs	4	(424)	 1.38	(3.85)	 <0.001	 8.93	 -6.16	
2	vs	5	(425)	 1.04	(3.24)	 <0.001	 7.38	 -5.31	
3	vs	4	(420)	 -0.13	(4.00)	 0.519	 7.72	 -7.97	
3	vs	5	(418)	 -0.46	(3.74)	 0.013	 6.88	 -7.80	


















The	 Bollinger	 scores	 were	 categorised	 as	 1=<3,	 2=3-5,	 3=6-8,	 4=≥9.	 The	 kappa	 values	















Sixty-six	 patients	were	 scored	by	 Scorer	 1	 as	 part	 of	 both	 the	pilot	 study	 and	matched	
cohorts,	 twenty	 patients	without	DM	and	 46	with	DM.	 This	 represents	 30.5%	of	 the	 pilot	
cohort	and	21.5%	of	the	matched	cohorts.	Due	to	the	difference	in	how	the	popliteal	artery	




The	Bland-Altman	plot	was	 similar	 to	 those	obtained	 in	 the	 inter-observer	analysis,	 the	














noted	 that	 the	 popliteal	 segment	 as	 described	 by	 Bollinger	 (from	 the	 distal	 end	 of	 the	
adductor	 canal	 until	 bifurcation	 into	 PTA	 and	 PEA)	 regularly	 had	 a	 different	 pattern	 of	
disease	in	the	TPT,	i.e.	distal	to	the	ATA	branch,	compared	to	rest	of	the	segment.	There	was	
a	high	proportion	of	missing	data	on	 individual	arterial	 segments	particularly	 in	 the	aorto-
iliac	segments,	and	this	proportion	seemed	to	be	higher	in	the	DM	group.	
The	inter-rater	reliability	results	were	mixed	and	in	particular	there	was	poorer	reliability	
































middle	3rd	of	 anterior	 tibial	 artery,	ATA3;	distal	3rd	of	 anterior	 tibial	 artery,	DPA;	dorsalis	
pedis	artery,	PEA;	peroneal	artery,	PEA1;	proximal	3rd	of	peroneal	artery,	PEA2;	middle	3rd	
of	 peroneal	 artery,	 PEA3	 distal	 3rd	 of	 peroneal	 artery,	 PTA;	 posterior	 tibial	 artery,	 PTA1;	















signed	 rank	 test.	 Categorical	 data	were	 compared	using	 Fisher’s	 exact	 test	 or	 Chi-squared	
test.	
The	Bollinger	score	runs	from	zero	to	15.	It	is	only	possible	to	score	integers,	and	it	is	not	
possible	 to	 score	 eleven	 or	 twelve,	 as	 such	 the	 scores	 are	 non-parametric	 data	 and	were	













Shapiro-Wilk	 statistic	 was	 0.993	 (p=0.141)	 meaning	 the	 null	 hypothesis	 that	 the	 data	 is	
normally	distributed	was	accepted.	The	corresponding	statistic	 for	 length	of	 follow-up	was	
0.973	(P<0.001)	meaning	the	null	hypothesis	was	rejected.	The	Q-Q	plots	demonstrated	for	
age	 at	 intervention	 a	 very	 close	 relationship	 between	 the	 observed	 and	 expected	 values	











above	 (Section	 3.5),	 155	 per	 cohort.	 During	 the	 process	 of	 collecting	 the	 data	 for	 the	
Bollinger	score	in	the	DM	cohort,	two	duplicate	entries	were	identified.	This	necessitated	the	
removal	 of	 the	matching	 pairs	 from	 the	NDM	group	 and	 reduced	 the	 cohort	 sizes	 to	 153	
patients.	Eight	other	patients	were	manually	 replaced	with	 the	next	nearest	match	due	 to	
the	 following	 reasons.	 Five	 patients	 had	 iliac	 images	 only	 saved,	 two	 patients	 underwent	
their	angiogram	to	plan	for	plastic	surgery	rather	than	for	peripheral	arterial	disease	(PAD),	
and	one	patient’s	angiogram	failed	with	no	images	stored.		






















Mean	age	(SD)*	 	 70.3	(9.4)	 70.3	(9.2)	 0.937	
Median	LoF	(IQR)**	 	 2.3	(1.24-3.34)	 2.4	(1.38-3.78)	 0.292	
Sex‡	 Male	 72.5	 71.9	 1.00	
	 Female	 27.5	 28.1	 	
Ethnic	group‡	 White	 97.4	 97.4	 1.00	
	 Asian	 1.3	 1.3	 	
	 Black	 1.3	 1.3	 	
Smoking‡	 Never	smoked	 11.1	 11.1	 1.00	
	 Ex-smoker	 67.3	 68.0	 	
	 Still	smoking	 21.6	 20.9	 	
Hypertension‡	 Yes	 16.3	 16.3	 1.00	
	 No	 83.7	 83.7	 	
Hypercholesterolaemia‡	 Yes	 38.6	 39.2	 1.00	
	 No	 61.4	 60.8	 	
Renal	function‡	 Normal	 96.7	 96.7	 1.00	
	 Renal	Failure	 3.3	 3.3	 	
Indication‡	 Asymptomatic	 7.8	 7.2	 <0.001	
	 Claudication	 60.1	 37.9	 	
	 Critical	ischaemia	 32.0	 54.9	 	
Timing	of	procedure‡	 Elective	 89.5	 70.6	 <0.001	
	 Emergency	 10.5	 29.4	 	
*Paired	 T-test,	 **Wilcoxon	 signed	 rank	 test,	 ‡Chi-squared	 test,	 LoF:	 Length	 of	 Follow-up,	
SD=standard	deviation	
3.8.2. Bollinger	score	results	















Superficial	femoral		 15	(12-15)	 15	(13-15)	 0.880	
Profunda	femoris		 2	(0-2)	 0	(0-2)	 0.606	
Popliteal		 10	(3-14)	 13	(4-13)	 0.674	
TP	Trunk		 3	(0-4)	 3	(0-7)	 0.740	
Anterior	tibial		 13	(2-15)	 3	(0-15)	 0.652	
Peroneal		 0	(0-3)	 0	(0-13)	 0.847	
Posterior	tibial		 2	(0-15)	 15	(3-15)	 0.116	
Dorsalis	pedis		 14	(2-15)	 0	(0-13)	 0.161	
Lateral	plantar	 0	(0-15)	 15	(1-15)	 0.397	












Superficial	femoral		 9	(6-13)	 8	(6-13)	 0.871	
Profunda	femoris		 0	(0-0)	 0	(0-0)	 0.225	
Popliteal		 3	(0-13)	 3	(0-5)	 0.339	
TP	Trunk		 0	(0-2)	 0	(0-3)	 0.763	
Anterior	tibial		 0	(0-15)	 13	(2-15)	 0.121	
Peroneal		 2	(0-13)	 2	(0-13)	 0.745	
Posterior	tibial		 0	(0-13)	 0	(0-13)	 0.516	
Dorsalis	pedis		 4	(0-15)	 15	(0-15)	 0.125	
Lateral	plantar	 15	(0-15)	 13	(0-15)	 0.092	













Superficial	femoral		 7	(4-13)	 7	(3-13)	 0.653	
Profunda	femoris		 0	(0-2)	 0	(0-3)	 0.505	
Popliteal		 3	(3-9)	 5	(3-9)	 0.526	
TP	Trunk		 3	(0-8)	 3	(0-7)	 0.795	
Anterior	tibial		 13	(1-15)	 13	(3-15)	 0.377	
Peroneal		 4	(0-13)	 3	(1-15)	 0.621	
Posterior	tibial		 13	(4-15)	 15	(2-15)	 0.404	
Dorsalis	pedis		 4	(0-15)	 13	(0-15)	 0.643	
Lateral	plantar	 15	(15-15)	 15	(0-15)	 0.015	
Medial	plantar		 15	(4-15)	 13	(0-15)	 0.006	
*Mann-Whitney	U	Test	
	
When	 the	 crural	 vessels	 were	 divided	 into	 thirds	 there	 was	 no	 significant	 difference	
between	 the	 groups	 with	 the	 exception	 of	 the	 distal	 segment	 of	 the	 PTA	 in	 the	
asymptomatic	group	(NDM,	n=11,	0	(0-13)	vs	DM,	n=11,	13	(3-15),	p=0.023).	
Overall	 those	 with	 DM	 had	 a	 higher	 burden	 of	 disease	 throughout	 the	 infra-inguinal	

















missing	Missing	 %	 Missing	 %	
Superficial	femoral	 2	 1.31	 0	 0.00	 1.31	
Profunda	femoris	 12	 7.84	 17	 11.11	 3.27	
Popliteal	 2	 1.31	 2	 1.31	 0.00	
TP	Trunk	 2	 1.31	 2	 1.31	 0.00	
Anterior	tibial		 10	 6.54	 4	 2.61	 3.93	
Dorsalis	pedis	 34	 22.22	 32	 20.92	 1.31	
Peroneal		 9	 5.88	 4	 2.61	 3.27	
Posterior	tibial		 7	 4.58	 2	 1.31	 3.27	
Medial	plantar	 44	 28.76	 43	 28.10	 0.65	






was	 consistently	 lower	 in	 the	 DM	 group	 for	 minor	 and	 major	 amputation,	 mortality,	
amputation-free	 survival	 and	 further	 revascularisation	 (Table	 3.8-6).	 Examination	 of	 the	






Minor	Amputation	 98.0	(1.1)	 91.3	(2.3)	 0.011	
Major	Amputation	 98.6	(1.0)	 91.9	(2.2)	 0.009	
Mortality	 91.5	(2.3)	 87.6	(2.7)	 0.002	
Amputation-Free	Survival	 90.2	(2.4)	 81.0	(3.2)	 0.001	











kidneys	 and	 peripheral	 nerves188.	 Histological	 examination	 of	 capillaries	 has	 shown	
thickening	of	 the	basement	membrane	 compared	 to	non-diabetic	patients37,40,41.	Different	
methods	to	quantifiably	examine	the	microcirculation	and	its	function	have	been	developed;	
these	include	capillary	microscopy	(CM),	transcutaneous	oxygen	pressure	(TcPO2)	and	laser	
Doppler	 fluxmetry	 (LDF).	 For	 the	purposes	of	 this	 thesis	 the	microcirculation	 is	 defined	as	
arterioles,	 capillaries	 and	 venules	 and	 includes	 any	 vessel	 that	 measures	 less	 than	 200-
150µm189.		
The	aim	of	this	paper	 is	to	examine	the	common	non-invasive	tests	that	claim	to	assess	
the	microcirculation	of	 the	 foot.	This	 includes	a	 review	of	 the	current	evidence	within	 the	







Capillaries	 in	 the	 skin	 were	 first	 observed	 using	 a	 microscope	 as	 early	 as	 1879191.	 The	
technique	 was	 formalised	 and	 details	 published	 in	 the	 literature	 in	 the	 1940s	 and	
50s190,192,193.	The	basic	requirements	are	a	binocular	microscope	and	a	powerful	 light192.	As	
the	 technique	 has	 developed	 it	 has	 become	 possible	 to	 record	 both	 static	 and	 dynamic	
images.	 Videocapillaroscopy	 allows	 dynamic	 assessment	 of	 the	 microcirculation	 and	
sequential	 magnification	 of	 areas	 of	 interest194.	 As	 part	 of	 the	 technique	 paraffin	 oil	 is	





be	 quantitatively	 assessed	 include	 capillary	 density,	 capillary	 diameter	 and	 red	 blood	 cell	
velocity	(at	rest	and	as	part	of	post	occlusive	reactive	hyperaemia	(PORH))	95,197-199.		






with	 DM	 have	 been	 found	 to	 have	 dilated	 capillaries	 and	 delayed	 hyperaemia	 following	
occlusion95.	In	ischaemic	ulcers	there	is	a	paucity	of	capillaries	in	areas	with	no	evidence	of	
	73	
granulation,	 areas	 of	 granulation	 had	 significantly	 higher	 capillary	 density	 and	 areas	 of	
normal	 skin	 surrounding	 the	 ulcer	 had	 a	 higher	 density	 again208.	 There	 is	 lower	 capillary	
density	 in	 ischaemic	 ulcers	 compared	 to	 venous200	 but	 on	 dependency	 those	with	 severe	
ischaemia	 show	 an	 increase	 in	 skin	 perfusion	 which	 does	 not	 occur	 in	 patients	 with	 less	
severe	disease198.	There	has	also	been	shown	to	be	lower	capillary	blood	velocity	in	patients	
with	PND	compared	to	those	without209.		
By	 staging	 the	 changes	 in	 the	 morphology	 of	 capillaries	 it	 has	 been	 shown	 that	 it	 is	
possible	 to	 discriminate	 between	 patients	 with	 critical	 limb	 ischaemia	 and	 intermittent	
claudication93.	 There	 is	 good	 sensitivity	 and	 specificity	 when	 discriminating	 between	 the	
stages	of	morphological	changes195,196.	There	is	also	good	inter	and	intra-observer	reliability	
of	for	capillary	density93,195	and	measurement	of	capillary	width195.		
There	 are	 limitations	 to	 the	 use	 of	 CM,	 particularly,	 interpretation	 of	 images	 requires	




with	velocity	measurments95.	Within	 the	 literature	 there	 is	no	consensus	on	definitions	or	












causes	vasodilatation	of	 the	surface	capillaries	and	 increasing	 local	blood	 flow.	Secondly	 it	




blood212.	The	temperature	that	 the	skin	 is	heated	too	 is	between	37-45oC213.	The	resulting	













225.	 Ueno	 et	 al	 demonstrated	 that	 resting	 TcPO2	 was	 influenced	 by	 arterial	 stenosis	 or	
occlusions	in	an	angiosomal	distribution	i.e.	TcPO2	of	the	dorsum	of	the	foot	was	influenced	
by	the	status	of	the	proximal	vessels	and	the	anterior	tibial	artery	and	the	TcPO2	of	the	calf	
was	 influenced	 by	 the	 proximal	 vessels	 and	 the	 posterior	 tibial	 arteries226.	 A	 recent	 study	
performed	in	Greece	has	supported	that	TcPO2	is	low	in	patients	with	DM	and	patients	with	
diabetic	 peripheral	 neuropathy	 but	 these	 results	 were	 independent	 of	 the	 presence	 of	
PAD224.	Other	studies	have	also	demonstrated	that	there	is	not	a	linear	relationship	between	
arterial	 supply	 and	 oxygenation	 of	 distal	 tissues	 in	 patients	 with	 DM223-225.	 As	 these	 are	
cross-sectional	 studies	 they	were	 unable	 to	 comment	 on	 the	 pathophysiology	 behind	 the	
results.	
In	the	lower	limbs	TcPO2	has	been	shown	to	have	variable	reproducibility93,227.	However	
good	sensitivity	and	specificity	 for	 the	detection	of	PAD226,	 for	 the	healing	of	diabetic	 foot	
ulcers228	 and	 the	 prediction	 of	 major	 amputation	 has	 been	 shown229.	 Current	 guidelines	
include	 TcPO2	 of	 <30mmHg	 as	 a	 predictor	 of	 poor	 outcome	 in	 patients	with	 diabetic	 foot	
ulcers	and	critical	limb	ischamia74,184.	





The	 laser	 Doppler	 technique	 for	 examining	 blood	 flow	 in	 the	 microcirculation	 was	
developed	by	Stern	and	Lappe	in	the	early	1970s97,230.	It	was	developed	as	a	method	to	non-
invasively	 monitor	 the	 microcirculation	 and	 as	 a	 replacement	 for	 techniques	 that	 used	
radioisotopes	to	assess	blood	flow96.	
The	LDF	probe	delivers	a	 laser	via	an	optical	fibre	to	the	tissue	under	investigation.	This	
light	 is	 scattered	 by	 the	 tissue	 encountered,	 and	 if	 that	 tissue	 is	 a	moving	 red	 blood	 cell	














variability231,232.	 Reactivity	 tests	 have	 been	 shown	 to	 be	more	 reproducible;	 these	 include	
thermal	 challenge,	 iontophoresis,	 post	 occlusive	 reactive	 hyperaemia	 (PORH)	 and	 skin	
perfusion	pressure	(SPP).	A	thermal	challenge	 is	generally	delivered	using	 localised	heating	
to	 the	 same	 area	 where	 the	 probe	 is	 placed	 (ideally	 using	 an	 integrated	 probe)	 and	
monitoring	the	response	over	a	period	of	time100-102.	There	has	been	shown	to	be	a	decrease	
in	response	in	people	with	DM	compared	to	controls41,50,102.		
Iontophoresis	 involves	 the	 delivery	 of	 a	 low	 current	 through	 a	 chamber	 containing	 a	
vasoactive	 solution.	 The	 current	 causes	 ionisation	 of	 the	 substance	 towards	 the	 skin	
resulting	 in	 vasodilatation102.	 The	 probe	 is	 either	 placed	 within	 the	 chamber	 or	 in	 close	
proximity	 to	 it.	 The	 substances	 generally	 used	 are	 acetylcholine	 and	 sodium	nitroprusside	
which	 assess	 endothelium-dependent	 and	 endothelium-independent	 vasodilatation	









curve	 which	 are	 based	 on	magnitude	 and	 temporal	 relationships234.	 The	 parameters	 that	
have	been	found	to	have	the	best	reproducibility	and	discrimination	are	time	to	maximum	
flux,	time	to	half	recovery,	time	to	resting	flux,	maximum	flux	(difference	between	maximum	








with	 rest	 pain	 or	 disabling	 claudication93.	 Diabetic	 patients	 have	 demonstrated	 severely	
impaired	PORH47,49.	Within	the	literature,	there	is	no	evidence	linking	improvement	in	PORH	
to	clinical	improvement.		















4.5. THE	 DIFFERENCE	 BETWEEN	 THE	 HEALING	 AND	 THE	 NON-HEALING	
DIABETIC	 FOOT	 ULCER.	 A	 REVIEW	 OF	 THE	 ROLE	 OF	 THE	
MICROCIRCULATION	
4.5.1. Methods	
A	 search	 of	 the	Medline,	 EMBASE	 and	Web	 of	 Science	 databases	 was	 performed.	 The	
search	 strategy	 consisted	 of	 the	 Medical	 Subject	 Headings	 (MESH)	 “microcirculation”,	
“wound	 healing”,	 “diabetic	 foot”,	 “skin	 ulcer”,	 “laser	 Doppler	 flowmetry”,	 “blood	 gas	
monitoring,	transcutaneous”,	“microscopic	angioscopy”,	“xenon	radioisotopes”.	In	addition,	




Table	 4.5-1;	 no	 limits	 were	 applied	 to	 length	 of	 follow-up	 or	 the	 number	 of	 patients	




















the	 final	 review	 (Figure	 4.6-1)	 225,228,237-253.	 The	 date	 of	 publication	 ranged	 from	 1985	 to	
2014,	 two	 studies	 were	 randomised	 control	 trials,	 there	 were	 three	 pseudo-randomised	
control	trials,	and	the	rest	were	observational	studies	(Table	4.6-1).	Not	all	studies	included	





























Padberg,	F.T240	 1996	 USA	 Case-control	 TcPO2	 129	 97	















Newton,	D.J.244	 2002	 UK	 Cross-sectional	 LDI	 5	 	











Petrofsky,	J.S.247	 2007	 USA	 Pseudo-RCT	 LDI	 29	 -	
Lawson,	D.248	 2007	 USA	 Pseudo-RCT	 LDI	 10	 10	
Ichioka,	S.249	 2009	 Japan	 Case-control	 TcPO2	 31	 22	
Petrofsky,	J.S.250	 2010	 USA	 RCT	 LDI	 20	 -	
Yang,	C.251	 2013	 China	 Cross-sectional	 TcPO2	 61	 -	
Wang,	A.252	 2014	 China	 Cross-sectional	 TcPO2	 194	 -	











who	 healed	 to	 those	 who	 did	 not	 heal225,228,237,238,243-246,249,251-253.	 Ten	 of	 these	 studies	
employed	 TcPO2225,228,238,243,245,246,249,251-253,	 five	 used	 LDF228,238,245,246,253,	 one	 used	 laser	
Doppler	 imaging	 (LDI)244	and	one	used	 isotope	washout	 to	measure	SPP237.	These	were	all	
observational	studies	apart	from	one	that	randomised	the	first	14	of	its	participants	but	not	
the	 final	 24245.	 For	 seven	 of	 the	 studies,	 the	 participants	 received	 only	 standard	
therapy225,228,237,238,251,252.	 Two	 studies	 examined	 the	 effects	 of	 HBO	 therapy,	 Kalani	 et	 al.	
(2002)	 had	 two	 cohorts,	 one	 of	 which	 received	 standard	 therapy	 and	 the	 other	 which	
received	HBO.	 The	 healed	 and	 unhealed	 groups	 in	 this	 study	 are	made	up	 of	 participants	
from	 either	 cohort245.	 Fife	 et	 al.	 performed	 a	 retrospective	 study	 of	 1144	 patients	 who	
received	 HBO	 therapy243.	 Klingel	 et	 al.	 reported	 the	 results	 of	 a	 very	 small	 pilot	 study	 (8	
patients)	all	of	whom	received	rheopheresis246.	Two	studies	treated	their	participants	with	
dermal	replacement	therapy;	Ichioka	et	al.	bone	marrow	impregnated	collagen,	Newton	et	
al.,	 collagen	 containing	 glycosaminoglycans)244,249.	 Five	 studies	 only	 investigated	 patients	
with	 both	 diabetes	 and	 ischaemia228,238,243,245,246,	 three	 studies	 excluded	 those	 with	
ischaemia225,244,249,	 in	 one	 study	 it	 was	 unclear251,	 and	 three	 included	 a	 mix	 of	




summarised	 in	 Table	 4.6-2.	 Five	 studies	 found	 that	 those	 with	 a	 higher	 TcPO2	 had	 a	
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statistically	 significant	 higher	 chance	 of	 healing,	 with	 results	 ranging	 from	 30±4mmHg	 to	
61.11±21.16mmHg	 228,238,246,251,252.	 Kalani	 et	 al.	 2002	 and	 Yotsu	 failed	 to	 find	 a	 significant	
difference	 between	 the	 two	 groups245,253.	 Pecoraro	 et	 al.	 found	 a	 significant	 difference	
between	 those	 who	 had	 early	 healing	 and	 those	 who	 did	 not	 (56.3±2.72mmHg	 vs	
26.9±8.26mmHg,	 p=0.003)	 however	 was	 unable	 to	 demonstrate	 that	 the	 difference	 had	
persisted	in	those	that	healed	overall	(53.67±2.99mmHg	vs	37.57±11.02mmHg,	p=0.126)225.	
4.6.1.2. Skin	perfusion	pressure	
Two	papers	 used	 SPP	 to	 compare	 the	 healed	 and	 unhealed	 groups237,253.	 Faris	et	 al.	 in	
1985	used	an	isotope	washout	method	on	64	patients	with	diabetes	and	foot	ulceration	or	
gangrene.	Those	who	healed	had	a	mean	SPP	of	59	±	16mmHg	compared	to	those	who	did	
not	 heal	 whose	 mean	 SPP	 was	 35	 ±	 11	 (p<0.001)237.	 Yotsu	 et	 al.	 in	 2014	 employed	 LDF	
instead	 of	 isotope	 washout	 to	 measure	 SPP	 on	 diabetic	 ulcers	 divided	 into	 the	 groups	
described	above.	They	 found	that	neuropathic	ulcers	had	a	higher	SPP	than	both	 ischemic	
and	 neuro-ischemic	 ulcers,	 65	 ±	 13.6mmHg,	 27	 ±	 14.1mmHg	 and	 34	 ±	 23.2mmHg	























































































































































Neuropathic	 67,	57-75	(34)	 65,	40-69	(5)	 0.192	
Ischemic	 37,	17-43	(9)	 20,	15-37	(11)	 0.341	



















TcPO2	(mmHg)	 30	±	4.0	 7	±	2.5*	 42	±	3.5	 2	±	1.6*	
LD-SBFV	(mV)	 98	±	13.0	 50	±	8.0*	 88	±	15.0	 37	±	2.0*	













success.	However,	 the	 accuracy	was	 still	 relatively	 poor	with	 sensitivity	 of	 67%,	 specificity	
50%,	PPV	35%	and	NPV	79%243.	
4.6.2. Diabetes	compared	to	no	diabetes	
Two	 out	 of	 nineteen	 studies	 compared	 subjects	 both	 with	 DM	 and	 without	 DM238,240.	
Both	of	 these	papers	used	TcPO2	 to	make	 their	 comparisons,	 in	addition,	Karanfilian	et	al.	
employed	LDF238		
Padberg	et	al.	reported	the	predictive	accuracy,	using	a	probability	approach,	for	healing	
of	 TcPO2	 in	 critically	 ischaemic	 wounds.	 204	 wounds	 were	 stratified	 depending	 on	 the	







Only	 one	 study	 identified	 compared	 the	 mean	 results	 of	 microcirculatory	 tests	 for	




PWA	 than	patients	with	 diabetes	who	did	 not	 heal.	 In	 the	 healed	 groups	 for	 the	 patients	





same	 group	 of	 patients239,241,244,246-250.	 One	 study	 detected	 no	 change,	 and	 two	 noted	 a	
decrease	in	reading,	a	further	two	noted	an	increase	and	three	noted	a	pattern	of	increasing	
then	decreasing.	 Jorneskog	et	al.	 used	LDF	and	CM	to	examine	 ten	patients	with	diabetes	
who	 received	 low	 molecular	 weight	 heparin	 for	 eight	 weeks.	 Measurements	 of	 the	
microcirculation	 (PORH,	 the	 structural	 appearance	 of	 capillaries	 in	 the	 forefoot	 and	 toes)	
were	undertaken	1-2	weeks	before	receiving	heparin,	after	4-7	weeks	of	treatment	and	two	
weeks	after	treatment	was	stopped.	They	found	that	there	was	no	significant	change	in	any	
of	 the	 laser	Doppler	 parameters	during	or	 after	 treatment.	 It	was	however	noted	 that	 six	
patients	who	had	improved	healing	also	had	an	improvement	in	their	capillary	stage,	three	
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others	 also	 improved	 clinically,	 but	 one	 had	 no	 change	 in	 their	 capillaries,	 one	 initially	
improved	 but	 then	 deteriorated	 again	 and	 in	 one	 it	 was	 not	 possible	 to	 determine	 their	
capillary	stage.	One	patient	deteriorated	both	clinically	and	on	microscopic	examination239.		
Petrofsky	et	al.	 published	on	electronic	 stimulation	 (ES)	 for	diabetic	 foot	ulcers	 in	both	
2007	 and	 2010247,250.	 In	 2007	 the	 study	 groups	 were	 ten	 patients	 who	 received	 global	
heating	 and	 ES,	 nine	 who	 received	 local	 heating	 and	 ES	 and	 ten	 patients	 who	 received	
conventional	 therapy	 only.	 The	measure	 of	 the	microcirculation	was	 blood	 flow	 using	 LDI	
(measured	in	arbitrary	unit	flux).	The	control	group	did	not	undergo	LDI	measurement,	only	
wound	 area	 was	 measured.	 In	 2010	 the	 aim	 of	 the	 study	 was	 to	 examine	 the	 role	 that	
heating	 had	 compared	 to	 ES	 and	 heating.	 Ten	 patients	 received	 local	 heating	 only	 and	 a	
further	ten	local	heating	and	ES.	The	treatment	period	for	both	studies	was	four	weeks.	 In	
both	studies,	the	blood	flow	around	and	in	the	ulcer	had	decreased	by	the	end	of	the	study.	
In	 the	 2007	 study,	 the	mean	blood	 flow	 at	 baseline	was	 reported	 for	 1cm	 from	 the	ulcer	




The	change	 in	blood	 flow	before	and	during	ES	at	baseline	and	 four	weeks	 is	displayed	 in	



















baseline,	 two	 weeks	 and	 four	 weeks.	When	 looking	 at	 the	 outside	 of	 the	 ulcer,	 the	 pre-
stimulation	results	for	the	DM	group	showed	a	larger	increase	in	the	blood	flow	than	for	the	
no	diabetes	mellitus	group	(DM,	0-2	weeks	35%,	0-4	weeks	21%;	Non-DM,	0-2	weeks	0%,	0-4	




an	 antithrombotic	 drug	 (sulodexide)	 with	 optimisation	 of	 insulin	 therapy	 and	 placebo	
injections	for	ten	weeks.	Measurements	were	taken	at	baseline	and	eight	weeks	using	LDF.	
The	parameters	measured	were	resting	flux	(RF),	peak	hyperaemic	flow	(pLDF),	time	to	peak	




pLDF	 for	 both	 the	 thirty	 (51.7±15.2	 to	 147.0±16.2,	 p<0.01)	 and	 sixty	 second	 occlusion	
(110.5±13.0	to	164.8	±15.4,	p<0.01)	significantly	increased	at	eight	weeks241.		
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The	 results	 from	 two	 studies	 with	 small	 numbers	 are	 presented	 in	 graphical	 form	 in	
Figure	4.6-2.	Newton	et	al.’s	seven	ulcers	all	healed	or	showed	improvement	at	eight	weeks.	
Four	measurements	using	LDI	were	performed	at	baseline,	two,	five	and	eight	weeks.	Four	
patients	had	an	 increase	 in	blood	 flow	over	 the	 first	 few	weeks	 followed	by	a	decrease	 to	
below	 baseline	 at	 eight	 weeks.	 One	 increased	 throughout	 the	measurement	 period.	 One	
decreased	at	 two	weeks,	 increased	at	weeks	 five	and	eight	but	did	not	 return	 to	baseline	
level.	One	decreased	throughout	(Figure	4.6-2a).	Those	that	had	healed	at	eight	weeks,	two	
increased	 then	 decreased,	 one	 increased	 throughout	 and	 the	 other	 decreased	
throughout244.	Of	Klingel’s	eight	patients	who	received	rheopheresis	 five	underwent	TcPO2	
at	 baseline,	 twelve	 and	 twenty-four	 weeks	 and	 three	 underwent	 TcPO2	 at	 baseline	 and	
twelve	weeks	(due	to	minor	amputation	in	one	patient	and	major	amputation	in	two).	Of	the	
four	patients	who	showed	an	improvement	in	their	ulcer	two	had	an	increase	in	blood	flow	




































































been	 used.	 Some	 of	 these	 methods	 have	 now	 fallen	 out	 of	 favour	 as	 technology	 has	
developed	less	invasive	methods.	This	includes	Xe	clearance	and	SPP	using	isotope	washout.	
LDF,	TcPO2	and	CM	remain	in	regular	use.	LDF	is	relatively	underrepresented	in	this	cohort,	





There	 is	 disagreement	 on	 how	 to	 carry	 out	 each	 of	 the	 methods	 of	 assessing	 the	




significant	 difference	 is	 their	 method	 of	 measurement253.	 Multiple	 measurements	 were	
taken	in	two	areas	of	the	foot	and	the	lowest	result	recorded.	Of	particular	note,	the	contra-








is	 functioning	 poorly	 then	 outcomes	 are	 likely	 to	 be	worse.	Most	 studies	 demonstrated	 a	
significantly	higher	TcPO2	in	those	patients	who	healed.	What	is	less	clear	is	the	threshold	at	
which	healing	occurs.	The	TcPO2	thresholds	quoted	for	a	successful	outcome	in	this	review	
range	 from	10mmHg	 to	 34mmHg.	 Karanfilian	quotes	 sensitivity	 of	 100%	and	 specificity	 of	
88%	for	healing	if	the	TcPO2	is	>10mmHg238.	Pecoraro	found	that	a	TcPO2	of	<20mmHg	was	
associated	with	a	39	fold	increased	risk	of	early	healing	failure225.	Both	Kalani	and	Yang	used	
the	 threshold	 of	 <25mmHg	 and	 quoted	 sensitivities	 and	 specificities	 of	 85%	 Vs	 92%	 and	
88.6%	Vs	82.4%	respectively228,251.	This	threshold,	when	looking	at	the	collated	results	in	the	










included	however	 there	was	 still	 significant	 heterogeneity	 and	difference	 in	 the	measures	
used.	 Their	 conclusions	 were	 based	 predominantly	 on	 three	 papers	 of	 acceptable	 rather	
than	high-quality	(Quality	in	Prognosis	Studies	Tool)228,237,256.	
Only	 one	 study	 in	 this	 current	 review	 truly	 compared	 the	 results	 of	 testing	 the	
microcirculation	 in	 patients	with	DM	and	 those	without238.	 Karanfilian	 found	 that	 the	DM	
patients	who	healed	had	a	lower	TcPO2	than	NDM	patients	who	healed.	Conversely,	the	LDF	
results	were	higher	 in	 the	DM	healed	group.	 In	 the	unhealed	groups,	 the	opposite	 is	 true.	
The	accuracy	of	TcPO2	 for	predicting	healing	 is	 shown	 to	be	 reasonable	 in	 those	with	DM,	
slightly	poorer	than	those	without	DM	but	better	than	those	with	CRF.	It	 is	not	possible	to	




The	 results	 from	 the	 repeated	 measures	 suggest	 that	 there	 is	 a	 change	 in	 the	
microcirculation	during	healing	but	the	true	trend	and	how	it	relates	to	healing	has	not	yet	
been	identified.	
As	 the	 heart,	 arteries,	 microcirculation	 and	 veins	 link	 into	 a	 circuit	 it	 is	 tempting	 to	
consider	that	there	is	a	direct	relationship	between	the	flow	of	blood	as	it	leaves	the	heart	
and	 how	 it	 flows	 through	 the	 microcirculation.	 However,	 anybody	 who	 has	 studied	 the	
basics	 in	fluid	biodynamics	will	be	aware	that	how	fluids,	 like	blood,	behave	is	different	on	
the	macro	and	microscopic	 scale257.	 This	 is	before	 the	 complex	 control	 systems	 related	 to	
maintaining	 homeostasis	 of	 blood	 pressure	 and	 tissue	 perfusion	 become	 involved258.	 A	
patient	with	diseased	macrocirculation	is	 likely	to	have	reduced	overall	blood	flow	through	
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any	 firm	 conclusions	 from	 a	 review	 of	 the	 current	 literature.	 The	 influence	 of	 DM	 and	
associated	neuropathy	 is	not	 clear,	 and	neither	 is	 the	degree	of	 improvement	 required	 to	
achieve	healing.	Studies	that	examine	a	clearly	defined	cohort	both	with	and	without	DM	are	
required.	 Accurate	 quantitative	 assessment	 of	 microcirculation	 will	 greatly	 aid	 predicting	
feet	at	risk,	of	predicting	wound	healing	with	and	without	surgery,	and	for	identifying	those	
at	 greatest	 risk	of	 amputation.	A	 study	was	designed	 to	examine	how	 the	 function	of	 the	









As	demonstrated	 in	 the	 literature	 review	above	 (Chapter	 4)	 there	 is	 a	 need	 for	 further	









The	 original	 plan	 for	 the	 cohort	 study	 was	 to	 recruit	 three	 groups	 of	 patients	 all	 with	
active	 pedal	 tissue	 loss.	 The	 groups	would	 have	 comprised	 a	 group	with	 diabetes	 but	 no	
significant	peripheral	arterial	disease	(PAD),	the	diabetic	tissue	loss	group	(DTL).	Two	groups	
with	 significant	 PAD	 which	 required	 a	 revascularisation	 procedure,	 those	 who	 had	 been	
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The	microcirculation	was	 to	 be	 assessed	 using	 laser	Dopper	 fluxmetry	 (LDF),	 toe	 blood	











55)	 in	the	PCA	groups.	Hence,	the	difference	 in	the	 improvement	between	the	two	groups	
was	27	seconds	(41-14).	
The	 pooled	 standard	 deviation	 from	 this	 data	 is	 30.	 If	 the	 pre	 and	 post-operative	
measurements	on	the	same	patient	are	assumed	to	be	independent,	the	standard	deviation	
of	the	change	will	be	30	times	the	square	root	of	2,	i.e.	42	
The	 study	was	 powered	 based	 on	 a	 t-test,	 assuming	 a	 standard	 deviation	 of	 42.	 For	 a	
detectable	difference	of	27,	a	sample	size	of	40	patients	per	group	(i.e.	80	total)	would	be	
sufficient	for	80%	power	at	5%	alpha.		
There	 is	 no	 equivalent	 data	 available	 with	 which	 it	 would	 be	 possible	 to	 calculate	 an	
appropriate	 sample	 size	 for	 the	 group	with	DM	and	 no	 PAD	 (DTL	 group).	 For	 this	 reason,	




a	 high	 dropout	 rate	 (up	 to	 20%)	 should	 be	 expected.	 This	 increases	 the	 size	 of	 our	 study	









low	 throughout	 the	 study	period,	 reasons	 for	 this	 include	 issues	with	 the	 identification	of	
potential	participants	and	issues	with	the	sites.	At	the	beginning	of	the	study,	at	all	sites,	the	
purpose	of	the	study	and	the	type	of	patient	being	recruited	was	presented	at	relevant	team	
meetings	 (vascular	 surgery	 and	 diabetes	 and	 endocrinology).	 In	 areas	 where	 clinics	 took	
place,	posters	were	placed	with	a	 list	of	 inclusion	criteria	and	contact	details	 for	the	study	
team.	 Despite	 this,	 no	 participants	 were	 identified	 unless	 the	 lead	 recruiter	 (DLL)	 was	
present	 in	 the	 clinic.	 In	 clinics	 which	 were	 specific	 diabetic	 foot	 clinics	 a	 relatively	 high	
proportion	of	patients	could	be	considered	as	potential	participants.	The	majority	of	 these	
would	be	eligible	for	the	DTL	group	rather	than	the	PCA	or	PBS	groups.	Potential	members	of	
the	 PCA	 and	 PBS	 groups	 were	 more	 likely	 to	 be	 identified	 from	 vascular	 surgery	 clinics.	
Within	 an	 individual	 clinic	 of	 fifteen	 to	 thirty	 patients,	 there	 may	 only	 be	 one,	 or	 less,	
patients	 potentially	 eligible	 for	 the	 study.	 It	was	 not	 possible	 for	 DLL	 to	 be	 present	 at	 all	








regular	member	 of	 staff	 at	 the	 other	 sites	 and	 so	would	 not	 normally	 have	 access	 to	 the	
appropriate	procedure	lists.		
This	 did	 improve	 recruitment	 of	 PCA	 patients	 slightly,	 but	 PBS	 patients	 remained	
challenging.	The	main	reason	behind	this	was	due	to	bed	pressures.	 Ideally,	patients	being	
admitted	for	major	surgery	would	be	admitted	on	the	evening	before	surgery.	Pressures	on	




























guidance	 2011)	 and	 assuming	 they	 were	 stable	 and	 well	 in	 themselves	 then	 the	
researchers	would	provide	basic	counselling	in	the	clinic	and	then	refer	them	to	their	
GP	 for	 further	 management	 and	 investigation	 of	 their	 diabetes.	 If	 there	 was	 any	
indication	the	patient	was	acutely	unwell,	the	researchers	would	organise	admission	
to	hospital	for	further	management.	In	both	cases,	these	patients	would	be	excluded	










Recruitment	 started	 on	 the	 1st	 January	 2015.	 As	 the	 recruitment	 period	 went	 on	 it	
became	 clear	 that	 it	 would	 not	 be	 possible	 to	 recruit	 the	 120	 planned	 patients	 in	 the	
available	time	period.	As	of	February	2016,	twenty-six	patients	had	been	recruited,	fourteen	
in	the	DTL	group,	ten	in	the	PCA	group	and	two	in	the	PBS	group	(Figure	5.5-1).	The	decision	





































































of	 the	 study	 team	 to	 be	 present	 in	 person	 in	 all	 relevant	 clinics	 review	 of	 referral	
documentation	 to	 clinics,	 theatre	 lists	 and	 angioplasty	 lists	 was	 conducted.	 This	 was	 only	
performed	at	the	University	Hospitals	Birmingham	site	due	to	restrictions	in	distributing	the	
relevant	 lists	beyond	those	who	would	normally	be	 in	 receipt	of	 them	due	to	 their	clinical	
responsibilities.	If	a	potential	patient	was	identified	from	these	lists	a	patient	invitation	letter	




call.	 If	 the	patient	 expressed	an	 interest	 at	 their	 next	 clinic	 appointment	or	on	 the	day	of	
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All	 participants	 were	 verbally	 invited	 to	 take	 part	 in	 the	 study	 by	 the	 clinical	 team	
providing	their	care.	They	were	given	written	information	with	regards	to	the	purpose	and	
design	 of	 the	 study	 (Appendix	 V).	 They	 were	 then	 invited	 to	 participate	 and,	 if	 agreed,	
consented	 using	 a	 standardised	 consent	 form	 (Appendix	 VI).	 This	 was	 performed	 and	
undertaken	by	a	member	of	the	study	team.	
Consent	 to	 participate	 included	 consent	 to	 the	 use	 of	 data	 obtained	 during	 their	
participation	in	the	final	analysis.	Participants	were	free	to	leave	the	study	with	only	a	verbal	





procedure.	 For	 the	 DTL	 group,	 the	 initial	 assessment	 was	 carried	 out	 following	 informed	
consent	being	gained.	If	possible,	this	was	during	the	same	attendance.	
Post-procedure	 assessment	 for	 the	 PCA	 group	 occurred	 at	 initial	 follow-up	 clinic	
appointment	 one	 month	 following	 their	 procedure.	 Subsequent	 re-examination	 occurred	
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monthly	 (within	 a	 week)	 at	 the	 hospital	 appointment	 that	 fell	 nearest	 this	 time.	 This	
included	 vascular,	 diabetes	 and	 podiatry	 appointments.	 Reassessment	 continued	 until	 the	
ulcer	was	decided	to	have	clinically	healed,	the	limb	was	amputated,	or	the	end	of	the	study	
was	reached.	
The	 DTL	 group	 had	 repeat	 assessments	 monthly	 until	 the	 ulcer	 was	 decided	 to	 have	
clinically	healed,	the	limb	was	amputated,	or	the	end	of	the	study	was	reached.	
5.6.7.2. Procedure	for	data	collection	




position	so	 they	could	acclimatise	 to	 the	 temperature	of	 the	room.	During	 the	 first	 fifteen	
minutes,	 the	NTSS-6	questionnaire	was	completed,	and	monofilament,	 ITT	and	VPT	testing	
was	carried	out	on	both	feet.	The	characteristics	of	the	ulcer/s	were	also	described.	During	





base	of	 the	 third	 and	 fifth	metatarsals18,120.	A	positive	or	negative	 response	 for	 each	area	
was	recorded.	Abnormal	was	defined	as	an	inability	to	detect	the	monofilament	in	one	area.	
	112	
If	 it	 was	 not	 possible	 to	 test	 any	 of	 the	 areas	 due	 to	 amputation	 or	 ulceration,	 this	 was	
recorded.	
Ipswich	Touch	Test	





VPT	 was	 assessed	 on	 the	 pulp	 of	 the	 hallux	 or	 next	 dominant	 toe	 if	 amputation	 had	
occurred	 in	 the	 past	 or	 the	 toe	 was	 necrotic.	 A	 neurothesiometer	 was	 used.	 The	 first	
measurement	was	taken	increasing	from	zero	to	maximum	and	the	level	at	which	vibration	
was	detected	recorded.	The	second	measurement	was	taken	from	maximum	to	zero	and	the	






full-thickness	 lesion	 of	 the	 skin	 not	 extending	 through	 the	 subcutis,	 and	 a	 deep	 ulcer	 is	 a	
lesion	of	the	skin	extending	through	the	subcutis.	An	infection	was	diagnosed	if	two	or	more	
of	 the	 following	signs	are	present:	 frank	purulence,	 local	warmth,	erythema,	 lymphangitis,	












Following	 this,	 the	 low-profile	 probe	 was	 placed	 adjacent	 to	 the	 ulcerated	 tissue	 and	
gently	 secured	with	 clingfilm,	which	 also	 protected	 the	 ulcerated	 area.	 A	 cuff	was	 placed	
over	around	the	foot.	SPP	was	measured	with	slow	deflation	of	the	cuff.	
















Initially,	 the	continuous	variables	were	 tested	 for	normality	The	only	variables	 found	 to	
meet	 the	 assumptions	 of	 normality	were	 systolic	 blood	 pressure,	 diastolic	 blood	 pressure	
and	 room	 temperature.	 Consequently,	 these	 variables	 where	 analysed	 using	 parametric	
tests.	 For	 the	 other	 variables	 comparison	 between	 groups	 was	 made	 using	 independent	




Demographics	 were	 analysed	 by	 group.	 The	 differences	 between	 characteristics	 of	 the	
ulcers	 and	 the	patients	 (days	 since	 the	 last	 appointment,	 time	of	 assessment,	 hours	 since	
last	 ate,	 hours	 since	 caffeine,	 ulcer	 area,	 neuropathy	 total	 symptom	 score	 –	 6,	 vibration	












per	 data	 protection	 and	 GCP	 guidelines	 then	 stored	 for	 the	 required	 five	 years	 before	
destruction.	
5.6.8.3. Source	data	
Source	data	was	kept	within	the	source	data	 file	 that	was,	 in	turn,	kept	 locked	within	a	
secure	 office	 locked	 and	 secure	 within	 the	 Vascular	 Department.	 It	 is	 accessible	 only	 by	
those	signatories	within	the	research	group	and	by	the	sponsors	as	requested.	
5.6.9. Ethical	Considerations 
Local	 Research	 Ethics	 Committee	 approval	 was	 sought	 from	 the	 South	 Birmingham	
Research	 Ethics	 Committee.	 Approval	 was	 granted	 on	 26th	 June	 2014.	 Approval	 was	 also	
sought	from	the	Research	and	Development	departments	of	the	three	study	sites,	University	





















the	 PCA	 group	 had	 a	 significantly	 lower	 estimated	 glomerular	 filtration	 rate	 than	 the	DTL	
















Age	(years)	 14	 52	(43-60)	 9	 76	(75-78)	 <0.001	
Male	(%)	 14	 71.4	 9	 66.7	 1.00††	
Type	II	DM	(%)	 14	 78.6	 9	 100	 0.253††	
Glycated	Haemoglobin	(mmol/mol)	 9	 75	(52-84)	 3	 52	(49-53)	 0.209	
Duration	of	DM	(years)	 14	 15	(9-20)	 8	 18	(11-24)	 0.525	























Study	Leg	(%	Right)	 14	 42.9	 9	 88.9	 0.040††	
Number	of	Comorbidities	 14	 1	(1-3)	 9	 2	(1-3)	 0.688	
Hypertension	(%)	 14	 57.1	 9	 77.8	 0.400††	
Estimated	Glomerular	Filtration	Rate	 14	 87	(61-90)	 8	 55	(43-71)	 0.024	
Total	Cholesterol	(mg/dL)	 7	 4.9	(4.8-5.3)	 4	 4.3	(3.4-4.9)	 0.109	
Thyroid	Stimulating	Hormone	(mU/L)	 7	 2.1	(0.9-3.5)	 3	 3.5	(2.6-4.1)	 0.183	
	118	
Free	T4	(pmol/L)	 4	 15.4	(14.6-17.6)	 3	 19.3	(14.0-22.6)	 1.000	
Vitamin	B12	(pg/ml)	 3	 467	(145-554)	 0	 -	 -	
Number	of	Medications	 13	 7	(2-9)	 9	 8	(7-9)	 0.357	
Cardioactive	Drugs	(%)	 14	 46.2	 9	 44.4	 1.000††	
























The	 median	 time	 of	 assessment	 was	 11:30	 (09:50-13:09)	 in	 the	 DTL	 group	 and	 11:00	


















in	 the	 depth	 of	 the	 ulcer	 by	 the	 second	 visit	 (Table	 5.7-2).	 By	 the	 last	 visit,	 there	 was	 a	

































*McNemar	Test	 		 		 		 		 		
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5.7.3.7. Infection	























































n	 Median	(IQR)	 n	 Median	(IQR)	
Days	since	last	appointment*	 27	 34	(28-50)	 19	 45	(35-70)	 0.030	
Time	of	assessment	 41	 11:30	(9:50-13:09)	 28	 11:00	(10:07-12:15)	 0.382	
Hours	since	last	ate	 41	 2.75	(1.50-3.25)	 28	 2.38	(1.75-3.00)	 0.594	
Hours	since	caffeine	 41	 3.00	(2.25-5.00)	 28	 2.50	(1.63-3.50)	 0.084	
Ulcer	area	(mm2)	 41	 182	(50-450)	 28	 180	(19-985)	 0.888	
Room	temperature†	(0C)	 41	 23.06±0.95	 28	 22.59±1.51	 0.117††	
Systolic	blood	pressure†	(mmHg)	 41	 138.15±20.63	 28	 139.00±17.89	 0.859††	











n	 Median	(IQR)	 n	 Median	(IQR)	 n	 Median	(IQR)	
Days	since	last	appointment	 DTL	 -	 -	 11	 31	(28-60)	 7	 35	(30-42)	 0.075	
PCA	 -	 -	 9	 60	(35-91)	 4	 38.5	(35-47)	 0.893	
Time	of	assessment	 DTL	 14	 11:55	(11:10-13:09)	 11	 10:45	(9:50-12:00)	 7	 11:30	(9:50-14:45)	 0.368	
PCA	 9	 11:45	(11:00-13:00)	 9	 11:30	(10:35-11:45)	 4	 10:07	(9:40-11:22)	 0.504	
Hours	since	ate	 DTL	 14	 2.75	(1.500-3.5)	 11	 3.00	(2.25-4.00)	 7	 2.00	(1.00-3.00)	 0.618	
PCA	 9	 2.50	(2.00-3.00)	 9	 2.75	(2.00-3.25)	 4	 2.13	(1.50-3.13)	 0.623	
Hours	since	caffeine	 DTL	 14	 2.88	(2.00-4.25)	 11	 3.00	(2.25-5.50)	 7	 6.00	(3.00-12.00)	 0.392	
PCA	 9	 2.50	(1.50-3.00)	 9	 3.25	(2.00-3.50)	 4	 2.13	(1.50-7.25)	 0.392	
Ulcer	area	(mm2)	 DTL	 14	 342.5	(80-782)	 11	 90	(10-400)	 7	 125	(0-260)	 0.002	
PCA	 9	 270	(180-1750)	 9	 150	(0-1200)	 4	 458	(195.5-1090.5)	 0.050	
Room	temperature	(0C)**	 DTL	 14	 23.29±1.18	 11	 22.91±0.91	 7	 23.14±0.66	 0.939†	
PCA	 9	 22.87±0.99	 9	 22.900±1.74	 4	 22.43±2.22	 0.943†	
Systolic	BP	(mmHg)**	 DTL	 14	 136.86±24.33	 11	 136.82±15.14	 7	 130.57±23.63	 0.385†	
PCA	 9	 139.78±19.62	 9	 146.78±10.22	 4	 129.75±23.10	 0.659†	
Diastolic	BP	(mmHg)**	 DTL	 14	 76.57±11.66	 11	 77.73±13.02	 7	 75.00±9.71	 0.385†	




The	 variables	 calculated	 for	 post	 occlusive	 reactive	 hyperaemia	 (PORH)	 are	 shown	 in	




(220.28s	 (93.65-279.8)	 vs	 8.05s	 (3.45-17.55),	 p<0.001).	 At	 the	 last	 visit	 for	 the	 study	 toe,	





(13.4s	 (3.68-73.85)	 vs	 27.08s	 (8.5-154.38),	 p=0.021)	 and	 those	 that	 healed	 (13.4s	 (6.33-
73.85)	 vs	 64.43	 (22.5-114.2),	 p=0.028).	 This	 was	 true	 for	 the	 study	 toe	 but	 only	 for	 all	
patients	combined	on	the	study	dorsum.	In	the	PCA	group,	there	was	a	decrease,	this	only	
reached	 significance	 in	 the	 study	 toe	 healed	 group	 (210.5	 (72.18-231)	 vs	 50.71	 (105.18-
105.18),	p=0.046).		
There	 was	 no	 significant	 difference	 between	 the	 baseline	 results	 and	 the	 second	 visit	
results	(Table	5.7-10	and	Figure	5.7-5	to	Figure	5.7-8)	apart	from	on	the	study	dorsum	in	the	
DTL	 unhealed	 group	where	 there	was	 a	 significant	 increase	 in	 TtM	 (11.2s	 (3.83-21.35)	 vs	
20.38s	(9.78-209.2),	p=0.043).		
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There	was	 no	 significant	 difference	 between	 the	 patients	who	had	healed	 by	 their	 last	
visit	and	those	who	did	not	(Table	5.7-11	and	Figure	5.7-9	to	Figure	5.7-12)	apart	from	in	one	
instance.	 In	 the	DTL	group	on	the	study	dorsum	at	 the	second	visit,	 those	 in	 the	unhealed	
group	had	a	significantly	longer	TtM	(3.09s	(2.15-5.28)	vs	20.38	(9.78-209.2),	p=0.030).		
When	the	study	leg	was	compared	to	the	non-study	leg,	both	on	the	toe	and	the	dorsum,	

















Study	toe	 Baseline	 13.40	(3.68-73.85)	 220.80	(200.20-288.78)	 0.002	
Last	 27.08	(8.50-154.38)	 54.50	(34.73-158.00)	 0.442	
%	Change	 94.47	(18.87-328.06)	 -42.14	(-80.90--2.17)	 0.001	
Study	
Dorsum	
Baseline	 8.05	(3.45-17.55)	 220.28	(93.65-279.80)	 <0.001	
Last	 13.50	(4.95-20.38)	 127.78	(30.08-227.13)	 0.015	
%	Change	 43.48	(-16.85-253.10)	 -20.03	(-64.01-84.71)	 0.126	
Non-study	
Toe	
Baseline	 38.98	(12.68-141.05)	 54.80	(13.95-127.43)	 0.689	
Last	 18.83	(11.83-215.65)	 35.33	(15.85-146.28)	 0.596	
%	Change	 47.32	(-11.92-115.76)	 2.92	(-72.27-196.30)	 0.884	
Non-study	
Dorsum	
Baseline	 15.40	(3.58-116.90)	 70.68	(31.10-138.60)	 0.149	
Last	 15.40	(12.13-215.65)	 119.03	(42.43-265.28)	 0.122	


















DTL	 All	(14/11)	 13.40	(3.68-73.85)	 27.08	(8.50-154.38)	 0.021	
Healed	(6/6)	 13.40	(6.33-73.85)	 64.43	(22.05-114.20)	 0.028	
Unhealed	(8/5)	 27.78	(3.44-83.36)	 9.68	(8.50-154.38)	 0.345	
PCA	 All	(9/8)	 220.80	(200.20-288.78)	 54.50	(34.73-158.00)	 0.050	
Healed	(6/6)	 210.50	(72.18-231.00)	 50.71	(27.38-105.18)	 0.046	







	 DTL	 All	(14/11)	 8.05	(3.45-17.55)	 13.50	(4.95-20.38)	 0.041	
Healed	(6/6)	 5.23	(2.85-9.28)	 13.15	(5.68-13.60)	 0.345	
Unhealed	(8/5)	 11.25	(3.83-21.35)	 20.38	(4.95-192.98)	 0.080	
PCA	 All	(9/7)	 220.28	(93.65-279.80)	 127.78	(30.08-227.13)	 0.398	
Healed	(6/6)	 198.79	(69.18-287.33)	 175.76	(105.20-227.13)	 0.753	








	 DTL	 All	(14/11)	 38.98	(12.68-141.05)	 18.83	(11.83-215.65)	 0.182	
Healed	(6/6)	 38.98	(12.68-262.10)	 87.20	(18.83-291.13)	 0.600	
Unhealed	(8/5)	 34.05	(10.68-123.23)	 11.83	(11.68-15.53)	 0.080	
PCA	 All	(7/7)	 54.80	(13.95-127.43)	 35.33	(15.85-146.28)	 0.917	
Healed	(4/5)	 34.38	(8.66-62.28)	 69.55	(35.33-146.28)	 0.273	











DTL	 All	(14/11)	 15.40	(3.58-116.90)	 70.68	(31.10-138.60)	 0.149	
Healed	(6/6)	 10.20	(2.30-55.38)	 17.05	(12.13-142.95)	 0.463	
Unhealed	(8/5)	 15.56	(5.91-117.88)	 13.90	(12.88-215.65)	 0.225	
PCA	 All	(7/6)	 70.68	(31.10-138.60)	 119.03	(42.43-265.28)	 0.686	
Healed	(4/5)	 91.74	(58.41-125.70)	 161.88	(76.18-265.28)	 0.715	

































DTL	 All	(14/11)	 13.40	(3.68-73.85)	 11.08	(4.40-27.08)	 0.722	
Healed	(6/6)	 13.40	(6.33-73.85)	 19.19	(6.83-27.08)	 0.753	
Unhealed	(8/5)	 27.78	(3.44-83.36)	 8.50	(4.28-11.08)	 0.686	
PCA	 All	(9/8)	 220.80	(200.20-288.78)	 53.79	(18.09-205.16)	 0.123	
Healed	(6/6)	 210.50	(72.18-231)	 53.79	(27.38-177.83)	 0.116	











Unhealed	(8/5)	 11.25	(3.83-21.35)	 20.38	(9.78-209.2)	 0.043	
PCA	 All	(9/7)	 220.28	(93.65-279.80)	 127.78	(55.05-227.13)	 0.398	
Healed	(6/6)	 198.79	(69.18-287.33)	 142.33	(80.13-227.13)	 0.753	








	 DTL	 All	(14/11)	 38.98	(12.68-141.05)	 12.23	(8.73-120.95)	 0.790	
Healed	(6/6)	 38.98	(12.68-262.10)	 15.53	(6.98-120.95)	 0.345	
Unhealed	(8/5)	 34.05	(10.68-123.23)	 11.83	(11.68-105.38)	 0.080	
PCA	 All	(7/7)	 54.80	(13.95-127.43)	 30.03	(15.18-69.55)	 0.600	
Healed	(4/5)	 34.38	(8.66-62.28)	 65.4	(30.03-69.55)	 0.465	











DTL	 All	(14/10)	 15.40	(3.58-116.90)	 24.15	(12.88-118.20)	 0.114	
Healed	(6/5)	 10.20	(2.30-55.38)	 18.7	(18.15-102.18)	 0.500	
Unhealed	(8/5)	 15.56	(5.91-117.88)	 29.6	(12.88-234.58)	 0.138	
PCA	 All	(7/6)	 70.68	(31.10-138.60)	 70.63	(60.08-243.90)	 0.500	
Healed	(4/5)	 91.74	(58.41-125.7)	 76.18	(65.08-243.9)	 1.000	




































DTL	 Baseline	(6/8)	 13.40	(6.33-73.85)	 27.78	(3.44-83.36)	 0.662	
Second	(6/5)	 19.19	(6.83-27.08)	 8.50	(4.28-11.08)	 0.429	
Last	(6/5)	 64.43	(22.05-114.20)	 9.68	(8.50-154.38)	 0.792	
PCA	 Baseline	(6/3)	 210.50	(72.18-231.00)	 288.78	(204.98-288.78)	 0.381	
Second	(6/2)	 53.79	(27.38-177.83)	 120.65	(8.80-232.50)	 1.000	







	 DTL	 Baseline	(6/8)	 5.23	(2.85-9.28)	 11.25	(3.83-21.35)	 0.282	
Second	(6/5)	 3.09	(2.15-5.28)	 20.38	(9.78-209.20)	 0.030	
Last	(6/5)	 13.15	(5.68-13.60)	 20.38	(4.95-192.98)	 0.429	
PCA	 Baseline	(6/3)	 198.79	(69.18-287.33)	 220.28	(93.65-271.38)	 1.000	
Second	(6/1)	 142.33	(80.13-227.13)	 55.05	 0.571	








	 DTL	 Baseline	(6/8)	 38.98	(12.68-262.10)	 34.05	(10.68-123.23)	 0.662	
Second	(6/5)	 15.53	(6.98-120.95)	 11.83	(11.68-105.38)	 0.931	
Last	(6/5)	 87.20	(18.83-291.13)	 11.83	(11.68-15.53)	 0.082	
PCA	 Baseline	(4/3)	 34.38	(8.66-62.28)	 127.43	(54.73-237.73)	 0.299	
Second	(5/2)	 65.40	(30.03-69.55)	 10.85	(6.53-15.18)	 0.095	











DTL	 Baseline	(6/8)	 10.20	(2.30-55.38)	 15.56	(5.91-117.88)	 0.491	
Second	(5/5)	 18.70	(18.15-102.18)	 29.60	(12.88-234.58)	 0.690	
Last	(6/5)	 17.05	(12.13-142.95)	 13.90	(12.88-215.65)	 1.000	
PCA	 Baseline	(4/3)	 91.74	(58.41-125.70)	 31.1	(13.23-273.9)	 0.629	
Second	(5/1)	 76.18	(65.08-243.90)	 60.08	 0.667	



























DTL	 Baseline	(14/14)	 13.40	(3.68-73.85)	 38.98	(12.68-141.05)	 0.158	
Last	(11/11)	 27.08	(8.50-154.38)	 18.83	(11.83-215.65)	 0.656	
PCA	 Baseline	(9/7)	 220.80	(200.20-288.78)	 54.80	(13.95-127.43)	 0.028	









DTL	 Baseline	(14/14)	 8.05	(3.45-17.55)	 15.40	(3.58-116.90)	 0.300	
Last	(11/11)	 13.50	(4.95-20.38)	 15.40	(12.13-215.65)	 0.374	
PCA	 Baseline	(9/7)	 220.28	(93.65-279.80_	 70.68	(31.10-138.60)	 0.237	




At	 baseline,	 on	 both	 the	 study	 (76.2mmHg	 (60.2-102.1)	 vs	 46.8mmHg	 (10.1-52.8),	





for	 the	 unhealed	 patients	 at	 both	 the	 second	 (77.6mmHg	 (63-91.4)	 vs	 91.5mmHg	 (54.1-
103.2),	p=0.043)	and	last	visit	(77.6mmHg	(63-91.4)	vs	97.6mmHg	(91.5-103.2),	p=0.043).	On	
the	 study	 leg	 in	 the	 DTL	 group	 the	 healed	 patients	 had	 a	 significantly	 lower	 SPP	 at	 the	
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second	 visit	 (98.8mmHg	 (76.1-143.8)	 vs	 66.7mmHg	 (33.6-86.5),	 p=0.046),	 significance	was	




143.8)	 and	 those	 that	 did	 not	 heal	 74.6mmHg	 (52.3-86.6,	 p=0.138).	 In	 the	 PCA	 group	 the	





























































































































































































DTL	 Baseline	(6/7)	 98.80	(76.10-143.80)	 74.60	(52.30-85.60)	 0.138	
Second	(6/5)	 66.70	(33.60-86.50)	 92.00	(82.30-95.60)	 0.247	
Last	(6/5)	 71.50	(45.80-98.50)	 95.60	(82.30-111.50)	 0.429	
PCA	 Baseline	(4/2)	 49.9	(28.55-85.9)	 28.3	(10.1-46.5)	 0.267	
Second	(6/0)	 48.35	(44-61.6)	 -	 -	




DTL	 Baseline	(6/8)	 84.70	(82.00-88.80)	 77.60	(63.00-91.40)	 0.414	
Second	(6/5)	 89.70	(83.00-96.30)	 91.50	(54.10-103.20)	 0.792	
Last	(5/5)	 92.10	(83.40-96.40)	 97.60	(91.50-103.20)	 0.421	
PCA	 Baseline	(4/3)	 32.3	(18.8-49.7)	 50.3	(10.1-57)	 0.857	
Second	(5/0)	 60.3	(48.4-64.8)	 -	 -	









DTL	 Baseline	(13/14)	 76.20	(60.20-102.10)	 82.80	(72.2-88.80)	 0.402	
Last	(11/10)	 82.30	(45.80-99.50)	 94.30	(83.40-99.00)	 0.285	
PCA	 Baseline	(6/7)	 46.80	(10.10-52.80)	 37.10	(10.10-57.00)	 0.715	






At	baseline	the	PCA	group	had	significantly	 lower	TBP	 in	both	the	study	 leg	 (92.7mmHg	









those	who	did	not	heal	 (74.8mmHg	 (64.2-124.2),	p=0.142).	This	pattern	was	 similar	at	 the	
second	 visit,	 but	 by	 the	 last	 visit	 it	 had	 reversed	 (89.3mmHg	 (57.9-125.4)	 vs	 119.9mmHg	
(96.9-144.3),	 p=0.556).	 In	 the	PCA	group,	 the	 values	 stayed	 very	 similar	 at	 all	 visits	 (Table	
5.7-22).	
When	the	study	and	non-study	 leg	were	compared	 in	the	PCA	group,	 the	non-study	 leg	
































































































PCA	 All	(7/6)	 40.60	(35.90-41.50	 59.40	(53.40-73.90)	
	
0.345	




































































DTL	 Baseline	(6/8)	 117.40	(107.20-133.30)	 74.80	(64.20-124.20)	 0.142	
Second	(5/5)	 132.60	(60.50-151.70)	 81.10	(79.00-127.30)	 0.841	
Last	(5/4)	 89.30	(57.90-125.40)	 119.90	(96.90-144.30)	 0.556	
PCA	 Baseline	(4/3)	 63.10	(42.30-89.00)	 31.40	(23.30-79.00)	 0.400	
Second	(5/1)	 73.70	(72.60-80.10)	 81.40	 0.667	




DTL	 Baseline	(6/7)	 119.80	(93.30-136.60)	 99.80	(54.50-110.50)	 0.295	
Second	(6/5)	 114.90	(75.80-127.90)	 86.70	(76.50-118.40)	 1.000	
Last	(6/5)	 119.80	(75.80-142.70)	 86.70	(81.90-118.40)	 0.537	
PCA	 Baseline	(4/1)	 38.70	(34.00-65.70)	 40.60	 1.000	
Second	(5/1)	 63.10	(55.70-73.90)	 53.40	 0.667	










DTL	 Baseline	(14/13)	 92.70	(74.10-133.30)	 100.30	(67.50-122.20)	 0.422	
Last	(9/11)	 112.60	(81.10-127.30)	 105.90	(75.80-133.60)	 0.859	
PCA	 Baseline	(7/5)	 50.30	(31.40-79.00)	 40.60	(35.90-41.50)	 0.345	






the	 median	 VPT	 in	 the	 DTL	 group	 at	 baseline	 was	 31.13V	 (29-38.5)	 compared	 to	 42.25V	
(31.5-45)	in	the	PCA	group	(p=0.141).	The	binary	analysis	demonstrated	the	large	majority	of	
patients	in	both	groups	had	an	abnormal	VPT,	78.6%	at	baseline	in	the	DTL	group	and	88.9%	
in	 the	 PCA	 group	 (p=0.237).	 The	 levels	 were	 similar	 at	 the	 last	 visit	 (DTL	 90.9%	 and	 PCA	
85.7%,	p=0.237)	and	on	the	non-study	leg	(baseline	71.4%	vs	87.5%,	p=0.380	and	last	81.8%	
vs	83.3%,	p=0.728).	Whether	 the	patient	went	on	 to	heal	 or	not,	 there	was	no	 significant	
difference	between	the	baseline	and	the	last	VPT	(Table	5.7-24).	
Between	 the	 study	 and	 the	 non-study	 leg,	 there	 was	 no	 significant	 difference	 in	 the	
results.	The	median	VPT	for	 the	study	 leg	at	baseline	 in	 the	DTL	group	was	31.13V	(29.00-
38.5)	and	30.63V	(23.25-37.5,	p=0.196),	in	the	non-study	leg.	In	the	PCA	group,	the	baseline	




(31.5-46)	 and	 41.5V	 (25.5-42.25,	 p=0.381)	 respectively.	 There	 was	 also	 no	 significant	
difference	 in	 the	 proportion	 of	 patients	 with	 abnormal	 VPT	 results	 in	 the	 healed	 and	
unhealed	patients.	










DTL	 Baseline	(6/8)	 30.38	(29.00-35.50)	 32.00	(24.38-43.88)	 0.662	
Last	(6/5)	 33.25	(30.75-33.785)	 29.50	(28.00-37.25)	 1.000	
PCA	 Baseline	(6/3)	 44.25	(31.50-46.00)	 41.50	(25.50-42.25)	 0.381	




DTL	 Baseline	(6/8)	 24.13	(15.25-27.75)	 37.25	(30.13-38.13)	 0.043	
Last	(6/5)	 31.00	(26.75-34.00)	 36.25	(26.80-38.00)	 0.537	
PCA	 Baseline	(5/3)	 49.00	(30.90-49.00)	 32.00	(31.25-36.00)	 0.786	













healed	 had	 a	 significantly	 lower	 score	 at	 the	 last	 visit	 (3.66	 (1-10.32)	 vs	 0.00	 (0-3.33),	
p=0.043).	Those	who	did	not	heal	had	a	higher	score	at	 the	 last	visit	although	this	did	not	
reach	 significance	 (4.83	 (3.83-7.99)	 vs	 5.66	 (3.66-10.32),	 p=0.458).	 In	 the	 PCA	 group,	 the	
results	for	the	last	visit	(1.83	(0.00-8.66))	were	lower	than	at	baseline	(4.50	(0.00-6.99))	but	
did	 not	 reach	 significance	 (p=0.500).	 In	 the	DTL	 group	71%	of	 patients	who	had	 a	 normal	
baseline	result	also	had	a	normal	last	result,	in	the	PCA	group	this	was	true	of	60%.	
In	 the	 DTL	 group,	 the	 NTSS-6	 results	 for	 the	 unhealed	 patients	 were	 lower	 than	 the	
healed	patients,	although	the	results	did	not	reach	significance.	In	the	PCA	group	the	NTSS-6	
















DTL	 Baseline	(6/8)	 3.66	(1.00-10.32)	 4.83	(3.83-7.99)	 0.662	
Last	(6/5)	 0.00	(0.00-3.33)	 5.66	(3.66-10.32)	 0.126	
PCA	 Baseline	(6/3)	 4.50	(0.00-6.99)	 2.33	(2.00-3.00)	 1.000	








There	was	no	 significant	difference	 in	 the	proportion	of	 patients	with	 abnormal	 results	
when	the	baseline	result	was	compared	to	the	last	result.	On	the	study	leg,	DTL	group,	90%	
of	patients	who	had	an	abnormal	result	at	baseline	also	had	an	abnormal	result	at	the	last	






















































with	 abnormal	 being	 defined	 as	 unable	 to	 detect	 at	 least	 one	 point.	 Similarly	 to	 the	
monofilament,	the	results	suggested	that	there	was	significant	neuropathy	present.	A	lower	
proportion	of	patients,	compared	to	the	monofilament,	were	unable	to	detect	any	points	at	






There	was	no	 significant	difference	 in	 the	proportion	of	 patients	with	 abnormal	 results	

























































good	 in-line	 flow	 to	 the	 foot	 and	 so	 no	 angioplasty	was	 performed,	 the	 other	 underwent	
thrombolysis	after	a	superficial	femoral	artery	(SFA)	occlusion	was	crossed	and	immediately	
occluded.	 After	 twenty-four	 hours	 thrombolysis	 and	 an	 SFA	 stent,	 in-line	 flow	 to	 the	 foot	
was	achieved.	Only	two	patients	did	not	have	in-line	flow	by	the	end	of	the	procedure,	they	
both	had	patent	peroneal	run-off.	











In	 the	DTL	group	between	the	first	and	second	visit	 there	was	a	significant	reduction	 in	






































Assessment	 of	 the	 reliability	 of	 the	 Bollinger	 data	 demonstrated	 good	 correlation	
between	 assessors	 with	 good	 internal	 consistency.	 The	 intra-observer	 reliability	 also	
demonstrated	good	correlation	and	internal	consistency	(Sections	3.4.1	and	3.4.2).	
6.1.2. Primary	 Outcome:	 Difference	 between	 median	 Bollinger	 score	 in	 each	
arterial	segment	in	patients	with	DM	compared	to	patients	without	DM.	
When	the	results	were	separated	by	indication	for	procedure	the	only	vessels	that	had	a	




Overall	 those	 with	 DM	 had	 a	 higher	 burden	 of	 disease	 throughout	 the	 infra-inguinal	




one	 year.	 There	 was	 no	 significant	 difference	 in	 the	 rates	 of	 further	 revascularisation	
procedure	(section	3.8.3).	
6.2. WHAT	 IS	 THE	 RELATIONSHIP	 OF	 REVASCULARISATION	 AND	
IMPROVEMENT	 IN	 MICROCIRCULATION	 TO	 WOUND	 HEALING	 AND	
PERIPHERAL	 NEUROPATHY	 IN	 DIABETIC	 FOOT	 DISEASE?	 AN	
OBSERVATIONAL	COHORT	STUDY.	
Despite	the	small	recruitment	numbers,	it	was	possible	to	address	some	of	the	outcome	




of	 those	with	 larger	 ulcers	 continuing	 in	 the	 study	 longer	 than	 an	 actual	 increase	 in	 ulcer	
size,	as	Figure	6.2-1	demonstrates	all	but	a	few	patients	had	an	incremental	decrease	in	their	





6.2.1. Primary	 Outcome:	 Evidence	 of	 difference	 in	 the	 level	 of	 change	 in	 the	
time	to	maximum	flux	between	before	and	after	PCA.	
Despite	 the	 limitations	 of	 the	 study	 there	 was	 the	 suggestion	 that	 improving	 the	
macrocirculation,	by	way	of	PCA	 lead	 to	an	 improvement	 in	 the	microcirculation.	On	both	
the	 study	 toe	 and	 dorsum	 there	 was	 a	 reduction	 in	 the	 time	 to	 maximum	 flux	 (TtM)	
following	 angiography.	 By	 the	 last	 visit	 for	 the	 healed	 group	 on	 the	 study	 toe	 TtM	 had	
significantly	reduced	from	210.5s	(72.18-231)	to	50.71s	(27.38-105.18,	p=0.046).	At	baseline,	






















study	 toe	 and	 a	 non-significant	 increase	 on	 the	 study	 dorsum	 (5.23s	 vs	 13.15s	 p=0.345)	
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(Table	5.7-9).	Using	TtM,	it	was	not	possible	to	identify	patients	at	baseline	who	were	more	
































with	 diabetic	 foot	 disease	 improves	 wound	 healing	 and	 degree	 of	
peripheral	neuropathy.	
Due	 to	 the	 low	 numbers	 recruited	 it	 is	 not	 possible	 to	 accept	 or	 reject	 the	 overall	


















The	 examination	 of	 the	 distribution	 of	 disease	 was	 based	 on	 a	 large	 prospectively	





problem	with	 closely	matching	 cohorts	 is	 that	 they	may	 no	 longer	 represent	 the	 general	
population.	The	demographics	of	the	matched	cohorts	were	compared	to	the	raw	dataset	to	
examine	this	as	a	potential	weakness.	There	was	no	significant	difference	in	age	in	the	DM	





no	 unknown	 data,	 to	 the	 raw	 dataset,	which	 includes	 some	 unknown	 data,	 the	 unknown	
group	was	excluded.	The	summary	of	the	areas	of	significant	difference	is	presented	in	Table	
6.3-1.	The	full	breakdown	of	observed	values,	expected	values	and	residuals	can	be	found	in	
Appendix	 VIII.	 Smoking	 was	 the	 only	 demographic	 that	 had	 significantly	 different	
proportions	 in	both	groups.	The	NDM	group	had	more	areas	of	 significant	difference	 than	
the	DM	group	(four	compared	to	three).	This	suggests	that	the	NDM	group	had	been	more	
altered	from	the	general	population	than	the	DM	group.		




















(27/120)	 were	 recruited.	 This	 was	 particularly	 true	 in	 the	 peripheral	 bypass	 group	 where	
only	 two	 patients	 out	 of	 the	 proposed	 48	were	 recruited	 (4.2%).	 In	 the	 PCA	 group	 18.8%	
(9/48)	 were	 recruited	 and	 58.3%	 (14/24)	 in	 the	 DTL	 group.	 Much	 of	 the	 problem	 with	
recruitment	revolved	around	difficulties	 in	 identifying	patients	without	DM	as	described	 in	
Section	1.1.1.1.		
Of	 the	 twenty-six	 patients	 recruited	 only	 fifteen	 patients	 reached	 a	 defined	 endpoint	
during	 the	 period	 for	 recruitment	 and	 follow-up.	 Thirteen	 patients	 (50%)	 healed	 and	 two	
patients	 had	 a	major	 amputation	 (7.7%).	 Six	 patients	 were	 lost	 to	 follow-up	 (23%),	 three	
requested	to	 leave	the	study	(11.5%),	and	two	had	continuing	ulceration	at	the	end	of	the	
study	(7.7%).	Of	the	three	that	requested	to	leave	the	study,	one	was	an	elderly	patient	who	






been	 only	 to	 recruit	 those	 attending	 for	 their	 first	 clinic	 appointment	 for	 the	 ulcer	 in	
question.	Published	data	on	time	to	first	assessment	 in	a	specialist	clinic	suggests	that	this	
would	 have	 reduced	 the	 prior	 duration.	 In	 the	 most	 recent	 publication	 of	 the	 National	
Diabetes	Foot	Care	Audit	71.9%	of	patients	had	their	first	assessment	in	thirteen	days	or	less	







those	 without	 and	 this	 was	 particularly	 true	 below	 the	 knee.	 When	 our	 results	 were	
compared	 to	 the	 other	 two	 studies	 that	 had	 previously	 used	 the	 Bollinger	 score83,90	 the	
median	scores	were	generally	higher	than	ours.	This	was	true	of	both	study	groups.	Of	the	
studies	 that	 separated	 out	 the	 infrageniculate	 vessels	 both	 Jude	 et	 al.83	 and	Diehm	 et	 al.	
(2008)90,	using	the	Bollinger	score,	found	lower	scores	 in	the	peroneal	artery	(PEA)	 in	both	
the	control	and	the	DM	group.	However,	Menzoian	et	al.159	and	Ciavarella	et	al.157,	using	an	
alternative	 scoring	 system	 and	 presence	 of	 occlusion	 respectively,	 were	 unable	 to	
demonstrate	this.		
It	 would	 seem	 that	 the	 Bollinger	 score	 is	 a	 more	 sensitive	 method	 of	 detecting	 the	
differences	in	degree	of	disease	between	vessels.	An	aim	of	our	study	was	to	further	explore	
the	 differences	 between	 each	 arterial	 segment,	which	 included	 dividing	 each	 of	 the	 tibial	
vessels	 into	 three	 segments.	 These	 segments	 demonstrated	 that,	 when	 all	 patients	 were	
considered,	 the	only	vessels	 in	which	 there	was	 significant	difference	across	 the	segments	
were	the	anterior	tibial	artery	(ATA)	and	PEA	in	patients	with	claudication.	There	was	a	non-
significant	 trend	 towards	 worse	 disease	 distally	 (Table	 6.4-1).	 There	 were,	 however,	 no	
significant	differences	between	the	DM	group	and	the	control	group	in	the	individual	tibial	
segments	 (Section	 3.8.2).	 For	 this	 reason,	 it	 can	 be	 argued	 that	 the	 division	 of	 the	 crural	
vessels	 into	thirds	has	only	added	 limited	 information.	 In	Bollinger’s	original	description	of	
his	 scoring	 system,	 only	 the	 first	 3cm	of	 the	ATA	 and	5cm	of	 the	PEA	 and	posterior	 tibial	
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artery	 (PTA)	were	 included.	The	results	 from	these	segments	were	significantly	 lower	 than	
the	scores	for	the	whole	vessel	(Table	6.4-2).	This	shows	that	extending	the	segments	gives	a	
fuller	picture	of	the	extent	of	disease	present.	
















	 ATA	 23	 4	(0-15)	 23	 4	(0-15)	 22	 13	(0-15)	 0.201	
Asymptomatic	 PEA	 23	 0	(0-2)	 23	 0	(0-3)	 22	 0	(0-3)	 0.961	
	 PTA	 23	 2	(0-15)	 23	 4	(0-15)	 22	 11	(0-15)	 0.832	
Claudication	
ATA	 148	 2	(0-6)	 139	 0	(0-13)	 140	 1	(0-15)	 0.005	
PEA	 148	 0	(0-3)	 140	 0	(0-13)	 138	 0	(0-13)	 0.002	
PTA	 148	 0	(0-4)	 139	 0	(0-4)	 140	 0	(0-7)	 0.082	
Critical	
Ischaemia	
ATA	 133	 6	(0-13)	 131	 3	(0-15)	 130	 13	(0-15)	 0.407	
PEA	 132	 3	(0-13)	 131	 1	(0-15)	 130	 0	(0-15)	 0.598	











	 n	 Median	(IQR)	 n	 Median	(IQR)	
	 Anterior	tibial	 23	 2	(0-13)	 22	 13	(0-15)	 0.011	
Asymptomatic	 Peroneal	 23	 0	(0-0)	 22	 0	(0-3)	 0.077	
	 Posterior	tibial	 23	 3	(0-15)	 22	 13	(0-15)	 0.078	
Claudication	
Anterior	tibial	 148	 0	(0-3)	 140	 5	(0-15)	 <0.001	
Peroneal	 148	 0	(0-1)	 140	 2	(0-13)	 <0.001	
Posterior	tibial	 148	 0	(0-3)	 143	 0	(0-13)	 <0.001	
Critical	
Ischaemia	
Anterior	tibial	 133	 3	(0-7)	 130	 13	(2-15)	 <0.001	
Peroneal	 132	 1	(0-13)	 131	 3	(0-15)	 <0.001	
Posterior	tibial	 133	 4	(0-15)	 132	 14	(2-15)	 <0.001	
*Mann-Whitney	U	Test	
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Our	 results	 suggested	 that	 patients	without	 DM	 and	 presenting	with	 critical	 ischaemia	
had	more	 disease	 in	 the	 pedal	 vessels	 than	 patients	with	 DM.	 The	 trend	was	 also	 in	 this	
direction	in	the	claudication	group	but	not	in	the	asymptomatic	group	(Section	3.8.2).	In	the	
literature,	 this	 has	 been	 an	 inconsistent	 finding.	 Conrad	 in	 1967	 examined	 casts	 of	 the	
vascular	tree	from	amputated	limbs.	In	this	cohort	of	twenty	patients,	the	NDM	group	had	
more	pedal	disease.	The	groups	 from	this	 study	are	a	bit	unusual	 in	 that	almost	all	of	 the	
NDM	 group	 presented	 with	 acute	 symptoms	 whereas	 the	 DM	 group	 had	 chronic	
presentations169.	Ciavarella	et	al	also	 found	more	plantar	disease	 in	 the	DM	group	 in	 their	
1993	study	that	examined	patients	with	symptomatic	PAD157.	Menzoian	et	al	 in	1989	using	
LaMorte	et	 al’s	 scoring	 system	 (described	 in	 Section	 2.3.2)	 found	no	 significant	 difference	
between	 the	 groups159,161.	 Diehm	 et	 al	 in	 2008	 or	 Haine	 et	 al	 in	 2018	 were	 not	 able	 to	
demonstrate	a	significant	difference	between	patients	with	and	without	DM	either90,171.	The	
trend	 in	 both	 studies	 was	 for	 patients	 with	 DM	 to	 have	 a	 higher	 burden	 of	 disease	 than	
patients	without90,171.	Both	Haine	and	Diehm	separated	patients	with	DM	from	patients	with	














can	be	a	potential	 target	 for	bypass	and,	as	endovascular	 techniques	are	 improving,	are	a	
potential	 target	 or	 retrograde	 conduit	 for	 endovascular	 therapy266-271.	 In	 addition	 to	 that	
patients	 with	 pedal	 disease	 have	 been	 found	 to	 have	 higher	 rates	 of	 amputation	 and	
mortality	and	it	is	an	independent	predictor	of	failure	of	revascularisation269.	
Other	 studies	 have	 considered	 the	 outcomes	 of	 patients	 with	 DM	 following	 PCA	 or	
stenting.	Many	have	not	demonstrated	any	significant	difference	in	the	outcomes	between	





for	 major	 adverse	 events	 (p<0.001),	 all-cause	 mortality	 (p=0.001),	 major	 amputation	
(p=0.001)	 and	 further	 revascularisation	 (p=0.03).	 On	 multivariate	 analysis,	 DM	 remained	
associated	with	 significantly	 higher	 rates	 of	major	 adverse	 events,	 all-cause	mortality	 and	
major	 amputation	 (hazard	 ratio	 (HR)	 1.73	 (95%	 confidence	 interval	 1.35-2.23),	 1.83	 (1.33-
2.52)	and	5.52	(1.82-16.71)	respectively).	However	further	revascularisation	did	not	have	a	










with	DM	had	worse	 limb	 salvage	 (p<0.001),	 and	 survival	 (p=0.001).	 In	 addition,	 there	was	
worse	 primary	 patency	 (defined	 as	 the	 return	 of	 symptoms	 and	worsening	 ankle-brachial	
indices	 or	 pulse	 volume	 recordings,	 p=0.009)	 but	 comparable	 assisted	 patency	 (further	
endovascular	procedure,	excluding	surgical	bypass,	p=0.18).		
Inter	 and	 intra-observer	 reliability	 for	 the	 Bollinger	 score	was	 examined	 as	 part	 of	 the	
study	 to	 consider	whether	 the	 adjustments	 to	 the	 scoring	 system	were	 reproducible.	 The	
results	showed	good	inter-observer	agreement	and	good	intra-observer	agreement	(Section	
3.4.1).	 In	 Bollinger’s	 original	 description	 of	 the	 scoring	 system,	 they	 examined	 agreement	
between	 five	 scorers	on	six	angiograms	using	Kendall’s	 coefficient	of	 concordance	 (KCC)82.	
They	 state	 that	 the	 agreement	 appeared	 to	 be	 excellent	 with	 a	 p-value	 <0.001	 but	
unfortunately	do	not	quote	the	actual	value	of	KCC,	so	the	accuracy	of	this	statement	is	hard	
to	 assess.	 Since	 then	 a	 few	 other	 studies	 have	 addressed	 this	 question	 using	 a	 variety	 of	
methods.	Bradbury	et	al.	 (2010)84	 compared	 the	mean	 score	 for	 the	whole	 leg,	 above	 the	
knee	 and	below	 the	 knee,	 for	 two	observers.	 These	 scores	were	 further	 divided	 into	 four	
groups	 (<3,	 3-5,	 6-8,	 ³9)	 to	 allow	 comparison	 to	 the	 second	 Trans-Atlantic	 Inter-Society	
Consensus	Document	on	Management	of	Peripheral	Arterial	Disease	(TASC	II)	classification	





0.26	 (0.16)	 respectively),	 but	 the	 rest	 of	 the	 values	 were	 moderate	 to	 very	 good	 and	













(DTL	all	patients	at	baseline	13.4s	 (3.68-73.85)	and	 longer	 in	 those	 that	had	healed	at	 the	













PCA	 group	 had	 a	median	 TtM	of	 198.79s	 (69.18-287.33).	 Those	who	 did	 not	 heal	median	






laser	Doppler	 fluxmetry	 (LDF).	Data	previously	 obtained	at	 our	 institution	 showed	a	mean	
improvement	of	fourteen	seconds	at	six-weeks	following	PCA	in	ten	patients,	four	of	whom	
had	DM	(69±27	vs	55±30,	p=non-significant)261.	This	is	a	much	smaller	change	than	observed	
in	 the	 current	 study	 with	 the	 smallest	 difference	 at	 the	 second	 visit	 being	 92s.	 Using	
alternative	 methods	 to	 assess	 the	 microcirculation	 others	 have	 demonstrated	 this	






examples	 of	 other	 variables).	 This	 was	 chosen	 as	 throughout	 the	 comparisons	 it	 most	
frequently	 demonstrated	 a	 significant	 difference	 between	 measures.	 In	 addition	 to	 this	
within	 the	 literature	 TtM	 has	 regularly	 been	 found	 to	 be	 able	 to	 discriminate	 between	
groups107,231,232,285,286.	Other	variables	that	have	been	found	to	discriminate	include	time	to	
resting	flux	(time	from	release	of	cuff	until	value	of	resting	flux	reached),	 time	to	recovery	
(TtR),	 time	 to	half	 recovery	 (Tt1/2),	maximum	 flux	and	a	 ratio	of	maximum	 flux	 to	 resting	
flux231,232,285,286.	 Variables	 that	 have	 been	 found	 to	 be	 reliable	 and	 reproducible	 include	
resting	 flux,	 latency	 between	 cuff	 release	 and	 start	 of	 recovery,	 maximum	 flux,	 TtM,	
maximum	flux	above	resting	flux,	a	ratio	of	maximum	flux	to	biological	zero	and	reperfusion	
rate93,234,259.	 The	 other	 variables	 that	 we	 measured	 can	 be	 found	 in	 Appendix	 VII	 In	 this	
dataset,	 other	 than	 TtM,	 the	 variables	 that	 most	 commonly	 demonstrated	 a	 significant	
difference	were	Tt1/2	and	TtR.	The	trends	that	they	demonstrated	mirrored	that	of	TtM	and	
so	do	not	offer	up	any	further	insights	into	the	relationship.		















TcPO2	 despite	 low	 TBPI.	 The	 only	 group	with	 significantly	 lower	 TcPO2	was	 those	with	 all	
three	pathologies.	They	concluded	that	there	were	two	major	 influences	on	the	cutaneous	
perfusion	 in	 patients	with	 DM	 and	 PAD	 and	 those	were	 the	macrovascular	 disease	 and	 a	
global	 microcirculatory	 change	 related	 to	 DM287.	 Pardo	 et	 al	 in	 2014	 correlated	 ankle	
brachial	pressure	index	(ABPI)	with	TcPO2	in	patients	with	both	DM	and	PAD	before,	during	
and	 after	 PCA288.	 They	 found	 that	 both	 ABPI	 and	 TcPO2	 improved	 following	 PCA	 but	 the	
correlation	 between	 the	 two	 was	 poor288.	 No	 studies	 that	 correlated	 LDF	 parameters	 to	
degree	of	macrovascular	disease	were	identified.		
In	 our	 data	 the	 DM	 group	 had	 been	 clinically	 assessed	 to	 have	 no	 significant	
macrovascular	disease	and	this	was	assumed	to	remain	stable	through	the	study.	In	the	PCA	
group,	one	patient	was	found	to	not	have	significant	PAD	at	angiography	whilst	all	the	others	
had	 a	 procedure	 that	 improved	 the	 macrovascular	 flow.	 In	 one	 case	 thrombolysis	 was	
required	for	twenty-four	hours	before	flow	was	achieved	and	in	two	cases	the	flow	achieved	
was	 not	 in-line	 to	 the	 foot	 but	 via	 the	 peroneal	 artery	 only	 (Section	 5.7.8.1).	 The	
thrombolysis	patient	went	on	to	heal	and	had	a	reduction	from	231s	to	48s	in	TtM	at	second	
visit.	 Unfortunately,	 both	 patients	 with	 peroneal	 run-off	 only	 left	 the	 study	 early	 for	 the	
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reasons	discussed	in	Section	6.3.2.	One	only	had	baseline	measurements	the	other	had	two	
measurements	 post-procedure	 and	 demonstrated	 a	 reduction	 in	 TtM	 from	 289s	 to	 9s	 at	
second	visit.	The	patient	with	a	diagnostic	only	procedure	had	more	favourable	parameters	
than	the	other	members	of	the	group	at	baseline,	TtM	13.15s,	there	was	also	a	reduction	at	
second	 visit	 to	 3s.	 Using	 Spearman’s	 correlation	 coefficient,	 there	 was	 no	 significant	




Our	 results	 for	 SPP	were	 higher	 than	many	 published	 results	 in	 both	 the	DTL	 and	 PCA	
group.	 Yotsu	 et	 al.253,	 in	 their	 neuropathic	 group,	who	 are	 comparable	 to	 our	 DTL	 group,	
quoted	median	SPP	of	67mmHg	(57-75)	for	those	who	healed	and	65mmHg	(40-69)	for	those	
who	did	not.	Like	us,	 they	 found	no	significant	difference	between	the	groups.	The	neuro-













The	variability	 in	results	both	within	the	 literature	and	when	compared	to	our	results	 is	








critical	 ischaemia.	 TASC	 II	 considers	 that	 a	 TBP	 of	 <50mmHg	 is	 indicative	 of	 critical	 limb	
ischaemia	 (definition:	 ischaemic	 rest	 pain	 for	 more	 than	 two	 weeks,	 ulcers	 or	 gangrene	
related	to	arterial	disease)81.	The	International	Working	Group	on	the	Diabetic	Foot	felt	that	
a	 TBP	 of	 <30mmHg	 was	 an	 indication	 for	 revascularisation	 and	 patients	 with	 a	 TBP	 of	
³30mmHg	 should	 heal15.	 The	 most	 recent	 European	 guidelines	 on	 the	 diagnosis	 and	
treatment	of	PAD	includes	the	Wound,	Ischaemia	and	Foot	infection	(WIfI)	classification	for	
risk	 stratification	 of	 chronic	 limb	 threatening	 ischaemia184.	 In	 this	 classification	 a	 TBP	 of	










published.	Most	 cohorts,	of	patients	with	 tissue	 loss,	 in	 the	published	 literature,	 include	a	
mixture	 of	 patients	 with	 and	 without	 PAD	 and	 so	 are	 different	 to	 the	 cohorts	 presented	
here.	In	addition	to	this	TBP	values	vary	greatly	depending	on	the	device	use	and	so	it	can	be	
hard	 to	 compare	 between	 cohorts293.	 TBP	 whilst	 is	 a	 good	 marker	 for	 PAD	 it	 can	 be	








mechanisms	have	been	proposed	 involving	metabolic	 defects,	 inflammatory	 and	oxidative	
stress	and	vascular	disease295.	The	only	treatment	that	has	been	convincingly	found	to	have	
an	 impact	 on	 the	 development	 and	 progression	 of	 DPN	 is	 good	 glycaemic	 control63.	 No	
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studies	 have	 been	 able	 to	 demonstrate	 a	 causal	 relationship	 between	 improvement	 in	
macrovascular	disease	and	DPN.		
The	 improvement	 that	was	seen	 in	NTSS-6	 in	 the	DTL	group	can	also	be	explained	by	a	
reduction	in	the	symptoms	of	active	ulceration	or	infection.	
6.5. PLANS	FOR	FUTURE	STUDY	
From	 the	 studies	 presented	 above	 it	 is	 not	 possible	 to	 answer	 the	 overall	 hypothesis	
(Section	6.2.3).	One	option	for	future	work	would	be	to	refine	the	cohort	study	and	continue	
recruitment	 with	 a	 focus	 on	 recruiting	 patients	 without	 DM	 and	 those	 undergoing	 PBS.	
When	considering	this	as	an	option	the	sample	size	calculation	performed	 in	the	design	of	
the	pilot	study	(Section	5.3.2)	was	repeated	using	data	gained	from	this	study.	
When	 the	sample	 size	calculation	was	originally	performed	 there	was	no	available	data	
for	 the	DTL	 group.	 The	 results	 from	 the	 pilot	 study	make	 it	 possible	 to	 repeat	 the	 power	





the	 PCA	 groups.	 Hence,	 the	 difference	 in	 the	 change	 between	 the	 two	 groups	 was	 72	
seconds	(108-36).	







Due	 to	 the	 lack	 of	 recruitment	 in	 the	 PBS	 group	 the	 best	 data	 remains	 that	which	 the	
initial	 power	 calculation	 was	 performed	 using.	 However,	 it	 would	make	 sense	 to	 aim	 for	
equal	group	sizes	if	further	recruitment	was	to	take	place.	Therefore,	if	the	same	proportion	
of	 drop	 outs	was	 to	 be	 expected	 (20%)	 the	 group	 size	would	 increase	 to	 80	meaning	 the	
target	for	recruitment	would	be	240	patients.	
Based	 on	 the	 difficulties	 with	 the	 pilot	 study	 it	 is	 highly	 unlikely	 that	 this	 level	 of	
recruitment	 would	 be	 possible	 without	 involving	 a	 large	 number	 of	 sites.	 There	 are	 also	
questions	whether	 the	results	would	answer	the	hypothesis	proposed	and	so	 it	 is	 felt	 that	
proceeding	with	this	study	would	be	fruitless.	
To	 move	 forward	 with	 addressing	 the	 question	 of	 how	 the	microcirculation	 relates	 to	
wound	healing	 it	 is	 felt	that	a	better	understanding	of	how	the	macrocirculation	relates	to	
microcirculation	 is	 required	 first.	 In	addition,	how	the	microcirculation	 in	 the	 foot	changes	











hours	 preceding	 PCA.	 This	 is	 a	 development	 of	Williams’s287	 and	 Pardo’s288	 studies	with	 a	
focus	 on	 the	 burden	 of	 macrovascular	 disease.	 A	 progression	 of	 this	 study	 could	 be	 to	
recalculate	 Bollinger	 score	 and	 repeat	 skin	 perfusion	 tests	 following	 PCA	 as	 a	measure	 of	
success	of	the	procedure.	
The	 second	hypothesis	 is	 aimed	at	 further	examining	 the	 finding	 that	 in	our	DTL	group	
there	was	a	significant	reduction	in	TtM	on	the	study	toe	between	the	baseline	and	last	visit	
(Table	 5.7-9).	 Patients	 with	 active	 diabetic	 foot	 ulcers	 but	 no	 significant	 PAD	 would	 be	
recruited.	Patients	would	be	 recruited	at	 first	attendance	 for	 the	 index	ulcer	and	accurate	
volumes	 of	 the	 ulcer	 measured	 at	 the	 same	 time	 as	 assessment	 of	 skin	 perfusion	





is	 the	most	appropriate	measure	of	skin	perfusion	to	utilise.	This	 is	particularly	true	of	 the	
second	 study	 due	 to	 the	 number	 of	 assessments	 that	would	 be	 required.	 The	process	 for	
performing	 PORH	 is	 quite	 lengthy	 and	 cumbersome.	 In	 addition,	 using	 the	 placement	 of	
single	probes	adjacent	to	the	ulcers	it	is	hard	to	form	a	generalised	view	of	the	status	of	the	
microcirculation	surrounding	the	ulcer.	A	modality	that	 images	the	whole	of	the	ulcer	area	
with	surrounding	skin	 from	which	 it	 is	possible	 to	 take	an	average	of	clearly	defined	areas	
may	 be	 more	 appropriate.	 Examples	 include	 laser	 Doppler	 perfusion	 imaging	 and	 laser	
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speckle	contrast	 imaging297.	TcPO2	as	an	alternative	measure	should	also	be	considered	as	






vessels	 and	 the	 pedal	 vessels	 with	 good	 inter	 and	 intra-rater	 reliability.	 In	 well	 matched	
cohorts	 those	without	 DM	 and	 critical	 ischaemia	 were	 found	 to	 have	 a	 higher	 burden	 of	
disease	in	the	pedal	vessels	but	patients	with	DM	had	a	higher	burden	of	disease	overall.	In	
addition	 to	 this,	 it	 has	 been	 shown	 that	 there	 is	 no	 difference	 in	 the	 need	 for	 further	
revascularisation	 in	 the	 DM	 patients	 despite	 having	 poorer	 outcomes	 overall.	 The	 studies	
then	 moved	 on	 to	 examine	 the	 microcirculation	 in	 patients	 with	 DM	 and	 active	 foot	
ulceration.	This	demonstrated	that	patients	who	had	arterial	disease	and	required	a	PCA	had	
significantly	 impaired	 microcirculatory	 reactivity	 compared	 to	 patients	 without	 significant	
PAD.	The	study	showed	that	microvascular	reactivity	significantly	improved	following	a	PCA	
bringing	this	group	up	to	a	level	comparable	to	the	DTL	group.		
Overall	 these	 studies	 have	 added	 to	 the	 literature	 considering	 the	 nature	 of	 PAD	 in	














































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Patients	with	 active	 tissue	 loss	 and	 PAD	 confirmed	 clinically	 and	 on	Duplex	Ultrasound	









































Potential	 patients	 will	 be	 identified	 predominantly	 from	 diabetic	 foot	 clinics,	 vascular	
clinics	 and	 inpatient	 admissions	 at	 the	 study	 sites.	 The	 patients	 will	 be	 identified	 by	 the	
investigators	and	other	doctors	on	the	vascular	and	diabetes	teams.	As	it	will	not	be	possible	
for	a	member	of	 the	study	to	be	present	 in	person	at	all	 relevant	clinics	review	of	referral	
documentation	to	clinics,	theatre	lists	and	angioplasty	lists	will	be	conducted.	This	will	only	
be	 performed	 at	 the	 University	 Hospitals	 Birmingham	 site	 as	 I	 only	 have	 clinical	
responsibilities	at	 this	 site	and	 so	am	already	 in	 receipt	of	 the	 relevant	 lists.	 If	 a	potential	










All	 participants	 will	 be	 verbally	 invited	 to	 take	 part	 in	 the	 study	 by	 the	 clinical	 team	
providing	their	care.	They	will	be	given	written	information	with	regards	to	the	purpose	and	
design	 of	 the	 study	 (Appendix	 V).	 They	 will	 then	 be	 invited	 to	 participate	 and	 if	 agreed,	
consented	 using	 a	 standardised	 consent	 form	 (Appendix	 VI).	 This	 will	 be	 performed	 and	
undertaken	by	a	member	of	the	study	team.	
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Consent	 to	 participate	 will	 include	 consent	 to	 the	 use	 of	 data	 obtained	 during	 their	
participation	 in	 the	 final	 analysis.	 Participants	 will	 be	 free	 to	 leave	 the	 study	with	 only	 a	
verbal	 request,	 though	their	non-identifiable	data	will	continue	to	remain	within	the	study	






before	 their	 procedure.	 For	 the	 DTL	 group,	 the	 initial	 assessment	 will	 be	 carried	 out	






that	 falls	 nearest	 this	 time.	 This	 includes	 vascular,	 diabetes	 and	 podiatry	 appointments.	
Reassessment	will	 continue	until	 the	ulcer	 is	 decided	 to	 have	 clinically	 healed,	 the	 limb	 is	
amputated,	or	the	end	of	the	study	is	reached.	









position	 so	 they	 can	 acclimatise	 to	 the	 temperature	 of	 the	 room.	 During	 the	 first	 fifteen	
minutes,	 the	 NTSS-6	 questionnaire	 will	 be	 completed,	 and	 monofilament,	 ITT	 and	 VPT	


















VPT	will	 be	assessed	on	 the	pulp	of	 the	hallux	or	next	dominant	 toe	 if	 amputation	has	
occurred	 in	 the	 past	 or	 the	 toe	 is	 necrotic.	 A	 neurothesiometer	 will	 be	 used.	 The	 first	
measurement	 will	 be	 taken	 increasing	 from	 zero	 to	 maximum	 and	 the	 level	 at	 which	






the	 ulcer	 will	 be	 determined	 by	 multiplying	 the	 largest	 diameter	 by	 the	 second	 largest	
diameter	 perpendicular	 to	 the	 first.	 Depth	 will	 be	 described	 as	 superficial	 or	 deep:	 a	
superficial	ulcer	is	a	full-thickness	lesion	of	the	skin	not	extending	through	the	subcutis,	and	
a	 deep	 ulcer	 is	 a	 lesion	 of	 the	 skin	 extending	 through	 the	 subcutis.	 An	 infection	 will	 be	
diagnosed	if	two	or	more	of	the	following	signs	are	present:	frank	purulence,	local	warmth,	
erythema,	lymphangitis,	oedema,	pain,	fever	and	foul	smell.	The	anatomical	location	of	the	























































(69-55)	 in	 the	 PCA	 groups.	 Hence,	 the	 difference	 in	 the	 improvement	 between	 the	 two	
groups	was	27	seconds	(41-14).	
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The	 pooled	 standard	 deviation	 from	 this	 data	 is	 30.	 If	 the	 pre	 and	 post-operative	
measurements	on	the	same	patient	are	assumed	to	be	independent,	the	standard	deviation	
of	the	change	will	be	30	times	the	square	root	of	2,	i.e.	42	
The	 study	was	 powered	 based	 on	 a	 t-test,	 assuming	 a	 standard	 deviation	 of	 42.	 For	 a	
detectable	difference	of	27,	a	sample	size	of	40	patients	per	group	(i.e.	80	total)	would	be	
sufficient	for	80%	power	at	5%	alpha.		


















Initially,	 the	 data	 will	 be	 tested	 for	 normality,	 as	 this	 is	 an	 assumption	 underlying	
parametric	analyses.	If	the	data	are	normally	distributed,	then	a	t-test	will	be	performed	to	
compare	 means	 for	 mean	 temperature	 measurements	 and	 a	 repeated	 measures	 ANOVA	
model	will	be	produced,	to	compare	the	serial	measurements	of	the	outcome	between	the	





For	 binary	 data,	 the	 outcome	 rates	will	 initially	 be	 compared	 between	 the	 study	 arms	



















































In	 order	 to	 verify	 this,	 comparisons	 will	 be	 made	 between	 those	 patients	 with	 data	
available	and	those	with	missing	values.	 If	no	significant	differences	 in	the	demographic	or	
clinical	factors	of	these	groups	are	detected,	then	it	will	be	assumed	that	the	assumption	of	
data	 missing	 at	 random	 has	 been	 met.	 If	 differences	 between	 those	 patients	 with	 and	
without	missing	data	are	present,	then	the	degree	of	this	bias	will	be	compared	between	the	
treatment	 groups.	 If	 the	 levels	 of	 bias	 are	 similar	 in	 the	 three	 groups,	 then	 the	 effect	 of	
missing	data	on	the	conclusions	of	the	final	analysis	can	be	assumed	to	be	negligible.		
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If	 significant	 bias	 is	 present,	 and	 to	 a	 different	 degree	 in	 the	 three	 groups,	 this	will	 be	
quantified	as	a	limitation	in	the	results,	and	the	conclusions	of	the	analyses	interpreted	with	
caution.	
We	 anticipate	 that	 the	 data	 collection	 from	 follow-up	 appointments	 will	 be	 relatively	
complete,	 with	 the	 majority	 of	 missing	 data	 being	 as	 a	 result	 of	 patients	 either	 not	





analysis	 will	 be	 accepted.	 However,	 if	 there	 are	 discrepancies	 between	 the	 main	 and	
sensitivity	analyses,	the	conclusions	will	be	interpreted	in	light	of	this	potential	bias.		
ETHICAL	CONSIDERATIONS 
Local	 Research	 Ethics	 Committee	 approval	 was	 sought	 from	 the	 South	 Birmingham	
Research	 Ethics	 Committee.	 Approval	 was	 granted	 on	 26th	 June	 2014.	 Approval	 was	 also	
sought	from	the	Research	and	Development	departments	of	the	three	study	sites,	University	




























As	 you	 may	 be	 aware	 University	 Hospitals	 Birmingham	 NHS	 Foundation	 Trust	 is	
actively	involved	in	clinical	research	within	many	medical	specialities.		In	the	Vascular	
Surgery	 department	 we	 are	 currently	 conducting	 a	 study	 called	 “What	 is	 the	
relationship	 of	 revascularisation	 and	 improvement	 in	microcirculation	 to	 wound	

















































































Resting	Flux	(flux)	 53.15	(35.20-104.00)	 74.50	(66.00-106.60)	 0.277	
Biological	Zero	(flux)	 4.70	(3.10-7.20)	 3.80	(3.20-4.50)	 0.781	
Maximum	Flux	(flux)	 162.95	(107.70-212.40)	 84.60	(74.50-168.30)	 0.159	
Maximum	Flux/Biological	Zero		 34.35	(21.21-58.72)	 22.27	(15.26-41.18)	 0.336	
Maximum	Flux/Resting	Level		 2.76	(1.75-5.24)	 1.27	(1.13-1.74)	 0.016	
Time	to	Recovery	(s)	 1.26	(0.83-1.73)	 3.58	(2.58-45.13)	 0.013	
Time	to	Maximum	Flux	(s)	 13.40	(3.68-73.85)	 220.80	(200.20-288.78)	 0.002	




Resting	Flux	(flux)	 16.80	(8.70-22.90)	 28.70	(22.60-37.40)	 0.013	
Biological	Zero	(flux)	 4.60	(3.40-4.90)	 5.80	(4.10-10.20)	 0.201	
Maximum	Flux	(flux)	 45.75	(23.30-63.20)	 49.00	(37.80-86.50)	 0.403	
Maximum	Flux/Biological	Zero		 9.43	(6.98-17.11)	 9.61	(8.04-15.09)	 0.975	
Maximum	Flux/Resting	Level		 2.63	(1.70-3.85)	 1.76	(1.55-2.15)	 0.124	
Time	to	Recovery	(s)	 1.03	(0.75-2.05)	 2.68	(1.70-4.33)	 0.028	
Time	to	Maximum	Flux	(s)	 8.05	(3.45-17.55)	 220.28	(93.65-279.80)	 <0.001	
Time	to	Half	Recovery	(s)	 13.64	(8.40-20.48)	 171.00	(82.31-282.03)	 <0.002	





Biological	Zero	(flux)	 3.70	(3.10-9.10)	 3.80	(3.10-5.50)	 0.971	
Maximum	Flux	(flux)	 124.40	(49.10-178.60)	 106.10	(38.70-147.10)	 0.400	
Maximum	Flux/Biological	Zero		 18.02	(5.40-29.78)	 17.09	(7.04-40.87)	 0.743	
Maximum	Flux/Resting	Level		 2.26	(1.32-2.89)	 2.09	(1.82-2.57)	 0.856	
Time	to	Recovery	(s)	 1.51	(1.00-18.88)	 2.45	(1.78-3.75)	 0.287	
Time	to	Maximum	Flux	(s)	 38.98	(12.68-141.05)	 54.80	(13.95-127.43)	 0.689	




Resting	Flux	(flux)	 9.00	(7.60-10.90)	 16.20	(12.60-47.50)	 0.003	
Biological	Zero	(flux)	 4.30	(3.10-5.40)	 5.60	(4.20-9.10)	 0.110	
Maximum	Flux	(flux)	 23.55	(13.60-36.40)	 73.20	(22.30-97.30)	 0.016	
Maximum	Flux/Biological	Zero		 4.01	(3.61-6.91)	 10.69	(5.30-13.92)	 0.046	
Maximum	Flux/Resting	Level		 2.21	(1.75-2.80)	 2.23	(1.54-4.59)	 0.856	
Time	to	Recovery	(s)	 0.91	(0.68-1.48)	 1.75	(1.53-2.50)	 0.010	
Time	to	Maximum	Flux	(s)	 15.40	(3.58-116.90)	 70.68	(31.10-138.60)	 0.149	




















Resting	Flux	(flux)	 104.80	(32.30-138.90)	 33.80	(24.70-84.45)	 0.109	
Biological	Zero	(flux)	 3.70	(2.70-7.30)	 5.75	(3.70-7.80)	 0.351	
Maximum	Flux	(flux)	 170.00	(128.10-269.50)	 80.35	(54.05-138.10)	 0.007	
Maximum	Flux/Biological	Zero		 37.69	(23.27-90.92)	 22.21	(4.75-27.32)	 0.041	
Maximum	Flux/Resting	Level		 2.58	(1.39-3.97)	 1.94	(1.27-2.62)	 0.492	
Time	to	Recovery	(s)	 1.33	(0.98-6.35)	 3.04	(1.89-7.20)	 0.272	
Time	to	Maximum	Flux	(s)	 27.08	(8.50-154.38)	 54.50	(34.73-158.00)	 0.442	




Resting	Flux	(flux)	 16.20	(10.70-29.40)	 22.80	(15.00-30.40)	 0.536	
Biological	Zero	(flux)	 3.80	(3.30-4.60)	 5.40	(4.60-6.50)	 0.027	
Maximum	Flux	(flux)	 32.90	(21.10-87.30)	 38.00	(30.50-60.40)	 1.000	
Maximum	Flux/Biological	Zero		 7.14	(5.90-21.46)	 7.06	(4.72-9.95)	 0.536	
Maximum	Flux/Resting	Level		 1.99	(1.68-3.01)	 1.77	(1.20-3.34)	 0.479	
Time	to	Recovery	(s)	 0.93	(0.80-1.53)	 2.40	(0.78-4.53)	 0.179	
Time	to	Maximum	Flux	(s)	 13.50	(4.95-20.38)	 127.78	(30.08-227.13)	 0.015	




Resting	Flux	(flux)	 109.30	(21.00-184.50)	 34.60	(25.10-54.30)	 0.375	
Biological	Zero	(flux)	 4.00	(2.60-11.50)	 4.80	(3.20-6.50)	 0.791	
Maximum	Flux	(flux)	 220.00	(153.60-273.40)	 83.90	(56.80-208.80)	 0.085	
Maximum	Flux/Biological	Zero		 38.40	(12.24-85.43)	 22.43	(17.76-43.50)	 0.425	
Maximum	Flux/Resting	Level		 2.01	(1.41-4.04)	 2.27	(1.50-3.85)	 1.000	
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Time	to	Recovery	(s)	 2.03	(1.20-2.83)	 2.38	(1.75-3.93)	 0.375	
Time	to	Maximum	Flux	(s)	 18.83	(11.83-215.65)	 35.33	(15.85-146.28)	 0.596	




Resting	Flux	(flux)	 15.20	(8.00-17.90)	 15.60	(13.70-20)	 0.660	
Biological	Zero	(flux)	 3.90	(3.50-5.00)	 4.75	(3.90-5.90)	 0.301	
Maximum	Flux	(flux)	 24.80	(18.60-54.00)	 30.00	(21.00-55.60)	 0.884	
Maximum	Flux/Biological	Zero		 6.09	(5.27-10.81)	 5.41	(4.96-6.56)	 0.404	
Maximum	Flux/Resting	Level		 2.57	(1.22-3.67)	 1.74	(1.32-4.30)	 0.884	
Time	to	Recovery	(s)	 0.95	(0.30-1.43)	 2.90	(1.50-3.58)	 0.048	
Time	to	Maximum	Flux	(s)	 15.40	(12.13-215.65)	 119.03	(42.43-265.28)	 0.122	























Resting	Flux	(flux)	 98.11	(-32.85-447.37)	 -49.07	(-62.14-38.68)	 0.051	
Biological	Zero	(flux)	 -5.71	(-16.67-54.17)	 18.32	(-15.97-87.18)	 0.657	
Maximum	Flux	(flux)	 -4.40	(-29.67-154.97)	 -20.31	(-51.41-32.62)	 0.310	
Maximum	Flux/Biological	Zero		 5.14	(-29.38-123.73)	 -33.54	(-67.06-6.59)	 0.129	
Maximum	Flux/Resting	Level		 -30.36	(-59.24-72.73)	 32.61	(-2.24-74.07)	 0.206	
Time	to	Recovery	(s)	 25.57	(-33.33-85.71)	 -45.52	(-85.26--15.69)	 0.101	
Time	to	Maximum	Flux	(s)	 94.47	(18.87-328.06)	 -42.14	(-80.90--2.17)	 0.001	




Resting	Flux	(flux)	 22.99	(-22.54-86.21)	 2.36	(-65.41-38.81)	 0.285	
Biological	Zero	(flux)	 -3.13	(-24.00-15.38)	 -7.14	(-20.69-38.30)	 0.724	
Maximum	Flux	(flux)	 2.49	(-65.01-44.83)	 -22.65	(-50.49--14.80)	 0.536	
Maximum	Flux/Biological	Zero		 -4.70	(-38.92-16.02)	 -34.58	(-66.56-15.55)	 0.375	
Maximum	Flux/Resting	Level		 -21.89	(-35.51--1.18)	 -35.22	(-45.95-67.00)	 0.930	
Time	to	Recovery	(s)	 6.67	(-26.53-27.27)	 -58.82	(-68.37-50.00)	 0.126	
Time	to	Maximum	Flux	(s)	 43.48	(-16.85-253.10)	 -20.03	(-64.01-84.71)	 0.126	




Resting	Flux	(flux)	 112.97	(-29.46-212.71)	 -16.92	(-37.67-45.19)	 0.180	
Biological	Zero	(flux)	 -21.21	(-33.33-155.56)	 -9.50	(-25.81-30.77)	 0.808	
Maximum	Flux	(flux)	 101.55	(56.46-324.54)	 8.11	(-42.96-81.76)	 0.037	
Maximum	Flux/Biological	Zero		 126.38	(-4.07-304.92)	 -0.68	(-23.11-17.55)	 0.122	
Maximum	Flux/Resting	Level		 41.35	(-24.56-92.42)	 12.97	(-8.24-35.56)	 0.660	
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Time	to	Recovery	(s)	 -4.58	(-40.98-40.00)	 -17.72	(-74.65-32.31)	 0.958	
Time	to	Maximum	Flux	(s)	 47.32	(-11.92-115.76)	 2.92	(-72.27-196.30)	 0.884	




Resting	Flux	(flux)	 47.71	(0.00-123.68)	 -18.70	(-43.65-13.57)	 0.221	
Biological	Zero	(flux)	 2.94	(-25.53-73.91)	 5.36	(-20.41-30.56)	 0.827	
Maximum	Flux	(flux)	 56.62	(8.02-77.63)	 -62.56	(-67.24--42.86)	 0.052	
Maximum	Flux/Biological	Zero		 52.63	(-3.82-89.77)	 -58.82	(-63.42--28.96)	 0.052	
Maximum	Flux/Resting	Level		 19.64	(-44.19-65.32)	 -53.63	(-66.44--24.03)	 0.221	
Time	to	Recovery	(s)	 0.00	(-60.71-33.90)	 86.96	(68.85-225.71)	 0.180	
Time	to	Maximum	Flux	(s)	 278.23	(-38.48-801.20)	 -39.97	(-45.04-43.51)	 0.221	



















Study	Toe	 Diabetic	 Tissue	 Loss	
(n=14/11)	
Resting	Flux	(flux)	 53.15	(35.20-104.00)	 104.80	(32.30-138.90)	 0.248	
Biological	Zero	(flux)	 4.70	(3.10-7.20)	 3.70	(2.70-7.30)	 0.477	
Maximum	Flux	(flux)	 162.95	(107.70-212.40)	 170.00	(128.10-269.50)	 0.790	
Maximum	Flux/Biological	Zero		 34.35	(21.21-58.72)	 37.69	(23.27-90.92)	 0.859	
Maximum	Flux/Resting	Level		 2.76	(1.75-5.24)	 2.58	(1.39-3.97)	 0.213	
Time	to	Recovery	(s)	 1.26	(0.83-1.73)	 1.33	(0.98-6.35)	 0.424	
Time	to	Maximum	Flux	(s)	 13.40	(3.68-73.85)	 27.08	(8.50-154.38)	 0.021	




Resting	Flux	(flux)	 74.50	(66.00-106.60)	 33.80	(24.70-84.45)	 0.093	
Biological	Zero	(flux)	 3.80	(3.20-4.50)	 5.75	(3.70-7.80)	 0.575	
Maximum	Flux	(flux)	 84.60	(74.50-168.30)	 80.35	(54.05-138.10)	 0.401	
Maximum	Flux/Biological	Zero		 22.27	(15.26-41.18)	 22.21	(4.75-27.32)	 0.208	
Maximum	Flux/Resting	Level		 1.27	(1.13-1.74)	 1.94	(1.27-2.62)	 0.161	
Time	to	Recovery	(s)	 3.58	(2.58-45.13)	 3.04	(1.89-7.20)	 0.069	
Time	to	Maximum	Flux	(s)	 220.80	(200.20-288.78)	 54.50	(34.73-158.00)	 0.050	





Resting	Flux	(flux)	 16.80	(8.7-22.90)	 16.20	(10.70-29.40)	 0.722	
Biological	Zero	(flux)	 4.60	(3.4-4.90)	 3.80	(3.30-4.60)	 0.646	
Maximum	Flux	(flux)	 45.75	(23.3-63.20)	 32.90	(21.10-87.30)	 0.859	
Maximum	Flux/Biological	Zero		 9.43	(6.98-17.11)	 7.14	(5.90-21.46)	 0.477	
Maximum	Flux/Resting	Level		 2.63	(1.70-3.85)	 1.99	(1.68-3.01)	 0.021	
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Time	to	Recovery	(s)	 1.03	(0.75-2.05)	 0.93	(0.80-1.53)	 0.929	
Time	to	Maximum	Flux	(s)	 8.05	(3.45-17.55)	 13.50	(4.95-20.38)	 0.041	




Resting	Flux	(flux)	 28.70	(22.60-37.40)	 22.80	(15.00-30.40)	 0.735	
Biological	Zero	(flux)	 5.80	(4.10-10.20)	 5.40	(4.60-6.50)	 0.735	
Maximum	Flux	(flux)	 49.00	(37.80-86.50)	 38.00	(30.50-60.40)	 0.091	
Maximum	Flux/Biological	Zero		 9.61	(8.04-15.09)	 7.06	(4.72-9.95)	 0.128	
Maximum	Flux/Resting	Level		 1.76	(1.55-2.15)	 1.77	(1.20-3.34)	 0.866	
Time	to	Recovery	(s)	 2.68	(1.70-4.33)	 2.40	(0.78-4.53)	 0.237	
Time	to	Maximum	Flux	(s)	 220.28	(93.65-279.80)	 127.78	(30.08-227.13)	 0.398	





Resting	Flux	(flux)	 51.00	(32.80-95.60)	 109.3	(21.00-184.50)	 0.091	
Biological	Zero	(flux)	 3.70	(3.10-9.10)	 4.00	(2.60-11.50)	 0.929	
Maximum	Flux	(flux)	 124.40	(49.10-178.60)	 220.00	(153.60-273.40)	 0.026	
Maximum	Flux/Biological	Zero		 18.02	(5.40-29.78)	 38.40	(12.24-85.43)	 0.075	
Maximum	Flux/Resting	Level		 2.26	(1.32-2.89)	 2.01	(1.41-4.04)	 0.155	
Time	to	Recovery	(s)	 1.51	(1-18.88)	 2.03	(1.20-2.83)	 0.790	
Time	to	Maximum	Flux	(s)	 38.98	(12.68-141.05)	 18.83	(11.83-215.65)	 0.182	




Resting	Flux	(flux)	 37.40	(21.90-78.50)	 34.60	(25.10-54.30)	 0.463	
Biological	Zero	(flux)	 3.80	(3.10-5.50)	 4.80	(3.20-6.50)	 0.753	
Maximum	Flux	(flux)	 106.10	(38.70-147.10)	 83.90	(56.80-208.80)	 0.917	
Maximum	Flux/Biological	Zero		 17.09	(7.04-40.87)	 22.43	(17.76-43.50)	 0.753	
Maximum	Flux/Resting	Level		 2.09	(1.82-2.57)	 2.27	(1.50-3.85)	 0.345	
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Time	to	Recovery	(s)	 2.45	(1.78-3.75)	 2.38	(1.75-3.93)	 0.600	
Time	to	Maximum	Flux	(s)	 54.80	(13.95-127.43)	 35.33	(15.85-146.28)	 0.917	





Resting	Flux	(flux)	 9.00	(7.60-10.90)	 15.20	(8.00-17.90)	 0.074	
Biological	Zero	(flux)	 4.30	(3.10-5.40)	 3.90	(3.50-5.00)	 0.721	
Maximum	Flux	(flux)	 23.55	(13.60-36.40)	 24.80	(18.60-54.00)	 0.008	
Maximum	Flux/Biological	Zero		 4.01	(3.61-6.91)	 6.09	(5.27-10.81)	 0.248	
Maximum	Flux/Resting	Level		 2.21	(1.75-2.80)	 2.57	(1.22-3.67)	 0.859	
Time	to	Recovery	(s)	 0.91	(0.68-1.48)	 0.95	(0.30-1.43)	 0.610	
Time	to	Maximum	Flux	(s)	 15.40	(3.58-116.90)	 15.40	(12.13-215.65)	 0.182	




Resting	Flux	(flux)	 16.20	(12.60-47.50)	 15.60	(13.70-20.00)	 0.500	
Biological	Zero	(flux)	 5.60	(4.20-9.10)	 4.75	(3.90-5.90)	 0.893	
Maximum	Flux	(flux)	 73.20	(22.30-97.30)	 30.00	(21.00-55.60)	 0.080	
Maximum	Flux/Biological	Zero		 10.69	(5.30-13.92)	 5.41	(4.96-6.56)	 0.138	
Maximum	Flux/Resting	Level		 2.23	(1.54-4.59)	 1.74	(1.32-4.30)	 0.225	
Time	to	Recovery	(s)	 1.75	(1.53-2.50)	 2.90	(1.50-3.58)	 0.500	
Time	to	Maximum	Flux	(s)	 70.68	(31.10-138.60)	 119.03	(42.43-265.28)	 0.686	














Study	Toe	 Diabetic	 Tissue	 Loss	
(n=6/6)	
Resting	Flux	(flux)	 83.50	(48.10-151.50)	 59.75	(32.30-122.70)	 0.600	
Biological	Zero	(flux)	 5.00	(3.10-7.20)	 5.20	(2.60-7.30)	 0.917	
Maximum	Flux	(flux)	 171.55	(140.00-254.60)	 166.95	(128.00-190.90)	 0.463	
Maximum	Flux/Biological	Zero		 41.37	(21.21-58.72)	 35.19	(23.27-49.22)	 0.463	
Maximum	Flux/Resting	Level		 1.87	(1.68-2.91)	 3.00	(1.39-3.97)	 0.600	
Time	to	Recovery	(s)	 1.50	(1.25-1.73)	 1.50	(0.80-6.35)	 0.463	
Time	to	Maximum	Flux	(s)	 13.40	(6.33-73.85)	 64.43	(22.05-114.20)	 0.028	




Resting	Flux	(flux)	 66.40	(15.3-172.80)	 33.80	(29.7-56)	 0.116	
Biological	Zero	(flux)	 3.80	(3.20-4.20)	 5.30	(3.30-9.10)	 0.917	
Maximum	Flux	(flux)	 81.40	(74.50-168.30)	 80.40	(55.70-125.60)	 0.600	
Maximum	Flux/Biological	Zero		 20.01	(7.01-27.89)	 22.21	(6.12-25.12)	 0.463	
Maximum	Flux/Resting	Level		 1.25	(1.13-1.74)	 2.38	(1.56-2.79)	 0.116	
Time	to	Recovery	(s)	 3.23	(2.25-45.13)	 2.26	(1.68-4.88)	 0.028	
Time	to	Maximum	Flux	(s)	 210.50	(72.18-231.00)	 50.71	(27.38-105.18)	 0.046	





Resting	Flux	(flux)	 18.85	(11.80-22.90)	 11.15	(10.20-19.90)	 0.600	
Biological	Zero	(flux)	 4.85	(4.60-5.00)	 4.00	(3.40-4.60)	 0.686	
Maximum	Flux	(flux)	 45.75	(32.10-63.20)	 29.20	(20.10-37.40)	 0.600	
Maximum	Flux/Biological	Zero		 9.43	(6.98-9.66)	 6.61	(5.90-8.92)	 0.249	
Maximum	Flux/Resting	Level		 2.79	(2.49-2.92)	 2.19	(1.78-3.01)	 0.249	
Time	to	Recovery	(s)	 0.83	(0.48-1.15)	 0.86	(0.58-1.28)	 0.916	
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Time	to	Maximum	Flux	(s)	 5.23	(2.85-9.28)	 13.15	(5.68-13.60)	 0.345	




Resting	Flux	(flux)	 28.80	(21.90-43.30)	 24.80	(15.00-30.40)	 0.917	
Biological	Zero	(flux)	 5.50	(4.10-10.20)	 5.70	(4.60-6.50)	 0.916	
Maximum	Flux	(flux)	 65.60	(37.80-94.30)	 45.90	(32.50-60.40)	 0.173	
Maximum	Flux/Biological	Zero		 12.35	(8.04-15.21)	 8.18	(4.72-9.95)	 0.249	
Maximum	Flux/Resting	Level		 1.88	(1.59-2.22)	 1.88	(1.20-3.34)	 0.917	
Time	to	Recovery	(s)	 2.08	(1.60-2.68)	 2.13	(0.78-4.53)	 0.345	
Time	to	Maximum	Flux	(s)	 198.79	(69.18-287.33)	 175.76	(105.20-227.13)	 0.753	





Resting	Flux	(flux)	 65.65	(36.40-112.70)	 122.10	(51.00-184.50)	 0.463	
Biological	Zero	(flux)	 4.55	(3.10-10.20)	 5.55	(3.20-11.50)	 0.600	
Maximum	Flux	(flux)	 138.90	(120.00-303.20)	 221.50	(173.90-273.40)	 0.249	
Maximum	Flux/Biological	Zero		 18.02	(13.95-36.81)	 32.11	(22.57-85.43)	 0.116	
Maximum	Flux/Resting	Level		 1.75	(1.32-3.30)	 1.98	(1.21-9.29)	 0.345	
Time	to	Recovery	(s)	 1.64	(1.00-8.18)	 2.06	(1.40-6.48)	 0.600	
Time	to	Maximum	Flux	(s)	 38.98	(12.68-262.10)	 87.20	(18.83-291.13)	 0.600	




Resting	Flux	(flux)	 41.50	(32.60-63.20)	 50.30	(34.60-54.30)	 0.465	
Biological	Zero	(flux)	 4.40	(3.40-5.90)	 4.80	(3.20-6.50)	 0.465	
Maximum	Flux	(flux)	 111.70	(83.80-132.20)	 145.30	(83.90-208.80)	 0.715	
Maximum	Flux/Biological	Zero		 19.83	(16.59-35.01)	 36.49	(21.37-43.5)	 1.000	
Maximum	Flux/Resting	Level		 2.39	(2.02-2.71)	 2.27	(1.67-3.85)	 0.273	
Time	to	Recovery	(s)	 2.03	(1.70-10.95)	 2.38	(2.15-3.93)	 1.000	
Time	to	Maximum	Flux	(s)	 34.38	(8.66-62.75)	 69.55	(35.33-146.28)	 0.273	
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Resting	Flux	(flux)	 8.65	(8.10-10.90)	 17.00	(9.60-20.70)	 0.028	
Biological	Zero	(flux)	 4.15	(3.10-4.70)	 4.85	(3.90-5.50)	 0.249	
Maximum	Flux	(flux)	 24.45	(12.10-39.90)	 33.95	(20.10-54.00)	 0.028	
Maximum	Flux/Biological	Zero		 5.31	(3.40-10.22)	 5.50	(4.26-10.81)	 0.463	
Maximum	Flux/Resting	Level		 1.91	(1.70-2.80)	 2.38	(1.22-3.35)	 0.753	
Time	to	Recovery	(s)	 0.74	(0.68-0.85)	 0.95	(0.55-1.43)	 0.249	
Time	to	Maximum	Flux	(s)	 10.20	(2.30-55.38)	 17.05	(12.13-142.95)	 0.463	




Resting	Flux	(flux)	 16.20	(14.00-24.60)	 15.90	(13.70-20.00)	 1.000	
Biological	Zero	(flux)	 5.60	(4.90-9.10)	 4.80	(4.70-5.90)	 0.273	
Maximum	Flux	(flux)	 78.00	(64.10-97.30)	 30.80	(29.20-55.60)	 0.144	
Maximum	Flux/Biological	Zero		 13.09	(10.69-13.92)	 5.39	(4.96-6.56)	 0.144	
Maximum	Flux/Resting	Level		 4.59	(3.17-5.99)	 2.01	(1.47-4.30)	 0.273	
Time	to	Recovery	(s)	 1.73	(0.53-1.75)	 3.23	(1.50-3.58)	 0.715	
Time	to	Maximum	Flux	(s)	 70.68	(46.15-112.80)	 161.88	(76.18-265.28)	 0.715	



















Resting	Flux	(flux)	 50.10	(13.05-67.35)	 107.70	(104.80-138.90)	 0.043	
Biological	Zero	(flux)	 4.70	(2.75-7.10)	 3.40	(3.30-3.70)	 0.225	
Maximum	Flux	(flux)	 149.40	(105.95-204.50)	 192.90	(138.30-277.80)	 0.225	
Maximum	Flux/Biological	Zero		 30.46	(18.60-56.96)	 58.46	(37.69-97.10)	 0.225	
Maximum	Flux/Resting	Level		 4.16	(2.24-11.82)	 2.23	(1.84-2.58)	 0.080	
Time	to	Recovery	(s)	 0.85	(0.68-2.25)	 1.18	(1.03-1.38)	 0.500	
Time	to	Maximum	Flux	(s)	 27.78	(3.44-83.36)	 9.68	(8.50-154.38)	 0.345	




Resting	Flux	(flux)	 84.00	(74.50-106.60)	 69.30	(16.40-122.10)	 0.655	
Biological	Zero	(flux)	 4.50	(2.90-4.70)	 5.80	(5.10-6.40)	 0.180	
Maximum	Flux	(flux)	 137.40	(68.60-193.50)	 86.10	(21.50-150.60)	 0.180	
Maximum	Flux/Biological	Zero		 41.18	(15.26-47.39)	 16.45	(3.37-29.52)	 0.180	
Maximum	Flux/Resting	Level		 1.64	(0.92-1.82)	 1.27	(1.23-1.31)	 0.655	
Time	to	Recovery	(s)	 3.58	(2.93-117.55)	 8.35	(3.65-13.05)	 0.655	
Time	to	Maximum	Flux	(s)	 288.78	(204.98-288.78)	 141.08	(49.65-232.50)	 0.655	





Resting	Flux	(flux)	 16.05	(8.25-21.95)	 23.60	(16.20-29.40)	 0.345	
Biological	Zero	(flux)	 3.75	(3.05-4.70)	 3.30	(3.10-4.50)	 0.892	
Maximum	Flux	(flux)	 45.35	(21.90-63.50)	 72.40	(24.80-87.30)	 0.686	
Maximum	Flux/Biological	Zero		 12.93	(6.07-23.75)	 21.46	(6.82-26.45)	 0.893	
Maximum	Flux/Resting	Level		 2.06	(1.64-6.05)	 1.84	(1.68-2.46)	 0.043	
Time	to	Recovery	(s)	 1.44	(0.84-2.50)	 1.05	(0.90-1.58)	 0.893	
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Time	to	Maximum	Flux	(s)	 11.25	(3.83-21.35)	 20.38	(4.95-192.98)	 0.080	




Resting	Flux	(flux)	 28.70	(22.60-37.40)	 22.80	 0.317	
Biological	Zero	(flux)	 5.80	(4.00-10.70)	 4.60	 0.317	
Maximum	Flux	(flux)	 49.00	(35.00-61.60)	 30.50	 0.317	
Maximum	Flux/Biological	Zero		 8.76	(4.58-10.62)	 6.63	 0.317	
Maximum	Flux/Resting	Level		 1.55	(1.31-2.15)	 1.34	 0.317	
Time	to	Recovery	(s)	 4.33	(3.08-5.93)	 2.40	 0.317	
Time	to	Maximum	Flux	(s)	 220.28	(93.65-271.38)	 30.08	 0.317	





Resting	Flux	(flux)	 46.25	(17.25-75.10)	 109.30	(21.00-144.20)	 0.043	
Biological	Zero	(flux)	 3.60	(3.15-7.20)	 3.10	(2.60-6.90)	 0.686	
Maximum	Flux	(flux)	 95.20	(32.30-168.20)	 220.00	(84.80-269.60)	 0.043	
Maximum	Flux/Biological	Zero		 19.10	(5.05-28.47)	 42.39	(10.64-50.76)	 0.345	
Maximum	Flux/Resting	Level		 2.33	(1.66-2.68)	 2.01	(1.87-3.35)	 0.500	
Time	to	Recovery	(s)	 1.31	(0.95-27.29)	 1.48	(1.20-2.03)	 0.893	
Time	to	Maximum	Flux	(s)	 34.05	(10.68-123.23)	 11.83	(11.68-15.53)	 0.080	




Resting	Flux	(flux)	 21.90	(8.10-78.50)	 26.40	(20.60-32.10)	 0.655	
Biological	Zero	(flux)	 3.80	(3.10-5.50)	 4.20	(3.50-4.80)	 0.655	
Maximum	Flux	(flux)	 38.70	(17.00-155.30)	 54.70	(30.90-78.50)	 0.655	
Maximum	Flux/Biological	Zero		 7.04	(5.47-40.87)	 14.43	(6.43-22.43)	 0.655	
Maximum	Flux/Resting	Level		 1.98	(1.77-2.09)	 1.97	(1.5-2.44)	 0.655	
Time	to	Recovery	(s)	 2.55	(2.45-3.75)	 2.06	(1.75-2.38)	 0.180	
Time	to	Maximum	Flux	(s)	 127.43	(54.73-237.73)	 15.51	(15.18-15.85)	 0.180	
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Resting	Flux	(flux)	 9.25	(7.05-12.35)	 8.00	(6.80-15.20)	 1.000	
Biological	Zero	(flux)	 4.80	(2.85-6.95)	 3.50	(2.50-3.80)	 0.465	
Maximum	Flux	(flux)	 23.55	(15.25-34.55)	 21.30	(18.60-32.30)	 0.225	
Maximum	Flux/Biological	Zero		 4.01	(3.76-5.74)	 7.42	(6.09-8.07)	 0.345	
Maximum	Flux/Resting	Level		 2.27	(1.99-3.27)	 3.11	(1.90-3.67)	 0.500	
Time	to	Recovery	(s)	 1.21	(0.75-1.51)	 1.10	(0.30-1.43)	 0.144	
Time	to	Maximum	Flux	(s)	 15.56	(5.91-117.88)	 13.90	(12.88-215.65)	 0.225	




Resting	Flux	(flux)	 47.50	(11.30-86.60)	 15.30	 0.317	
Biological	Zero	(flux)	 6.40	(4.20-9.60)	 3.30	 0.317	
Maximum	Flux	(flux)	 73.20	(22.30-192.90)	 17.90	 0.317	
Maximum	Flux/Biological	Zero		 7.63	(5.30-30.15)	 5.42	 0.317	
Maximum	Flux/Resting	Level		 1.97	(1.54-2.23)	 1.17	 0.317	
Time	to	Recovery	(s)	 2	(1.53-2.50)	 2.58	 0.317	
Time	to	Maximum	Flux	(s)	 31.10	(13.23-273.90)	 17.23	 0.317	
















Study	Toe	 Diabetic	 Tissue	 Loss	
(n=14/11)	
Resting	Flux	(flux)	 53.15	(35.20-104.00)	 98.00	(14.80-107.70)	 0.286	
Biological	Zero	(flux)	 4.70	(3.10-7.20)	 3.30	(2.70-7.80)	 0.182	
Maximum	Flux	(flux)	 162.95	(107.70-212.40)	 190.90	(75.40-258.40)	 1.000	
Maximum	Flux/Biological	Zero		 34.35	(21.21-58.72)	 56.06	(25.33-90.92)	 0.534	
Maximum	Flux/Resting	Level		 2.76	(1.75-5.24)	 2.58	(1.84-5.03)	 0.286	
Time	to	Recovery	(s)	 1.26	(0.83-1.73)	 1.18	(0.88-1.38)	 0.540	
Time	to	Maximum	Flux	(s)	 13.40	(3.68-73.85)	 11.08	(4.40-27.08)	 0.722	




Resting	Flux	(flux)	 74.50	(66.00-106.60)	 38.35	(23.05-76.05)	 0.123	
Biological	Zero	(flux)	 3.80	(3.20-4.50)	 4.40	(4.15-8.65)	 0.575	
Maximum	Flux	(flux)	 84.60	(74.50-168.30)	 102.85	(63.20-142.35)	 0.575	
Maximum	Flux/Biological	Zero		 22.27	(15.26-41.18)	 22.18	(8.68-29.00)	 0.263	
Maximum	Flux/Resting	Level		 1.27	(1.13-1.74)	 2.20	(1.37-3.78)	 0.263	
Time	to	Recovery	(s)	 3.58	(2.58-45.13)	 2.01	(1.13-3.49)	 0.017	
Time	to	Maximum	Flux	(s)	 220.80	(200.20-288.78)	 53.79	(18.09-205.16)	 0.123	
Time	to	Half	Recovery	(s)	 213.74	(140.11-261.53)	 74.01	(22.94-206.06)	 0.345	
Study	Dorsum	 Diabetic	Tissue	Loss	
(n=14/11)	
Resting	Flux	(flux)	 53.15	(35.20-104.00)	 98.00	(14.80-107.70)	 0.505	
Biological	Zero	(flux)	 4.70	(3.10-7.20)	 3.30	(2.70-7.80)	 0.373	
Maximum	Flux	(flux)	 162.95	(107.70-212.40)	 190.90	(75.40-258.40)	 0.722	
Maximum	Flux/Biological	Zero		 34.35	(21.21-58.72)	 56.06	(25.33-90.92)	 0.477	
Maximum	Flux/Resting	Level		 2.76	(1.75-5.24)	 2.58	(1.84-5.03)	 0.328	
Time	to	Recovery	(s)	 1.26	(0.83-1.73)	 1.18	(0.88-1.38)	 0.374	
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Time	to	Maximum	Flux	(s)	 13.40	(3.68-73.85)	 11.08	(4.40-27.08)	 0.182	




Resting	Flux	(flux)	 74.50	(66.00-106.60)	 38.35	(23.05-76.05)	 0.398	
Biological	Zero	(flux)	 3.80	(3.20-4.50)	 4.40	(4.15-8.65)	 0.128	
Maximum	Flux	(flux)	 84.60	(74.50-168.30)	 102.85	(63.20-142.35)	 0.499	
Maximum	Flux/Biological	Zero		 22.27	(15.26-41.18)	 22.18	(8.68-29.00)	 0.735	
Maximum	Flux/Resting	Level		 1.27	(1.13-1.74)	 2.20	(1.37-3.78)	 0.263	
Time	to	Recovery	(s)	 3.58	(2.58-45.13)	 2.01	(1.13-3.49)	 0.176	
Time	to	Maximum	Flux	(s)	 220.80	(200.20-288.78)	 53.79	(18.09-205.16)	 0.398	
Time	to	Half	Recovery	(s)	 213.74	(140.11-261.53)	 74.01	(22.94-206.06)	 0.600	
Non-study	Toe	 Diabetic	Tissue	Loss	
(n=14/11)	
Resting	Flux	(flux)	 16.80	(8.70-22.90)	 16.60	(11.60-29.40)	 0.533	
Biological	Zero	(flux)	 4.60	(3.40-4.90)	 4.00	(3.10-4.70)	 0.248	
Maximum	Flux	(flux)	 45.75	(23.30-63.20)	 46.10	(35.70-87.30)	 0.021	
Maximum	Flux/Biological	Zero		 9.43	(6.98-17.11)	 11.01	(6.89-26.45)	 0.041	
Maximum	Flux/Resting	Level		 2.63	(1.70-3.85)	 2.60	(2.15-3.22)	 0.328	
Time	to	Recovery	(s)	 1.03	(0.75-2.05)	 0.93	(0.85-1.05)	 0.286	
Time	to	Maximum	Flux	(s)	 8.05	(3.45-17.55)	 5.28	(2.50-20.38)	 0.790	




Resting	Flux	(flux)	 28.70	(22.60-37.40)	 15.00	(10.60-30.40)	 0.249	
Biological	Zero	(flux)	 5.80	(4.10-10.20)	 5.00	(3.10-5.40)	 0.128	
Maximum	Flux	(flux)	 49.00	(37.80-86.50)	 35.50	(22.40-68.50)	 0.753	
Maximum	Flux/Biological	Zero		 9.61	(8.04-15.09)	 9.95	(4.72-13.71)	 0.735	
Maximum	Flux/Resting	Level		 1.76	(1.55-2.15)	 2.11	(1.33-3.12)	 0.116	
Time	to	Recovery	(s)	 2.68	(1.70-4.33)	 1.85	(0.93-4.08)	 0.600	
Time	to	Maximum	Flux	(s)	 220.28	(93.65-279.80)	 127.78	(55.05-227.13)	 0.600	
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Resting	Flux	(flux)	 9.00	(7.60-10.90)	 8.80	(6.50-17)	 0.953	
Biological	Zero	(flux)	 4.30	(3.10-5.40)	 3.80	(3.50-4.00)	 0.767	
Maximum	Flux	(flux)	 23.55	(13.60-36.40)	 24.20	(14.40-68.60)	 0.032	
Maximum	Flux/Biological	Zero		 4.01	(3.61-6.91)	 6.70	(4.73-9.94)	 0.114	
Maximum	Flux/Resting	Level		 2.21	(1.75-2.80)	 3.12	(2.65-3.94)	 0.241	
Time	to	Recovery	(s)	 0.91	(0.68-1.48)	 0.64	(0.33-1.10)	 0.161	
Time	to	Maximum	Flux	(s)	 15.40	(3.58-116.90)	 24.15	(12.88-118.20)	 0.114	




Resting	Flux	(flux)	 16.20	(12.60-47.50)	 16.90	(8.70-23.30)	 0.893	
Biological	Zero	(flux)	 5.60	(4.20-9.10)	 5.10	(4.80-6.70)	 0.684	
Maximum	Flux	(flux)	 73.20	(22.30-97.30)	 38.35	(29.5-59.00)	 0.138	
Maximum	Flux/Biological	Zero		 10.69	(5.30-13.92)	 7.53	(6.14-11.56)	 0.225	
Maximum	Flux/Resting	Level		 2.23	(1.54-4.59)	 3.12	(1.47-4.35)	 0.686	
Time	to	Recovery	(s)	 1.75	(1.53-2.50)	 1.88	(1.25-2.30)	 0.500	
Time	to	Maximum	Flux	(s)	 70.68	(31.10-138.60)	 70.63	(60.08-243.90)	 0.500	

















Study	Toe	 Diabetic	 Tissue	 Loss	
(n=6/6)	
Resting	Flux	(flux)	 83.50	(48.10-151.50)	 77.00	(33.40-104.20)	 0.917	
Biological	Zero	(flux)	 5.00	(3.10-7.20)	 3.40	(2.70-7.80)	 0.173	
Maximum	Flux	(flux)	 171.50	(140.00-254.60)	 184.00	(168.20-197.60)	 0.753	
Maximum	Flux/Biological	Zero		 41.37	(21.21-58.72)	 40.95	(25.33-65.56)	 0.917	
Maximum	Flux/Resting	Level		 1.87	(1.68-2.91)	 2.66	(1.81-4.32)	 0.463	
Time	to	Recovery	(s)	 1.50	(1.25-1.73)	 1.25	(1.05-4.60)	 0.527	
Time	to	Maximum	Flux	(s)	 13.40	(6.33-73.85)	 19.19	(6.83-27.08)	 0.753	




Resting	Flux	(flux)	 66.40	(15.30-172.80)	 38.40	(29.70-59.00)	 0.249	
Biological	Zero	(flux)	 3.80	(3.20-4.20)	 4.30	(4.10-10.90)	 0.753	
Maximum	Flux	(flux)	 81.40	(74.50-168.30)	 102.90	(80.80-152.40)	 0.917	
Maximum	Flux/Biological	Zero		 20.01	(7.01-27.89)	 22.18	(13.99-27.92)	 0.600	
Maximum	Flux/Resting	Level		 1.25	(1.13-1.74)	 2.55	(2.08-4.76)	 0.249	
Time	to	Recovery	(s)	 3.23	(2.25-45.13)	 1.80	(0.58-2.10)	 0.028	
Time	to	Maximum	Flux	(s)	 210.50	(72.18-231.00)	 53.79	(27.38-177.83)	 0.116	
Time	to	Half	Recovery	(s)	 200.20	(80.03-222.50)	 74.01	(29.00-178.9)	 0.465	
Study	Dorsum	 Diabetic	Tissue	Loss	
(n=6/6)	
Resting	Flux	(flux)	 18.90	(11.80-22.9)	 18.50	(11.60-23.10)	 0.833	
Biological	Zero	(flux)	 4.90	(4.60-5.00)	 4.00	(3.40-4.70)	 0.249	
Maximum	Flux	(flux)	 45.80	(32.10-63.20)	 37.40	(35.70-46.10)	 0.916	
Maximum	Flux/Biological	Zero		 9.43	(6.98-9.66)	 9.97	(6.89-14.88)	 0.463	
Maximum	Flux/Resting	Level		 2.79	(2.49-2.92)	 2.50	(2.15-3.22)	 0.917	
Time	to	Recovery	(s)	 0.83	(0.48-1.15)	 0.89	(0.75-0.95)	 0.917	
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Time	to	Maximum	Flux	(s)	 5.23	(2.85-9.28)	 3.09	(2.15-5.28)	 0.600	




Resting	Flux	(flux)	 28.80	(21.90-43.30)	 13.40	(10.60-26.80)	 0.249	
Biological	Zero	(flux)	 5.50	(4.10-10.20)	 4.40	(3.10-5.40)	 0.173	
Maximum	Flux	(flux)	 65.60	(37.80-94.30)	 29.10	(22.40-53.80)	 0.345	
Maximum	Flux/Biological	Zero		 12.35	(8.04-15.21)	 9.88	(4.72-11.46)	 0.600	
Maximum	Flux/Resting	Level		 1.88	(1.59-2.22)	 1.94	(1.33-3.12)	 0.600	
Time	to	Recovery	(s)	 2.08	(1.60-2.68)	 1.54	(0.93-4.08)	 0.249	
Time	to	Maximum	Flux	(s)	 198.79	(69.18-287.33)	 142.33	(80.13-227.13)	 0.753	
Time	to	Half	Recovery	(s)	 119.83	(70.00-291.73)	 143.80	(80.35-228.68)	 0.893	
Non-study	Toe	 Diabetic	Tissue	Loss	
(n=6/6)	
Resting	Flux	(flux)	 65.70	(36.40-112.70)	 93.80	(24.40-183.50)	 0.917	
Biological	Zero	(flux)	 4.60	(3.10-10.20)	 4.20	(2.90-4.50)	 0.075	
Maximum	Flux	(flux)	 138.90	(120.00-303.20)	 213.90	(131.00-454.90)	 0.173	
Maximum	Flux/Biological	Zero		 18.02	(13.95-36.81)	 41.48	(11.16-156.87)	 0.046	
Maximum	Flux/Resting	Level		 1.75	(1.32-3.30)	 1.86	(1.73-6.03)	 0.116	
Time	to	Recovery	(s)	 1.64	(1.00-8.18)	 1.36	(1.33-1.40)	 0.249	
Time	to	Maximum	Flux	(s)	 38.98	(12.68-262.10)	 15.53	(6.98-120.95)	 0.345	




Resting	Flux	(flux)	 41.50	(32.60-63.20)	 26.30	(21.90-54.30)	 0.273	
Biological	Zero	(flux)	 4.40	(3.40-5.90)	 4.80	(2.90-6.50)	 0.715	
Maximum	Flux	(flux)	 111.70	(83.80-132.20)	 80.40	(77.00-208.80)	 0.715	
Maximum	Flux/Biological	Zero		 19.83	(16.59-35.01)	 27.73	(22.59-43.50)	 1.000	
Maximum	Flux/Resting	Level		 2.39	(2.02-2.71)	 2.93	(2.58-3.85)	 0.068	
Time	to	Recovery	(s)	 2.03	(1.70-10.95)	 2.15	(1.98-2.98)	 1.000	
Time	to	Maximum	Flux	(s)	 34.38	(8.66-62.28)	 65.40	(30.03-69.55)	 0.465	
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Resting	Flux	(flux)	 8.70	(8.10-10.90)	 9.00	(8.60-17.50)	 0.686	
Biological	Zero	(flux)	 4.20	(3.10-4.70)	 3.90	(3.70-4.00)	 0.892	
Maximum	Flux	(flux)	 24.50	(12.10-39.90)	 27.10	(18.90-81.70)	 0.043	
Maximum	Flux/Biological	Zero		 5.31	(3.40-10.22)	 7.31	(4.73-20.95)	 0.138	
Maximum	Flux/Resting	Level		 1.91	(1.70-2.80)	 3.13	(2.92-3.94)	 0.500	
Time	to	Recovery	(s)	 0.74	(0.68-0.85)	 0.70	(0.58-0.93)	 0.715	
Time	to	Maximum	Flux	(s)	 10.20	(2.30-55.38)	 18.70	(18.15-102.18)	 0.500	




Resting	Flux	(flux)	 15.10	(13.30-20.40)	 13.70	(8.70-23.30)	 0.465	
Biological	Zero	(flux)	 5.30	(4.30-7.40)	 5.40	(4.80-6.70)	 0.713	
Maximum	Flux	(flux)	 71.10	(39.10-87.70)	 45.90	(30.80-59.00)	 0.273	
Maximum	Flux/Biological	Zero		 11.89	(7.30-13.51)	 8.49	(6.56-11.56)	 0.273	
Maximum	Flux/Resting	Level		 3.88	(2.15-5.29)	 4.30	(1.94-4.35)	 0.715	
Time	to	Recovery	(s)	 1.74	(1.13-7.86)	 1.50	(1.25-2.3)	 0.715	
Time	to	Maximum	Flux	(s)	 91.74	(58.41-125.70)	 76.18	(65.08-243.90)	 1.000	

















Study	Toe	 Diabetic	 Tissue	 Loss	
(n=8/5)	
Resting	Flux	(flux)	 50.10	(13.10-67.40)	 104.8	(7.7-107.7)	 0.043	
Biological	Zero	(flux)	 4.70	(2.80-7.10)	 3.3	(2.7-3.7)	 0.686	
Maximum	Flux	(flux)	 149.40	(105.90-204.50)	 192.9	(75.4-277.8)	 0.686	
Maximum	Flux/Biological	Zero		 30.46	(18.60-56.96)	 58.46	(34.28-97.1)	 0.345	
Maximum	Flux/Resting	Level		 4.16	(2.24-11.82)	 2.58	(2.23-8.07)	 0.080	
Time	to	Recovery	(s)	 0.85	(0.68-2.25)	 1.03	(0.85-1.18)	 0.715	
Time	to	Maximum	Flux	(s)	 27.78	(3.44-83.36)	 8.5	(4.28-11.08)	 0.686	




Resting	Flux	(flux)	 84.00	(74.50-106.60)	 54.80	(16.40-93.10)	 0.180	
Biological	Zero	(flux)	 4.50	(2.90-4.70)	 5.40	(4.40-6.40)	 0.655	
Maximum	Flux	(flux)	 137.40	(68.60-193.50)	 76.90	(21.50-132.30)	 0.180	
Maximum	Flux/Biological	Zero		 41.18	(15.26-47.39)	 16.73	(3.37-30.08)	 0.180	
Maximum	Flux/Resting	Level		 1.64	(0.92-1.82)	 1.37	(1.31-1.42)	 0.655	
Time	to	Recovery	(s)	 3.58	(2.93-117.55)	 3.49	(3.33-3.65)	 0.655	
Time	to	Maximum	Flux	(s)	 288.78	(204.98-288.78)	 120.65	(8.80-232.50)	 0.655	
Time	to	Half	Recovery	(s)	 290.63	(204.98-295.23)	 124.30	(15.38-233.23)	 0.655	
Study	Dorsum	 Diabetic	Tissue	Loss	
(n=8/5)	
Resting	Flux	(flux)	 16.10	(8.30-22.00)	 16.2	(15.9-29.4)	 0.500	
Biological	Zero	(flux)	 3.80	(3.10-4.70)	 3.3	(2.8-4.5)	 1.000	
Maximum	Flux	(flux)	 45.40	(21.90-63.50)	 72.4	(48.8-87.3)	 0.686	
Maximum	Flux/Biological	Zero		 12.93	(6.07-23.75)	 21.46	(9.56-26.45)	 0.893	
Maximum	Flux/Resting	Level		 2.06	(1.64-6.05)	 2.6	(2.46-3.07)	 0.138	
Time	to	Recovery	(s)	 1.44	(0.84-2.50)	 1.03	(0.9-1.05)	 0.225	
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Time	to	Maximum	Flux	(s)	 11.25	(3.83-21.35)	 20.38	(9.78-209.2)	 0.043	




Resting	Flux	(flux)	 28.70	(22.60-37.40)	 31.80	 0.317	
Biological	Zero	(flux)	 5.80	(4.00-10.70)	 5.00	 0.317	
Maximum	Flux	(flux)	 49.00	(35.00-61.60)	 68.50	 0.317	
Maximum	Flux/Biological	Zero		 8.76	(4.58-10.62)	 13.71	 0.317	
Maximum	Flux/Resting	Level		 1.55	(1.31-2.15)	 2.16	 0.317	
Time	to	Recovery	(s)	 4.33	(3.08-5.93)	 3.40	 0.317	
Time	to	Maximum	Flux	(s)	 220.28	(93.65-271.38)	 55.05	 0.317	
Time	to	Half	Recovery	(s)	 222.18	(94.63-272.33)	 60.43	 0.317	
Non-study	Toe	 Diabetic	Tissue	Loss	
(n=8/5)	
Resting	Flux	(flux)	 46.30	(17.30-75.10)	 36.70	(9.80-144.20)	 0.225	
Biological	Zero	(flux)	 3.60	(3.20-7.20)	 5.00	(3.10-6.30)	 0.893	
Maximum	Flux	(flux)	 95.20	(32.30-168.20)	 53.20	(33.00-269.60)	 0.043	
Maximum	Flux/Biological	Zero		 19.10	(5.05-28.47)	 10.64	(8.44-50.76)	 0.500	
Maximum	Flux/Resting	Level		 2.33	(1.66-2.68)	 1.87	(1.72-2.43)	 0.686	
Time	to	Recovery	(s)	 1.31	(0.95-27.29)	 1.48	(1.13-2.30)	 0.893	
Time	to	Maximum	Flux	(s)	 34.05	(10.68-123.23)	 11.83	(11.68-105.38)	 0.080	




Resting	Flux	(flux)	 21.90	(8.10-78.50)	 35.40	(20.60-50.10)	 0.655	
Biological	Zero	(flux)	 3.80	(3.10-5.50)	 4.00	(3.10-4.80)	 0.655	
Maximum	Flux	(flux)	 38.70	(17.00-155.30)	 90.00	(30.90-149.00)	 0.655	
Maximum	Flux/Biological	Zero		 7.04	(5.47-40.87)	 27.25	(6.43-48.06)	 0.180	
Maximum	Flux/Resting	Level		 1.98	(1.77-2.09)	 2.24	(1.50-2.97)	 0.655	
Time	to	Recovery	(s)	 2.55	(2.45-3.75)	 2.14	(1.90-2.38)	 0.180	
Time	to	Maximum	Flux	(s)	 127.43	(54.73-237.73)	 10.85	(6.53-15.18)	 0.180	
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Resting	Flux	(flux)	 9.30	(7.10-12.40)	 6.80	(5.40-12.60)	 0.715	
Biological	Zero	(flux)	 4.80	(2.90-7.00)	 3.50	(3.30-4.00)	 0.715	
Maximum	Flux	(flux)	 23.60	(15.30-34.60)	 21.30	(14.40-32.30)	 0.345	
Maximum	Flux/Biological	Zero		 4.01	(3.76-5.74)	 6.09	(6.00-8.07)	 0.500	
Maximum	Flux/Resting	Level		 2.27	(1.99-3.27)	 3.11	(2.65-3.67)	 0.345	
Time	to	Recovery	(s)	 1.21	(0.75-1.51)	 0.33	(0.30-1.10)	 0.068	
Time	to	Maximum	Flux	(s)	 15.56	(5.91-117.88)	 29.60	(12.88-234.58)	 0.138	




Resting	Flux	(flux)	 47.50	(11.30-86.60)	 20.10	 0.317	
Biological	Zero	(flux)	 6.40	(4.20-9.60)	 4.80	 0.317	
Maximum	Flux	(flux)	 73.20	(22.30-192.90)	 29.50	 0.317	
Maximum	Flux/Biological	Zero		 7.63	(5.30-30.15)	 6.14	 0.317	
Maximum	Flux/Resting	Level		 1.97	(1.54-2.23)	 1.47	 0.317	
Time	to	Recovery	(s)	 20	(1.53-2.50)	 2.25	 0.317	
Time	to	Maximum	Flux	(s)	 31.10	(13.23-273.9)	 60.08	 0.317	
















Study	Toe	 Diabetic	 Tissue	 Loss	
(n=6/8)	
Resting	Flux	(flux)	 83.50	(48.10-151.50)	 50.10	(13.10-67.40)	 0.142	
Biological	Zero	(flux)	 5.00	(3.10-7.20)	 4.70	(2.80-7.10)	 0.662	
Maximum	Flux	(flux)	 171.50	(14.00-254.60)	 149.40	(105.90-204.50)	 0.491	
Maximum	Flux/Biological	Zero		 41.37	(21.21-58.72)	 30.46	(18.60-56.96)	 0.755	
Maximum	Flux/Resting	Level		 1.87	(1.68-2.91)	 4.16	(2.24-11.82)	 0.142	
Time	to	Recovery	(s)	 1.50	(1.25-1.73)	 0.85	(0.68-2.25)	 0.228	
Time	to	Maximum	Flux	(s)	 13.40	(6.33-73.85)	 27.78	(3.44-83.36)	 0.662	




Resting	Flux	(flux)	 66.40	(15.30-172.80)	 84.00	(74.50-106.60)	 0.548	
Biological	Zero	(flux)	 3.80	(3.20-4.20)	 4.50	(2.90-4.70)	 0.714	
Maximum	Flux	(flux)	 81.40	(74.50-168.30)	 137.40	(68.60-193.50)	 0.905	
Maximum	Flux/Biological	Zero		 20.01	(7.01-27.89)	 41.18	(15.26-47.39)	 0.584	
Maximum	Flux/Resting	Level		 1.25	(1.13-1.74)	 1.64	(0.92-1.82)	 1.000	
Time	to	Recovery	(s)	 3.23	(2.25-45.13)	 3.58	(2.93-117.55)	 0.548	
Time	to	Maximum	Flux	(s)	 210.50	(72.18-231.00)	 288.78	(204.98-288.78)	 0.381	
Time	to	Half	Recovery	(s)	 200.20	(80.03-222.50)	 290.63	(204.98-295.23)	 0.143	
Study	Dorsum	 Diabetic	Tissue	Loss	
(n=6/8)	
Resting	Flux	(flux)	 18.90	(11.80-22.90)	 16.10	(8.30-22.00)	 0.573	
Biological	Zero	(flux)	 4.90	(4.60-5.00)	 3.80	(3.10-4.70)	 0.142	
Maximum	Flux	(flux)	 45.80	(32.10-63.20)	 45.40	(21.90-63.50)	 0.852	
Maximum	Flux/Biological	Zero		 9.43	(6.98-9.66)	 12.93	(6.07-23.75)	 0.662	
Maximum	Flux/Resting	Level		 2.79	(2.49-2.92)	 2.06	(1.64-6.05)	 0.852	
	
	 273	
Time	to	Recovery	(s)	 0.83	(0.48-1.15)	 1.44	(0.84-2.50)	 0.181	
Time	to	Maximum	Flux	(s)	 5.23	(2.85-9.28)	 11.25	(3.83-21.35)	 0.282	




Resting	Flux	(flux)	 28.80	(21.90-43.30)	 28.70	(22.60-37.40)	 1.000	
Biological	Zero	(flux)	 5.50	(4.10-10.20)	 5.80	(4.00-10.70)	 1.000	
Maximum	Flux	(flux)	 65.60	(37.80-94.30)	 49.00	(35.00-61.60)	 0.714	
Maximum	Flux/Biological	Zero		 12.35	(8.04-15.21)	 8.76	(4.58-10.62)	 0.548	
Maximum	Flux/Resting	Level		 1.88	(1.59-2.22)	 1.55	(1.31-2.15)	 0.548	
Time	to	Recovery	(s)	 2.08	(1.60-2.68)	 4.33	(3.08-5.93)	 0.167	
Time	to	Maximum	Flux	(s)	 198.79	(69.18-287.33)	 220.28	(93.65-271.38)	 1.000	
Time	to	Half	Recovery	(s)	 119.83	(70.00-291.73)	 222.18	(94.63-272.33)	 1.000	
Non-study	Toe	 Diabetic	Tissue	Loss	
(n=6/8)	
Resting	Flux	(flux)	 65.70	(36.40-112.70)	 46.30	(17.30-75.10)	 0.282	
Biological	Zero	(flux)	 4.60	(3.10-10.20)	 3.60	(3.20-7.20)	 0.573	
Maximum	Flux	(flux)	 138.90	(12.00-303.20)	 95.20	(32.30-168.20)	 0.282	
Maximum	Flux/Biological	Zero		 18.02	(13.95-36.81)	 19.10	(5.05-28.47)	 0.755	
Maximum	Flux/Resting	Level		 1.75	(1.32-3.30)	 2.33	(1.66-2.68)	 1.000	
Time	to	Recovery	(s)	 1.64	(1.00-8.18)	 1.31	(0.95-27.29)	 1.000	
Time	to	Maximum	Flux	(s)	 38.98	(12.68-262.10)	 34.05	(10.68-123.23)	 0.662	




Resting	Flux	(flux)	 41.50	(32.60-63.20)	 21.90	(8.10-78.50)	 0.400	
Biological	Zero	(flux)	 4.40	(3.40-5.90)	 3.80	(3.10-5.50)	 1.000	
Maximum	Flux	(flux)	 111.70	(83.80-132.20)	 38.70	(17.00-155.30)	 0.629	
Maximum	Flux/Biological	Zero		 19.83	(16.59-35.01)	 7.04	(5.47-40.87)	 0.400	
Maximum	Flux/Resting	Level		 2.39	(2.02-2.71)	 1.98	(1.77-2.09)	 0.229	
Time	to	Recovery	(s)	 2.03	(1.70-10.95)	 2.55	(2.45-3.75)	 0.400	
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Time	to	Maximum	Flux	(s)	 34.38	(8.66-62.28)	 127.43	(54.73-237.73)	 0.229	





Resting	Flux	(flux)	 8.70	(8.10-10.90)	 9.30	(7.10-12.40)	 1.000	
Biological	Zero	(flux)	 4.20	(3.10-4.70)	 4.80	(2.90-7.00)	 0.573	
Maximum	Flux	(flux)	 24.50	(12.10-39.90)	 23.60	(15.30-34.60)	 1.000	
Maximum	Flux/Biological	Zero		 5.31	(3.40-10.22)	 4.01	(3.76-5.74)	 0.852	
Maximum	Flux/Resting	Level		 1.91	(1.70-2.80)	 2.27	(1.99-3.27)	 0.573	
Time	to	Recovery	(s)	 0.74	(0.68-0.85)	 1.21	(0.75-1.51)	 0.228	
Time	to	Maximum	Flux	(s)	 10.20	(2.30-55.38)	 15.56	(5.91-117.88)	 0.491	




Resting	Flux	(flux)	 15.10	(13.30-20.40)	 47.50	(11.30-86.60)	 0.629	
Biological	Zero	(flux)	 5.30	(4.30-7.40)	 6.40	(4.20-9.60)	 0.629	
Maximum	Flux	(flux)	 71.10	(39.10-87.70)	 73.20	(22.30-192.90)	 0.857	
Maximum	Flux/Biological	Zero		 11.89	(7.30-13.51)	 7.63	(5.30-30.15)	 1.000	
Maximum	Flux/Resting	Level		 3.88	(2.15-5.29)	 1.97	(1.54-2.23)	 0.400	
Time	to	Recovery	(s)	 1.74	(1.13-7.86)	 2.00	(1.53-2.50)	 0.857	
Time	to	Maximum	Flux	(s)	 91.74	(58.41-125.70)	 31.10	(13.23-273.90)	 0.629	















Study	Toe	 Diabetic	 Tissue	 Loss	
(n=6/5)	
Resting	Flux	(flux)	 77.00	(33.40-104.20)	 104.80	(7.70-107.70)	 1.000	
Biological	Zero	(flux)	 3.40	(2.70-7.80)	 3.30	(2.70-3.70)	 1.000	
Maximum	Flux	(flux)	 184.00	(168.20-197.60)	 192.90	(75.40-277.80)	 0.792	
Maximum	Flux/Biological	Zero		 40.95	(25.33-65.56)	 58.46	(34.28-97.10)	 0.537	
Maximum	Flux/Resting	Level		 2.66	(1.81-4.32)	 2.58	(2.23-8.07)	 0.429	
Time	to	Recovery	(s)	 1.25	(1.05-4.60)	 1.03	(0.85-1.18)	 0.177	
Time	to	Maximum	Flux	(s)	 19.19	(6.83-27.08)	 8.50	(4.28-11.08)	 0.429	




Resting	Flux	(flux)	 38.40	(29.70-59.00)	 54.80	(16.40-93.10)	 1.000	
Biological	Zero	(flux)	 4.30	(4.10-10.90)	 5.40	(4.40-6.40)	 0.643	
Maximum	Flux	(flux)	 102.90	(80.80-152.40)	 76.90	(21.50-132.30)	 0.643	
Maximum	Flux/Biological	Zero		 22.18	(13.99-27.92)	 16.73	(3.37-30.08)	 1.000	
Maximum	Flux/Resting	Level		 2.55	(2.08-4.76)	 1.37	(1.31-1.42)	 0.286	
Time	to	Recovery	(s)	 1.80	(0.58-2.10)	 3.49	(3.33-3.65)	 0.286	
Time	to	Maximum	Flux	(s)	 53.79	(27.38-177.83)	 120.65	(8.80-232.50)	 1.000	
Time	to	Half	Recovery	(s)	 74.01	(29.00-178.90)	 124.30	(15.38-233.23)	 1.000	
Study	Dorsum	 Diabetic	Tissue	Loss	
(n=6/5)	
Resting	Flux	(flux)	 18.50	(11.60-23.10)	 16.20	(15.90-29.40)	 1.000	
Biological	Zero	(flux)	 4.00	(3.40-4.70)	 3.30	(2.80-4.50)	 0.429	
Maximum	Flux	(flux)	 37.40	(35.70-46.10)	 72.40	(48.80-87.30)	 0.429	
Maximum	Flux/Biological	Zero		 9.97	(6.89-14.88)	 21.46	(9.56-26.45)	 0.662	
Maximum	Flux/Resting	Level		 2.50	(2.15-3.22)	 2.60	(2.46-3.07)	 0.792	
Time	to	Recovery	(s)	 0.89	(0.75-0.95)	 1.03	(0.90-1.05)	 0.247	
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Time	to	Maximum	Flux	(s)	 3.09	(2.15-5.28)	 20.38	(9.78-209.20)	 0.030	




Resting	Flux	(flux)	 13.40	(10.60-26.80)	 31.80	 0.286	
Biological	Zero	(flux)	 4.40	(3.10-5.40)	 5.00	 0.857	
Maximum	Flux	(flux)	 29.10	(22.40-53.80)	 68.50	 0.571	
Maximum	Flux/Biological	Zero		 9.88	(4.72-11.46)	 13.71	 0.571	
Maximum	Flux/Resting	Level		 1.94	(1.33-3.12)	 2.16	 0.857	
Time	to	Recovery	(s)	 1.54	(0.93-4.08)	 3.40	 0.857	
Time	to	Maximum	Flux	(s)	 142.33	(80.13-227.13)	 55.05	 0.571	
Time	to	Half	Recovery	(s)	 143.8	(80.35-228.68)	 60.43	 0.571	
Non-study	Toe	 Diabetic	Tissue	Loss	
(n=6/5)	
Resting	Flux	(flux)	 93.80	(24.40-183.50)	 36.70	(9.80-144.20)	 0.537	
Biological	Zero	(flux)	 4.20	(2.90-4.50)	 5.00	(3.10-6.30)	 0.662	
Maximum	Flux	(flux)	 213.90	(131.00-454.90)	 53.20	(33.00-269.60)	 0.329	
Maximum	Flux/Biological	Zero		 41.48	(11.16-156.87)	 10.64	(8.44-50.76)	 0.329	
Maximum	Flux/Resting	Level		 1.86	(1.73-6.03)	 1.87	(1.72-2.43)	 0.792	
Time	to	Recovery	(s)	 1.36	(1.33-1.40)	 1.48	(1.13-2.30)	 0.931	
Time	to	Maximum	Flux	(s)	 15.53	(6.98-120.95)	 11.83	(11.68-105.38)	 0.931	




Resting	Flux	(flux)	 26.30	(21.90-54.30)	 35.40	(20.60-50.10)	 1.000	
Biological	Zero	(flux)	 4.80	(2.90-6.50)	 4.00	(3.10-4.80)	 1.000	
Maximum	Flux	(flux)	 80.40	(77.00-208.80)	 90.00	(30.90-149.00)	 0.571	
Maximum	Flux/Biological	Zero		 27.73	(22.59-43.50)	 27.25	(6.43-48.06)	 1.000	
Maximum	Flux/Resting	Level		 2.93	(2.58-3.85)	 2.24	(1.50-2.97)	 1.000	
Time	to	Recovery	(s)	 2.15	(1.98-2.98)	 2.14	(1.90-2.38)	 1.000	
Time	to	Maximum	Flux	(s)	 65.40	(30.03-69.55)	 10.85	(6.53-15.18)	 0.095	
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Resting	Flux	(flux)	 9.00	(8.60-17.50)	 6.80	(5.40-12.60)	 0.310	
Biological	Zero	(flux)	 3.90	(3.70-4.00)	 3.50	(3.30-4.00)	 0.548	
Maximum	Flux	(flux)	 27.10	(18.90-81.70)	 21.30	(14.40-32.30)	 0.548	
Maximum	Flux/Biological	Zero		 7.31	(4.73-20.95)	 6.09	(6.00-8.07)	 0.841	
Maximum	Flux/Resting	Level		 3.13	(2.92-3.94)	 3.11	(2.65-3.67)	 0.841	
Time	to	Recovery	(s)	 0.70	(0.58-0.93)	 0.33	(0.30-1.10)	 0.548	
Time	to	Maximum	Flux	(s)	 18.70	(18.15-102.18)	 29.60	(12.88-234.58)	 0.690	




Resting	Flux	(flux)	 13.70	(8.70-23.30)	 20.10	 1.000	
Biological	Zero	(flux)	 5.40	(4.80-6.70)	 4.80	 0.667	
Maximum	Flux	(flux)	 45.90	(30.80-59.00)	 29.50	 0.667	
Maximum	Flux/Biological	Zero		 8.49	(6.56-11.56)	 6.14	 0.667	
Maximum	Flux/Resting	Level		 4.30	(1.94-4.35)	 1.47	 0.667	
Time	to	Recovery	(s)	 1.50	(1.25-2.30)	 2.25	 1.000	
Time	to	Maximum	Flux	(s)	 76.18	(65.08-243.9)	 60.08	 0.667	















Study	Toe	 Diabetic	 Tissue	 Loss	
(n=6/5)	
Resting	Flux	(flux)	 59.80	(32.30-122.70)	 107.70	(104.80-138.90)	 0.537	
Biological	Zero	(flux)	 5.20	(2.60-7.30)	 3.40	(3.30-3.70)	 0.792	
Maximum	Flux	(flux)	 167.00	(128.00-190.90)	 192.90	(138.30-277.80)	 0.329	
Maximum	Flux/Biological	Zero		 35.19	(23.27-49.22)	 58.46	(37.69-97.10)	 0.329	
Maximum	Flux/Resting	Level		 3.00	(1.39-3.97)	 2.23	(1.84-2.58)	 0.537	
Time	to	Recovery	(s)	 1.50	(0.80-6.35)	 1.18	(1.03-1.38)	 1.000	
Time	to	Maximum	Flux	(s)	 64.43	(22.05-114.20)	 9.68	(8.50-154.38)	 0.792	




Resting	Flux	(flux)	 33.80	(29.70-56.00)	 69.30	(16.40-122.10)	 1.000	
Biological	Zero	(flux)	 5.30	(3.30-9.10)	 5.80	(5.10-6.40)	 1.000	
Maximum	Flux	(flux)	 80.40	(55.70-125.60)	 86.10	(21.50-150.60)	 1.000	
Maximum	Flux/Biological	Zero		 22.21	(6.12-25.12)	 16.45	(3.37-29.52)	 1.000	
Maximum	Flux/Resting	Level		 2.38	(1.56-2.79)	 1.27	(1.23-1.31)	 0.286	
Time	to	Recovery	(s)	 2.26	(1.68-4.88)	 8.35	(3.65-13.05)	 0.286	
Time	to	Maximum	Flux	(s)	 50.71	(27.38-105.18)	 141.08	(49.65-232.50)	 0.429	
Time	to	Half	Recovery	(s)	 67.24	(29.15-106.15)	 142.73	(52.23-233.23)	 0.429	
Study	Dorsum	 Diabetic	Tissue	Loss	
(n=6/5)	
Resting	Flux	(flux)	 11.20	(10.20-19.90)	 23.60	(16.20-29.40)	 0.177	
Biological	Zero	(flux)	 4.00	(3.40-4.60)	 3.30	(3.10-4.50)	 0.329	
Maximum	Flux	(flux)	 29.20	(20.10-37.40)	 72.40	(24.80-87.30)	 0.429	
Maximum	Flux/Biological	Zero		 6.61	(5.90-8.92)	 21.46	(6.82-26.45)	 0.247	
Maximum	Flux/Resting	Level		 2.19	(1.78-3.01)	 1.84	(1.68-2.46)	 0.792	
Time	to	Recovery	(s)	 0.86	(0.58-1.28)	 1.05	(0.90-1.58)	 0.247	
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Time	to	Maximum	Flux	(s)	 13.15	(5.68-13.60)	 20.38	(4.95-192.98)	 0.429	




Resting	Flux	(flux)	 24.80	(15.00-30.40)	 22.80	 1.000	
Biological	Zero	(flux)	 5.70	(4.60-6.50)	 4.60	 0.571	
Maximum	Flux	(flux)	 45.90	(32.50-60.40)	 30.50	 0.571	
Maximum	Flux/Biological	Zero		 8.18	(4.72-9.95)	 6.63	 1.000	
Maximum	Flux/Resting	Level		 1.88	(1.20-3.34)	 1.34	 1.000	
Time	to	Recovery	(s)	 2.13	(0.78-4.53)	 2.40	 0.857	
Time	to	Maximum	Flux	(s)	 175.76	(105.20-227.13)	 30.08	 0.571	
Time	to	Half	Recovery	(s)	 176.43	(106.03-228.68)	 43.38	 0.571	
Non-study	Toe	 Diabetic	Tissue	Loss	
(n=6/5)	
Resting	Flux	(flux)	 122.10	(51.00-184.50)	 109.30	(21.00-144.20)	 0.662	
Biological	Zero	(flux)	 5.60	(3.20-11.50)	 3.10	(2.60-6.90)	 0.537	
Maximum	Flux	(flux)	 221.50	(173.90-273.40)	 220.00	(84.80-269.60)	 0.662	
Maximum	Flux/Biological	Zero		 32.11	(22.57-85.43)	 42.39	(10.64-50.76)	 0.792	
Maximum	Flux/Resting	Level		 1.98	(1.21-9.29)	 2.01	(1.87-3.35)	 0.792	
Time	to	Recovery	(s)	 2.06	(1.40-6.48)	 1.48	(1.20-2.03)	 0.429	
Time	to	Maximum	Flux	(s)	 87.20	(18.83-291.13)	 11.83	(11.68-15.53)	 0.082	




Resting	Flux	(flux)	 50.30	(34.60-54.30)	 26.40	(20.60-32.10)	 0.190	
Biological	Zero	(flux)	 4.80	(3.20-6.50)	 4.20	(3.50-4.80)	 1.000	
Maximum	Flux	(flux)	 145.30	(83.90-208.80)	 54.70	(30.90-78.50)	 0.190	
Maximum	Flux/Biological	Zero		 36.49	(21.37-43.50)	 14.43	(6.43-22.43)	 0.381	
Maximum	Flux/Resting	Level		 2.27	(1.67-3.85)	 1.97	(1.50-2.44)	 1.000	
Time	to	Recovery	(s)	 2.38	(2.15-3.93)	 2.06	(1.75-2.38)	 0.571	
Time	to	Maximum	Flux	(s)	 69.55	(35.33-146.28)	 15.51	(15.18-15.85)	 0.095	
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Resting	Flux	(flux)	 17.00	(9.60-20.70)	 8.00	(6.80-15.20)	 0.082	
Biological	Zero	(flux)	 4.90	(3.90-5.50)	 3.50	(2.50-3.80)	 0.030	
Maximum	Flux	(flux)	 34.00	(20.10-54.00)	 21.30	(18.60-32.30)	 0.662	
Maximum	Flux/Biological	Zero		 5.50	(4.26-10.81)	 7.42	(6.09-8.07)	 0.247	
Maximum	Flux/Resting	Level		 2.38	(1.22-3.35)	 3.11	(1.90-3.67)	 0.537	
Time	to	Recovery	(s)	 0.95	(0.55-1.43)	 1.10	(0.30-1.43)	 1.000	
Time	to	Maximum	Flux	(s)	 17.05	(12.13-142.95)	 13.90	(12.88-215.65)	 1.000	




Resting	Flux	(flux)	 15.90	(13.70-20.00)	 15.30	 1.000	
Biological	Zero	(flux)	 4.80	(4.70-5.90)	 3.30	 0.333	
Maximum	Flux	(flux)	 30.80	(29.20-55.60)	 17.90	 0.333	
Maximum	Flux/Biological	Zero		 5.39	(4.96-6.56)	 5.42	 1.000	
Maximum	Flux/Resting	Level		 2.01	(1.47-4.30)	 1.17	 0.333	
Time	to	Recovery	(s)	 3.23	(1.50-3.58)	 2.58	 1.000	
Time	to	Maximum	Flux	(s)	 161.88	(76.18-265.28)	 17.23	 0.333	












Observed	 Expected	 Residual	 X2	(df)	 p-value*	 Observed	 Expected	 Residual	 X2	(df)	 p-value*	
Sex																								Female	 43	 48.7	 -5.7	 0.963	
(1)	
0.326	
42	 56.8	 -14.8	 6.104	
(1)	
0.013	
Male	 110	 104.3	 5.7	 111	 96.2	 14.8	







0.300	Asian	 2	 15.1	 -13.1	 2	 3	 -1	
Black	 2	 9.7	 -7.7	 2	 5.2	 -3.2	







0.001	Ex-smoker	 104	 88.5	 15.5	 103	 79.8	 23.2	
	Still	Smoking	 32	 29.8	 2.2	 33	 47	 -14	
Hypertension													No	 25	 29.5	 -4.5	 27.776	
(1)	
0.356	
25	 56.5	 -31.5	 0.708	
(1)	
<0.001	
Yes	 128	 123.5	 4.5	 128	 96.5	 31.5	
High	Cholesterol							No	 60	 55.1	 4.9	 0.687	
(1)	




	Yes	 93	 97.9	 -4.9	 94	 85.8	 8.2	
Renal																				Normal	 148	 122.4	 25.6	 26.727	
(1)	
<0.001	
148	 142.5	 5.5	 3.059	
(1)	
0.080	
Failure	 5	 30.6	 -25.6	 5	 10.5	 -5.5	
Timing																		Elective	 108	 98.5	 9.5	 2.561	
(1)	
0.110	
137	 119.6	 17.4	 11.598	
(1)	
0.001	
	Emergency	 45	 54.5	 -9.5	 16	 33.4	 -17.4	
*Chi2	Goodness-of	Fit	Test,	df-degrees	of	freedom	
	
